Methods and compositions for selectively enriching methylation signals

By hybridizing alleles and chain-specific methyl enrichment decoys with nucleic acid molecules, transforming and amplifying nucleic acid molecules, the problems of low signal-to-noise ratio and high background signal in DNA methylation pattern detection in existing technologies are solved, achieving efficient methylation pattern enrichment and detection.

CN123125341APending Publication Date: 2026-11-17FOUNDATION MEDICINE INC
View PDF 19 Cites 0 Cited by

Patent Information

Application Number
CN202480085571.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-12-13
Filing Date
2024-12-12
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies for detecting DNA methylation patterns suffer from low signal-to-noise ratios and high background signals, making it difficult to achieve robust and sensitive detection.

Method used

Allele-specific and chain-specific methyl enrichment baits are used to hybridize with nucleic acid molecules. By converting unmethylated cytosine to uracil or methylated C to U, an amplicon group is formed and hybridized with the specific bait to separate unhybridized nucleic acid molecules, thereby selectively capturing high-methylation or low-methylation signals.

Benefits of technology

It improves the enrichment ability of methylation patterns, reduces background signal, enhances signal-to-noise ratio, and improves detection sensitivity and robustness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123125341A_ABST
    Figure CN123125341A_ABST
Patent Text Reader

Abstract

This article provides compositions, such as decoy sets, for selectively enriching nucleic acid molecules corresponding to one or more hypermethylation signals or one or more hypomethylation signals. Furthermore, methods for using such compositions and methods for designing such compositions are described.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references to related applications

[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 609,810, filed December 13, 2023, which is hereby incorporated in its entirety by reference. Technical Field

[0003] This article provides compositions, such as decoy sets, for selectively enriching nucleic acid molecules corresponding to one or more hypermethylation signals or one or more hypomethylation signals. Furthermore, methods for using such compositions and methods for designing such compositions are described. Background Technology

[0004] Many diseases and conditions are products of both the genome and the epigenome. For example, epigenetic modifications are known to work synergistically with gene alterations to drive cancer development. DNA methylation is a type of epigenetic modification characterized by the addition of a methyl group to the C-5 position of cytosine (one of the four nucleotide bases of DNA). 5-Methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) are two major types of DNA methylation occurring in mammalian genomes, commonly found in the CpG environment (where a cytosine nucleotide is followed by a guanine nucleotide in the base linear sequence along its 5' to 3' direction). Many cancers exhibit severe epigenetic dysregulation, resulting in aberrant DNA methylation patterns, including hypermethylation and hypomethylation, which are distinctly different from healthy samples. These characteristics can be used to develop cancer diagnostic assays based on, for example, next-generation sequencing (NGS) for methylation analysis (Methyl-seq). Methyl-seq relies on chemical processes (e.g., bisulfite, enzymatic, pull-down, etc.) that convert unmethylated cytosine to thymine while preserving methylated cytosine. Methyl-seq is employed during library construction for NGS. Therefore, the DNA methylation status of the original DNA molecules in the input material can be inferred and compared to identify healthy versus cancer samples, thereby determining or quantifying the amount of residual disease molecules in the sample or monitoring treatment response.

[0005] There is still a need for improved methods and systems that provide robust and sensitive detection of methylation patterns in DNA, while offering low background signal and an increased signal-to-noise ratio. Summary of the Invention

[0006] This document discloses methods and systems for selectively capturing nucleic acid molecules from samples using allele-specific methyl enrichment decoys and / or chain-specific methyl enrichment decoys described herein. The decoy sets described herein are designed to hybridize with nucleic acids transformed and amplified from methylated nucleic acids containing a target methylation pattern (target hypomethylation pattern or target hypermethylation pattern). The allele-specific decoys described herein are double-stranded and are either hypomethylation-specific or hypermethylation-specific. The chain-specific decoys described herein are single-stranded and are either hypomethylation-specific or hypermethylation-specific. Both the allele-specific and chain-specific decoys described herein improve the enrichment of methylation patterns compared to conventional decoy designs. The chain-specific decoys described herein can be further designed to achieve further improvements in enrichment beyond the capabilities of allele-specific decoys, for example, by avoiding off-target guanine / thymine (G:T) mismatches and / or promoting off-target adenine / cytosine (A:C) mismatches.

[0007] In one aspect, this article provides a method for selectively capturing nucleic acid molecules from a sample from a subject, the method comprising: converting unmethylated cytosine (C) in one or more nucleic acid molecules to uracil (U), or converting methylated C in one or more nucleic acid molecules to U, to form a transformed nucleic acid molecule; amplifying the transformed nucleic acid molecule into an amplicon set; hybridizing the single-stranded nucleic acid decoy set with the amplicon set to form a plurality of hybrids, wherein at least a portion of the plurality of hybrids comprises decoys from the single-stranded nucleic acid decoy set that have hybridized with each other without mismatch and a nucleic acid molecule containing a target nucleic acid pattern, wherein the target nucleic acid pattern corresponds to a target methylation pattern at a genomic locus in the pre-transformed nucleic acid molecule; and separating the plurality of hybrids from nucleic acid molecules that have not hybridized with the decoys. In some embodiments of this aspect, the target methylation pattern corresponds to a hypermethylation signal indicating a disease or condition. In some embodiments of this aspect, the target methylation pattern corresponds to a hypomethylation signal indicating a disease or condition.

[0008] In one aspect, this document provides a method for selectively capturing nucleic acid molecules from a sample from a subject, the method comprising: converting unmethylated cytosine (C) in one or more nucleic acid molecules to uracil (U), or converting methylated C in one or more nucleic acid molecules to U, to form a transformed nucleic acid molecule; amplifying the transformed nucleic acid molecule into an amplicon set; hybridizing the nucleic acid decoy set with the amplicon set to form a plurality of hybrids, wherein the nucleic acid decoy set selectively hybridizes with a target nucleic acid pattern, wherein the target nucleic acid pattern corresponds to a target methylation pattern at a genomic locus in the untransformed nucleic acid molecule, wherein the target methylation pattern corresponds to a hypermethylation signal indicating a disease or condition; and separating the plurality of hybrids from nucleic acid molecules not hybridized with the decoy. In some embodiments of this aspect, the nucleic acid decoy set does not contain a nucleic acid decoy that selectively hybridizes with a nucleic acid pattern corresponding to a hypomethylation signal at a genomic locus.

[0009] In one aspect, this document provides a method for selectively capturing nucleic acid molecules from a sample from a subject, the method comprising: converting unmethylated cytosine (C) in one or more nucleic acid molecules to uracil (U), or converting methylated C in one or more nucleic acid molecules to U, to form a transformed nucleic acid molecule; amplifying the transformed nucleic acid molecule into an amplicon set; hybridizing the nucleic acid decoy set with the amplicon set to form a plurality of hybrids, wherein the nucleic acid decoy set selectively hybridizes with a target nucleic acid pattern, wherein the target nucleic acid pattern corresponds to a target methylation pattern at a genomic locus in the pre-transformed nucleic acid molecule, wherein the target methylation pattern is associated with a hypomethylation signal indicating a disease or condition; and separating the plurality of hybrids from nucleic acid molecules not hybridized with the decoy. In some embodiments of this aspect, the nucleic acid decoy set does not contain a nucleic acid decoy that selectively hybridizes with a nucleic acid pattern corresponding to a hypermethylation signal at a genomic locus.

[0010] In any of the foregoing embodiments, the method may include converting multiple target methylation patterns at multiple genomic loci in a nucleic acid molecule from a sample of a subject into multiple target nucleic acid patterns at multiple genomic loci, and hybridizing multiple nucleic acid decoy sets with an amplicon set, wherein each of the multiple nucleic acid decoy sets selectively hybridizes with a target nucleic acid pattern among the multiple target nucleic acid patterns. In some embodiments, the multiple target methylation patterns include a first target methylation pattern and a second target methylation pattern, wherein the second target methylation pattern is associated with a hypermethylation signal indicating a disease or condition. In some embodiments, the multiple target methylation patterns include a first target methylation pattern and a second target methylation pattern, wherein the second target methylation pattern is associated with a hypomethylation signal indicating a disease or condition. In some embodiments, the first target methylation pattern and the second target methylation pattern are associated with hypomethylation or hypermethylation signals indicating different diseases or conditions. In some embodiments, the first target methylation pattern and the second target methylation pattern are associated with hypomethylation or hypermethylation signals indicating the same disease or condition.

[0011] In some embodiments, the nucleic acid decoy is double-stranded. In some embodiments, the nucleic acid decoy is single-stranded.

[0012] In any of the foregoing embodiments, the hybrids among the plurality of hybrids may not contain guanine / thymine (G:T) mismatch.

[0013] In some embodiments, a second hybrid in a plurality of hybrids comprises a single-stranded nucleic acid decoy from a single-stranded nucleic acid decoy set and a nucleic acid molecule that does not contain a target nucleic acid pattern, wherein the hybrid in the second hybrid contains one or more adenine / cytosine (A:C) mismatches. In some embodiments, the method further comprises separating the partial hybrid from the second hybrid.

[0014] In any of the foregoing embodiments, the method may further include attaching the hybrid to the substrate and washing the substrate, wherein nucleic acid molecules that have not hybridized with the decoy are depleted. In some embodiments, the method may include attaching the hybrid to the substrate and washing the substrate, wherein nucleic acid molecules in the second portion of the hybrid are depleted. In some embodiments, the substrate is washed at a temperature below the melting temperature (Tm) of the portion of the hybrid containing single-stranded nucleic acid decoys from a plurality of hybrids and nucleic acid molecules containing the target nucleic acid pattern.

[0015] In any of the foregoing embodiments, the transformation may include enzymatic transformation and / or bisulfite transformation. In some embodiments, the transformation is enzymatic transformation. In some embodiments, the transformation is bisulfite transformation. In any of the foregoing embodiments, the transformation may include the transformation of unmethylated C residues of cytosine (C) to uracil (U). In any of the foregoing embodiments, the transformation may include the transformation of methylated C residues of C to U.

[0016] In any of the foregoing embodiments, amplification may include the conversion of uracil (U) to thymine (T).

[0017] In any of the foregoing embodiments, the target methylation pattern may include one or more CpG sites. In any of the foregoing embodiments, the target methylation pattern may lack one or more methylated CpG sites compared to different methylation patterns at the same genomic locus that do not indicate a disease or condition. In any of the foregoing embodiments, the target methylation pattern may include one or more 3mC, 4mC, 5mC, and / or 5hmC sites. In some embodiments, the disease or condition includes tissue-specific markers, cancer, autoimmune diseases, infectious diseases, and / or the state of transplanted tissues or organs. In some embodiments, the disease is cancer.

[0018] In any of the foregoing embodiments, the sample may include cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), or a combination of both. In any of the foregoing embodiments, the decoy may be biotinylated. In some embodiments, separation includes contacting the decoy with streptavidin-coated beads.

[0019] In any of the foregoing embodiments, the transformation may include TET-assisted bisulfite treatment, TET-assisted pyridineborane treatment, oxidized bisulfite treatment, APOBEC treatment, and / or other DNA deaminase treatment. In any of the foregoing embodiments, the method may include fragmenting nucleic acid molecules from a sample. In any of the foregoing embodiments, amplification may include polymerase chain reaction (PCR) amplification, non-PCR amplification, or isothermal amplification.

[0020] In any of the foregoing embodiments, the subject may be a bacterial subject, a plant subject, a fungal subject, or an animal subject. In some embodiments, the subject is an animal subject. In some embodiments, the subject is a mammalian subject. In some embodiments, the subject is a human subject.

[0021] In any of the foregoing embodiments, the method may include sequencing nucleic acid molecules in a plurality of hybrids. In some embodiments, the method may include sequencing a plurality of nucleic acid molecules from a second portion of the hybrid after exhausting the nucleic acid molecules in that portion of the hybrid. In some embodiments, the method may include determining a hypermethylation score and / or a hypomethylation score.

[0022] In any of the foregoing embodiments, the method may include diagnosing the subject with a disease or condition. In some embodiments, the disease is cancer. In any of the foregoing embodiments, the subject may be suspected of having cancer or confirmed to have cancer. In some embodiments, cancer may include B. Multiple myeloma, melanoma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, bladder cancer, brain cancer, central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine cancer, endometrial cancer, oral cancer, pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small intestine cancer, appendix cancer, salivary gland cancer, thyroid cancer, adrenal cancer, osteosarcoma, chondrosarcoma, hematologic malignancies, adenocarcinoma, inflammatory myofibroblastic tumor, gastrointestinal stromal tumor (GIST), colon cancer, multiple myeloma (MM), myelodysplastic syndrome (MDS), myeloproliferative disorders (MPD), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL) Polycythemia vera, Hodgkin's lymphoma, non-Hodgkin's lymphoma (NHL), soft tissue sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, osteosarcoma, chordoma, angiosarcoma, endothelial sarcoma, lymphangiosarcoma, lymphangioendothelial sarcoma, synovoma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, substrate cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, nipple Adenocarcinoma, medullary carcinoma, bronchial carcinoma, renal cell carcinoma, liver cancer, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, nephroblastoma, bladder cancer, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pineal tumor, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, hepatocellular carcinoma, thyroid cancer, gastric cancer, head and neck cancer, small cell carcinoma, primary thrombocytosis, idiopathic myeloid metaplasia, eosinophilia, systemic mastocytosis, familial eosinophilia, chronic eosinophilic leukemia, neuroendocrine tumors or carcinoids.

[0023] In some embodiments, cancers may include acute lymphoblastic leukemia (Philadelphia chromosome positive), acute lymphoblastic leukemia (progenitor B cell), acute myeloid leukemia (FLT3+), acute myeloid leukemia (with IDH2 mutation), anaplastic large cell lymphoma, basal cell malignant epithelial tumor, B-cell chronic lymphocytic leukemia, bladder cancer, breast cancer (HER2 overexpression / amplification), breast cancer (HER2+), breast cancer (HR+, HER2-), cervical cancer, cholangiocarcinoma, chronic lymphocytic leukemia, chronic lymphocytic leukemia (17p deletion), chronic myeloid leukemia, chronic myeloid leukemia (Philadelphia chromosome positive), classical Hodgkin lymphoma, colorectal cancer, colorectal cancer (dMMR / MSI-H), colorectal cancer (KRAS wild-type), cryopyridine-associated periodic syndrome, cutaneous T-cell lymphoma, dermatofibrosarcoma protuberans, diffuse large B-cell lymphoma, fallopian tube cancer, follicular B-cell lymphoma. Cellular non-Hodgkin lymphoma, follicular lymphoma, gastric cancer, gastric cancer (HER2+), gastroesophageal junction (GEJ) adenocarcinoma, gastrointestinal stromal tumor, gastrointestinal stromal tumor (KIT+), giant cell tumor of bone, glioblastoma, granulomatous polyangiitis, squamous cell malignant epithelial tumor of the head and neck, hepatocellular malignant epithelial tumor, Hodgkin lymphoma, juvenile idiopathic arthritis, lupus erythematosus, mantle cell lymphoma, medullary thyroid carcinoma, melanoma, melanoma with BRAF V600 mutation, melanoma with BRAF V600E or V600K mutation, Merkel cell malignant epithelial tumor, multicentric Castleman's disease, multiple hematologic malignancies (including Philadelphia chromosome-positive ALL). (and CML), multiple myeloma, myelofibrosis, non-Hodgkin's lymphoma, unresectable subependymal giant cell astrocytoma associated with tuberous sclerosis, non-small cell lung cancer, non-small cell lung cancer (ALK+), non-small cell lung cancer (PD-L1+), non-small cell lung cancer (with ALK fusion or ROS1 gene alteration), non-small cell lung cancer (with BRAF V600E mutation).Non-small cell lung cancer (with EGFR exon 19 deletion or exon 21 substitution (L858R) mutation), non-small cell lung cancer (with EGFR T790M mutation), ovarian cancer, ovarian cancer (with BRCA mutation), pancreatic cancer, pancreatic neuroendocrine tumors, gastrointestinal neuroendocrine tumors or pulmonary neuroendocrine tumors, childhood neuroblastoma, peripheral T-cell lymphoma, peritoneal cancer, prostate cancer, malignant renal cell carcinoma, rheumatoid arthritis, small lymphocytic lymphoma, soft tissue sarcoma, solid tumors (MSI-H / dMMR), head and neck squamous cell carcinoma, squamous non-small cell lung cancer, thyroid cancer, malignant thyroid epithelial tumors, urothelial carcinoma, malignant urothelial epithelial tumors, or Waldenström macroglobulinemia.

[0024] In some embodiments, the cancer is glioblastoma, breast cancer, bladder cancer, cervical cancer, colorectal cancer, hepatocellular carcinoma, lung cancer, ovarian cancer, esophageal cancer, pancreatic cancer, gastric cancer, or prostate cancer. In some embodiments, the method further includes treating the subject with an anticancer therapy. In some embodiments, the anticancer therapy includes targeted anticancer therapy. In some embodiments, targeted anticancer therapy includes abexicillin (Verzenio), abiraterone acetate (Zytiga), acalabrutinib (Calquence), trastuzumab emtansine (Kadcyla), afatinib bismaleate (Gilotrif), interleukin (Proleukin), alectinib (Alecensa), alemtuzumab (Campath), and alivitamin A. Panretin, Piqray, Rybrevant, Arimidex, Erleada, Scimblix, Tecentriq, Ayvakit, Bavencio, Yescarta, Inlyta, Blenrep, Benlysta, Beleodaq, Welireg, Avastin, Targretin, Mektovi, Blincyto, Velcade, Bosultinib ), brutus vesinate (Adcetris), brigatinib (Alunbrig), cabazitaxel (Jevtana), cabozantinib (Cabometyx), cabozantinib (Cabometyx, Cometriq), canatumab (Ilaris), carmatinib hydrochloride (Tabrecta), carfilzomib (Kyprolis), cimiprimumab (Libtayo), ceritinib (LDK378 / Zykadia), cetuximab (Erbitux), cobitinib (Cotellic), colpanixol hydrochloride (Aliqopa), crizotinib (Xalkori), dabrafenib (Tafinlar), dacomitinib (Vizimpro), daratumumab (Darzalex), daratumumab and hyaluronidase (Darzalex) Faspro, darotamibamide (Nubeqa), dasatinib (Sprycel), denosumab (Ontak), denosumabXgeva, Unituxin (denutucizumab), Jemperli, Imfinzi (duvariumumab), Copiktra (duveliximab), Empliciti (elotocilizumab), Idhifa (enxidipine mesylate), Braftovi (encofenib), Padcev (entrotinib), Rozlytrek (entrectinib), Xtandi (enzalutamide), Balversa (erlotinib), Tarceva (erlotinib), Afinitor (everolimus), Aromasin (exemestane), Enhertuzumab (detroituzumab) ), fenzotinib hydrochloride (Inrebic), fulvestrant (Faslodex), gefitinib (Iressa), gemutuzumab ozogamicin (Mylotarg), giratetinib (Xospata), glasgibrum maleate (Daurismo), hyaluronidase (Phesgo), ibrutinib (Imbruvica), teimomab (Zevalin), iridecane (Abecma), ederalixib (Zydelig), imatinib mesylate (Gleevec), truseltiq phosphate, osmutuzumab (Besponsa), iodobenzylguanidine I131 (Azedra), Ipilimumab (Yervoy), Ixatuximab (Sarclisa), Ivosildini (Tibsovo), Ixazomib Citrate (Ninlaro), Lanrevitinib Acetate (Somatuline Depot), Lapatinib (Tykerb), Larotrectinib Sulfate (Vitrakvi), Lenvatinib Mesylate (Lenvima), Letrozole (Femara), Breyanzi, Lansetuximab (Zynlonta), Lorbrena, Lutetane 177-O-Octreotide (Lutathera), Margenza, Rydapt, Exkivity, Potegilumab, Lumoxiti, Danyelza, Portrazza, Nerlynx, Tasigna, Zejula, Opdivo, Gazyva, Arzerra, Lynparza, OlaparibLartruvo, Osimertinib (Tagrisso), Pebocicilline (Ibrance), Panitumumab (Vectibix), Pembrolizumab (Farydak), Pazopanib (Votrient), Pebolizumab (Keytruda), Pemitinib (Pemazyre), Pertuzumab (Perjeta), Pericidatinib Hydrochloride (Turalio), Polotuzumab (Polivy), Ponatinib Hydrochloride (Iclusig), Pralatrexar (Folotyn), Praciltinib (Gavreto), Radium-223 Dichloride (Xofigo), Ramoximumab (Cyramza), Regorafenib (Stivarga), Ribociclib (Kisqali), Ripretinib (Qinlock), Rituximab (Rituxan), Rituximab and Hyaluronidase (Rituxan) Hycela, Romidixin (Istodax), Rucapanicarmapamate (Rubraca), Ruxotinib phosphate (Jakafi), Goxatozumab (Trodelvy), Celiciximab, Celiniso (Xpovio), Septinib (Retevmo), Selmetinib sulfate (Koselugo), Sylvant (Sylxiximab), Ciprolus-T Provenge, Sirolimus protein-binding particles (Fyarro), Sonicaci (Odomzo), Sorafenib (Nexavar), Sotorazib (Lumakras), Sunitinib (Sutent), Tafacitinib (Monjuvi), Tarazorib (Elzonris), Taprazole palitoxate (Talzenna), Tamoxifen (Nolvadex), Tazestat hydrobromide (Tazverik), Tibantav (Kimmtrak), Tesirolimus (Torisel), Terpoxetine hydrochloride (Tepmetko), Tessarenx (Kymriah), Tessautomomumab (Tivdak), Tocilizumab (Actemra), Tofacitinib (Xeljanz), Tosimomumab (Bexxar), Trametinib (Mekinist), Trastuzumab (Herceptin), Vitamin A Vesanoid, Tevozaniol hydrochloride (Fotivda), Toremifen (Fareston), Tucatinib (Tukysa), Ulbrichtose (Ukoniq), Vandetanib (Caprelsa), Vemolfenib (Zelboraf), Venclexta, Erivedge, Vorinostat(Zolinza), zanubrutinib (Brukinsa), aflibercept (Zaltrap), or any combination thereof.

[0025] In any of the foregoing embodiments, the method may further include obtaining a sample from the subject. In any of the foregoing embodiments, the sample may include a tissue biopsy sample, a liquid biopsy sample, or a normal control. In some embodiments, the sample is a liquid biopsy sample and includes blood, plasma, cerebrospinal fluid, sputum, feces, urine, or saliva. In some embodiments, the sample is a liquid biopsy sample and includes circulating tumor cells (CTCs). In some embodiments, the sample is a liquid biopsy sample and contains cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), or any combination thereof.

[0026] In any of the foregoing embodiments, the sample may include a mixture of tumor nucleic acid molecules and non-tumor nucleic acid molecules. In some embodiments, the tumor nucleic acid molecules are derived from the tumor portion of a heterogeneous tissue biopsy sample, and the non-tumor nucleic acid molecules are derived from the normal portion of the heterogeneous tissue biopsy sample. In some embodiments, the sample comprises a liquid biopsy sample, wherein the tumor nucleic acid molecules are derived from the circulating tumor DNA (ctDNA) portion of the liquid biopsy sample, and the non-tumor nucleic acid molecules are derived from the non-tumor cell-free DNA (cfDNA) portion of the liquid biopsy sample.

[0027] In any of the foregoing embodiments, the method may further include, before or after the transformation of the methylation pattern, but before amplifying the transformed nucleic acid molecule, linking one or more adapters to one or more nucleic acid molecules, wherein the one or more adapters comprise amplification primers, flow cell adapter sequences, substrate adapter sequences, or sample index sequences.

[0028] In any of the foregoing embodiments, amplification can be performed by polymerase chain reaction (PCR). In some embodiments, sequencing includes using massively parallel sequencing (MPS), whole-genome sequencing, whole-exome sequencing, targeted sequencing, direct sequencing, or Sanger sequencing. In some embodiments, sequencing includes using MPS technology, and the MPS technology includes next-generation sequencing (NGS). In some embodiments, sequencing includes using a next-generation sequencer. In some embodiments, multiple sequencing reads are generated, and one or more of the multiple sequencing reads overlap with one or more loci within one or more subgenomic regions in the sample. In some embodiments, one or more genomes comprise at least 10 genomes, each genome containing more than two CpG sites.

[0029] In some embodiments, one or more loci include ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, ALOX12B, AMER1, APC, AR, ARAF, ARFRP1, ARID1A, ASXL1, ATM, ATR, ATRX, AURKA, AURKB, AXIN1, AXL, BAP1, BARD1, BCL2, BCL2L1, BCL2L2, BCL6, BCOR, BCORL1, BCR, BRAF, BRCA1, BRCA2, BRD4, BRIP1, BTG1, BTG2, BTK, CALR, CARD11, CASP8, CBFB, CBL, CCND1 , CCND2, CCND3, CCNE1, CD22, CD274, CD70, CD74, CD79A, CD79B, CDC73, CDH1, CDK12, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEBPA, CH EK1, CHEK2, CIC, CREBBP, CRKL, CSF1R, CSF3R, CTCF, CTNNA1, CTNNB1, CUL3, CUL4A, CXCR4, CYP17A1, DAXX, DDR1, DDR2, DIS3, DNMT3A, DOT1L, EED, EGFR, EMSY (C11orf30), ​​EP300, EPHA3, EPHB1, EPHB4, ERBB2, ERBB3, ERBB4, ERCC4, ERG, ERRFI1, ESR1, ETV4, ETV5, ETV6, EWSR1, EZH2, EZR, FAM46C, FANCA, FANCC, FANCG, FANCL, F AS, FBXW7, FGF10, FGF12, FGF14, FGF19, FGF23, FGF3, FGF4, FGF6, FGFR1, FGFR2, FGFR3, FGFR4, FH, FLCN, FLT1, FLT3, FOXL2, FUBP1, GABRA6, GATA3, GATA4, GATA6, GID4 (C17orf39), GNA11, GNA13, GNAQ, GNAS, GRM3, GSK3B, H3F3A, HDAC1, HGF, HNF1A, HRAS, HSD3B1, ID3, IDH1, IDH2, IGF1R, I KBKE, IKZF1, INPP4B, IRF2, IRF4, IRS2, JAK1, JAK2, JAK3, JUN, KDM5A, KDM5C, KDM6A, KDR, KEAP1, KEL, KIT, KLHL6, KMT2A (MLL), KMT2D(MLL2), KRAS, LTK, LYN, MAF, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAP3K13, MAPK1, MCL1, MDM2, MDM4, MED12, MEF2B, MEN1, MERTK, MET, MITF , MKNK1, MLH1, MPL, MRE11A, MSH2, MSH3, MSH6, MST1R, MTAP, MTOR, MUTYH, MYB, MYC, MYCL, MYCN, MYD88, NBN, NF1, NF2, NFE2L2, NFKBIA, NK X2-1, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, NT5C2, NTRK1, NTRK2, NTRK3, NUTM1, P2RY8, PALB2, PARK2, PARP1, PARP2, PARP3, PAX5, PBRM1 , PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PDK1, PIK3C2B, PIK3C2G, PIK3CA, PIK3CB, PIK3R1, PIM1, PMS2, POLD1, POLE, PPARG, PPP2R1A, PPP2R 2A, PRDM1, PRKAR1A, PRKCI, PTCH1, PTEN, PTPN11, PTPRO, QKI, RAC1, RAD21, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RAF1, RARA, RB1, RBM10, REL, RET, RICTOR, RNF43, ROS1, RPTOR, RSPO2, SDC4, SDHA, SDHB, SDHC, SDHD, SETD2, SF3B1, SGK1, SLC34A2, SMAD2, SMAD4, SM ARCA4, SMARCB1, SMO, SNCAIP, SOCS1, SOX2, SOX9, SPEN, SPOP, SRC, STAG2, STAT3, STK11, SUFU, SYK, TBX3, TEK, TERC, TERT, TET2, TGFBR2, TIPARP, TMPRSS2, TNFAIP3, TNFRSF14, TP53, TSC1, TSC2, TYRO3, U2AF1, VEGFA, VHL, WHSC1, WHSC1L1, WT1, XPO1, XRCC2, ZNF217, ZNF703, or any combination thereof. In some embodiments, one or more loci containABL, ALK, ALL, B4GALNT1, BAFF, BCL2, BRAF, BRCA, BTK, CD19, CD20, CD3, CD30, CD319, CD38, CD52, C DK4, CDK6, CML, CRACC, CS1, CTLA-4, dMMR, EGFR, ERBB1, ERBB2, FGFR1-3, FLT3, GD2, HDAC, HER1, HER 2. HR, IDH2, IL-1β, IL-6, IL-6R, JAK1, JAK2, JAK3, KIT, KRAS, MEK, MET, MSI-H, mTOR, PARP, PD-1, PD GFR, PDGFRα, PDGFRβ, PD-L1, PI3Kδ, PIGF, PTCH, RAF, RANKL, RET, ROS1, SLAMF7, VEGF, VEGFA, VEGFB or any combination thereof.

[0030] In any of the foregoing embodiments, the method may further include generating a report indicating the presence or absence of a target methylation pattern. In some embodiments, the method may further include transmitting the report to a healthcare provider. In some embodiments, the report is transmitted via a computer network or peer-to-peer connection. In some embodiments, the sample contains less than 1% of the total nucleic acids as tumor nucleic acid fraction. In some embodiments, the sample contains less than 0.1% of the total nucleic acids as tumor nucleic acid fraction. In some embodiments, the sample contains at least 0.01% of the total nucleic acids as tumor nucleic acid fraction. In some embodiments, the method may further include determining the prognosis of the subject. In some embodiments, the method may include predicting the survival of the subject.

[0031] In any of the foregoing embodiments, the method may further include predicting the survival of the subject, wherein the predicted survival of the subject is lower than the survival of individuals whose samples do not contain target methylation patterns associated with hypermethylation signals indicating a disease or condition. In any of the foregoing embodiments, the method may further include predicting the survival of the subject, wherein the predicted survival of the subject is lower than the survival of individuals whose samples do not contain target methylation patterns associated with hypomethylation signals indicating a disease or condition.

[0032] In some embodiments, where the subject has cancer, the method further includes predicting the subject's tumor burden, wherein the predicted tumor burden of the subject is increased compared to the tumor burden of subjects whose samples do not contain target methylation patterns associated with hypermethylation signals indicative of disease or condition. In some embodiments where the subject has cancer, the method may further include predicting the subject's tumor burden, wherein the predicted tumor burden of the subject is increased compared to the tumor burden of subjects whose samples do not contain target methylation patterns associated with hypomethylation signals indicative of disease or condition.

[0033] In any of the foregoing embodiments, the subject may have cancer, and the targeted methylation pattern may be associated with hypermethylation or hypomethylation signals indicating responsiveness to cancer treatment, further including predicting the subject's responsiveness to cancer treatment.

[0034] In another aspect, this document provides a method for monitoring cancer in a subject, the method comprising: (a) selectively capturing nucleic acid molecules from a first sample of the subject by means of any one of claims 1 to 83 to quantify the amount of a target methylation pattern present in the first sample; (b) selectively capturing nucleic acid molecules from a second sample of the subject by means of any one of claims 1 to 83 to quantify the amount of the target methylation pattern in the second sample, wherein the second sample is obtained from the subject after the first sample; and (c) determining the difference between the first sample and the second sample in terms of the amount of the target methylation pattern, thereby monitoring cancer in the individual.

[0035] In another aspect, this article provides a method for monitoring the response of an individual undergoing treatment for cancer, the method comprising: (a) selectively capturing nucleic acid molecules from a first sample from the subject by a method according to any one of claims 1 to 83 to quantify the amount of a target methylation pattern present in the first sample; (b) administering treatment to the subject after obtaining the first sample from the subject; (c) selectively capturing nucleic acid molecules from a second sample from the subject by a method according to any one of claims 1 to 83 to quantify the amount of a target methylation pattern in the second sample, wherein the second sample is obtained from the subject after administering treatment; and (d) determining the difference between the first sample and the second sample in terms of the amount of the target methylation pattern, thereby monitoring the individual's response to treatment.

[0036] In some embodiments, the method further includes ligating one or more adapters to one or more nucleic acid molecules before or after the conversion of the methylation pattern but before amplification of the converted nucleic acid molecule, wherein the one or more adapters comprise amplification primers, flow cell adapter sequences, substrate adapter sequences, or sample index sequences.

[0037] On the other hand, this article provides a sample mixed with a decoy in a vial, the sample comprising: a transformed nucleic acid molecule corresponding to a nucleic acid molecule from a sample from a subject, wherein the transformed nucleic acid molecule contains uracil (U) replacing unmethylated cytosine (C) or U replacing methylated C, compared to the nucleic acid molecule from the sample; an amplicon set generated by amplifying the transformed nucleic acid molecule; and a single-stranded nucleic acid decoy set; wherein the single-stranded nucleic acid decoy set hybridizes with the amplicon set to form a plurality of hybrids, wherein at least a portion of the plurality of hybrids comprises a decoy from the single-stranded nucleic acid decoy set that hybridizes with each other without mismatch and a nucleic acid molecule containing a target nucleic acid pattern, wherein the target nucleic acid pattern corresponds to a target methylation pattern at a genomic locus in the nucleic acid molecule from the sample; and wherein the plurality of hybrids are separable from nucleic acid molecules that have not hybridized with the decoy. In some embodiments, the target methylation pattern corresponds to a hypermethylation signal indicating a disease or condition. In some embodiments, the target methylation pattern corresponds to a hypomethylation signal indicating a disease or condition.

[0038] In another aspect, this document provides a sample mixed with a decoy in a vial, the sample comprising: a transformed nucleic acid molecule corresponding to a nucleic acid molecule from a sample from a subject, wherein the transformed nucleic acid molecule contains uracil (U) replacing unmethylated cytosine (C) or U replacing methylated C, compared to the nucleic acid molecule from the sample; an amplicon set generated by amplifying the transformed nucleic acid molecule; and a nucleic acid decoy set; wherein the nucleic acid decoy set hybridizes with the amplicon set to form a plurality of hybrids, wherein the nucleic acid decoy set selectively hybridizes with a target nucleic acid pattern, wherein the target nucleic acid pattern corresponds to a target methylation pattern at a genomic locus in the nucleic acid molecule from the sample, wherein the target methylation pattern corresponds to a hypermethylation signal indicating a disease or condition; and wherein the plurality of hybrids are separable from nucleic acid molecules not hybridized with the decoy. In some embodiments, the nucleic acid decoy set does not contain a nucleic acid decoy that selectively hybridizes with a nucleic acid pattern corresponding to a hypomethylation signal at a genomic locus.

[0039] On the other hand, this article provides a sample mixed with a decoy in a vial, the sample comprising: a transformed nucleic acid molecule corresponding to a nucleic acid molecule from a sample from a subject, wherein the transformed nucleic acid molecule contains uracil (U) replacing unmethylated cytosine (C) or U replacing methylated C, compared to the nucleic acid molecule from the sample; an amplicon set generated by amplifying the transformed nucleic acid molecule; and a nucleic acid decoy set; wherein the nucleic acid decoy set hybridizes with the amplicon set to form a plurality of hybrids, wherein the nucleic acid decoy set selectively hybridizes with a target nucleic acid pattern, wherein the target nucleic acid pattern corresponds to a target methylation pattern at a genomic locus in the nucleic acid molecule from the sample, wherein the target methylation pattern corresponds to a hypomethylation signal indicating a disease or condition; and wherein the plurality of hybrids are separable from nucleic acid molecules not hybridized with the decoy. In some embodiments, the nucleic acid decoy set does not contain a nucleic acid decoy that selectively hybridizes with a nucleic acid pattern corresponding to a hypermethylation signal at a genomic locus.

[0040] In any of the foregoing embodiments involving samples mixed with decoys in vials, the transformed nucleic acid molecule may include multiple target nucleic acid patterns transformed from multiple target methylation patterns at multiple genomic loci in a nucleic acid molecule from a subject, and may further include multiple sets of nucleic acid decoys, wherein the multiple sets of nucleic acid decoys hybridize with an amplicon set, wherein each of the multiple sets of nucleic acid decoys selectively hybridizes with a target nucleic acid pattern among the multiple target nucleic acid patterns. In some embodiments, the multiple target methylation patterns include a first target methylation pattern and a second target methylation pattern, wherein the second target methylation pattern is associated with a hypermethylation signal indicating a disease or condition. In some embodiments, the multiple target methylation patterns include a first target methylation pattern and a second target methylation pattern, wherein the second target methylation pattern is associated with a hypomethylation signal indicating a disease or condition. In some embodiments, the first target methylation pattern and the second target methylation pattern are associated with hypomethylation or hypermethylation signals indicating different diseases or conditions. In some embodiments, the first target methylation pattern and the second target methylation pattern are associated with hypomethylation or hypermethylation signals indicating the same disease or condition. In some embodiments, the nucleic acid decoy is double-stranded. In some embodiments, the nucleic acid decoy is single-stranded. In some embodiments, the hybrids in the plurality of hybrids do not contain guanine / thymine (G:T) mismatches. In some embodiments, a second hybrid in the plurality of hybrids comprises a single-stranded nucleic acid decoy from the single-stranded nucleic acid decoy group and a nucleic acid molecule that does not contain the target nucleic acid pattern, wherein the hybrid in the second hybrid contains one or more adenine / cytosine (A:C) mismatches.

[0041] On the other hand, this paper provides a method for designing decoy sets, the method comprising: identifying a target hypermethylation pattern at a genomic locus, wherein the target hypermethylation pattern comprises a positive strand and a negative strand; determining nucleic acid sequences for: (i) a positively converted nucleic acid corresponding to the positive strand of the target hypermethylation pattern; (ii) an inverse complementary nucleic acid of the positively converted nucleic acid; (iii) an inversely converted nucleic acid corresponding to the negative strand of the target hypermethylation pattern; and / or (iv) an inverse complementary nucleic acid of the inversely converted nucleic acid; wherein, compared to the target hypermethylation pattern at the genomic locus, the converted nucleic acid sequence comprises uracil (U) replacing unmethylated cytosine (C) or uracil (U) replacing methylated cytosine (C); and designing a double-stranded nucleic acid decoy molecule set, wherein each double-stranded nucleic acid decoy molecule in the double-stranded nucleic acid decoy molecule set comprises two single-stranded nucleic acid molecules that hybridize with each other without mismatch, wherein the first portion of the double-stranded nucleic acid decoy molecule set comprises (i) (ii) a nucleic acid sequence complementary to the forward-converted nucleic acid, and (iii) a nucleic acid sequence complementary to the reverse complementary nucleic acid of the forward-converted nucleic acid; and / or the second part of the double-stranded nucleic acid decoy molecule group contains (iii) a nucleic acid sequence complementary to the reverse-converted nucleic acid, and (iv) a nucleic acid sequence complementary to the reverse complementary nucleic acid of the reverse-converted nucleic acid.

[0042] In another aspect, this paper provides a method for designing decoy sets, which includes: identifying target hypomethylation patterns at genomic loci, wherein the target hypomethylation patterns contain both positive and negative strands;

[0043] Identify nucleic acid sequences for: (i) forward-converted nucleic acids of the positive strand corresponding to the target hypomethylation pattern; (ii) the reverse complementary nucleic acid of the forward-converted nucleic acid; (iii) the reverse-converted nucleic acid of the negative strand corresponding to the target hypomethylation pattern; and / or (iv) the reverse complementary nucleic acid of the reverse-converted nucleic acid; wherein, compared to the target hypomethylation pattern at the genomic locus, the converted nucleic acid sequence contains uracil (U) replacing unmethylated cytosine (C) or uracil (U) replacing methylated cytosine (C); and design a set of double-stranded nucleic acid decoy molecules, wherein each double-stranded nucleic acid decoy molecule in the set comprises two single-stranded nucleic acid molecules that hybridize to each other without mismatch, wherein the first portion of the double-stranded nucleic acid decoy molecule in the set comprises (i) a nucleic acid sequence complementary to the forward-converted nucleic acid, and (ii) The nucleic acid sequence complementary to the reverse complementary nucleic acid of the forward-converted nucleic acid; and / or the second part of the double-stranded nucleic acid decoy molecule group contains (iii) a nucleic acid sequence complementary to the reverse-converted nucleic acid, and (iv) a nucleic acid sequence complementary to the reverse complementary nucleic acid of the reverse-converted nucleic acid.

[0044] In a further aspect, this paper provides a method for designing a decoy set, the method comprising: identifying a target hypermethylation pattern at a genomic locus, wherein the target hypermethylation pattern comprises a positive strand and a negative strand; determining nucleic acid sequences for: (i) a positively converted nucleic acid corresponding to the positive strand of the target hypermethylation pattern; (ii) an inverse complementary nucleic acid of the positively converted nucleic acid; (iii) an inversely converted nucleic acid corresponding to the negative strand of the target hypermethylation pattern; and / or (iv) an inverse complementary nucleic acid of the inversely converted nucleic acid; wherein, compared to the target hypermethylation pattern at the genomic locus, the converted nucleic acid sequence comprises uracil (U) replacing unmethylated cytosine (C) or uracil (U) replacing methylated cytosine (C); and designing a single-stranded nucleic acid decoy molecule set, wherein a first portion of the single-stranded nucleic acid decoy molecule set comprises (i) The single-stranded nucleic acid decoy molecule in the first part of the single-stranded nucleic acid decoy molecule set contains (ii) a nucleic acid sequence complementary to the reverse complementary nucleic acid of the positively converted nucleic acid; and / or the single-stranded nucleic acid decoy molecule in the second part of the single-stranded nucleic acid decoy molecule set contains (iii) a nucleic acid sequence complementary to the reverse converted nucleic acid; and / or the single-stranded nucleic acid decoy molecule in the fourth part of the single-stranded nucleic acid decoy molecule set contains (iv) a nucleic acid sequence complementary to the reverse complementary nucleic acid of the reverse converted nucleic acid.

[0045] On the other hand, this paper provides a method for designing a decoy set, the method comprising: identifying a target hypomethylation pattern at a genomic locus, wherein the target hypomethylation pattern comprises a positive strand and a negative strand; determining nucleic acid sequences for: (i) a positively converted nucleic acid corresponding to the positive strand of the target hypomethylation pattern; (ii) an inverse complementary nucleic acid of the positively converted nucleic acid; (iii) an inversely converted nucleic acid corresponding to the negative strand of the target hypomethylation pattern; and / or (iv) an inverse complementary nucleic acid of the inversely converted nucleic acid; wherein, compared to the target hypomethylation pattern at the genomic locus, the converted nucleic acid sequence comprises uracil (U) replacing unmethylated cytosine (C) or uracil (U) replacing methylated cytosine (C); and designing a single-stranded nucleic acid decoy molecule set, wherein a first portion of the single-stranded nucleic acid decoy molecule set comprises (i) a nucleic acid sequence complementary to the positively converted nucleic acid; and / or wherein a second portion of the single-stranded nucleic acid decoy molecule set comprises (ii) The nucleic acid sequence complementary to the reverse complementary nucleic acid of the forward-converted nucleic acid; and / or the third part of the single-stranded nucleic acid decoy molecule in the single-stranded nucleic acid decoy molecule group contains (iii) a nucleic acid sequence complementary to the reverse-converted nucleic acid; and / or the fourth part of the single-stranded nucleic acid decoy molecule in the single-stranded nucleic acid decoy molecule group contains (iv) a nucleic acid sequence complementary to the reverse complementary nucleic acid of the reverse-converted nucleic acid.

[0046] In some embodiments of the methods for designing decoy sets provided herein, the nucleic acid sequence of the forward-converted nucleic acid may include cytosine residues at positions corresponding to methylated cytosine residues in the target hypermethylation pattern, and uracil or thymine residues at positions corresponding to unmethylated cytosine residues in the target hypermethylation pattern. In some embodiments of the methods for designing decoy sets provided herein, the nucleic acid sequence of the reverse-converted nucleic acid may include cytosine residues at positions corresponding to methylated cytosine residues in the target hypomethylation pattern, and uracil or thymine residues at positions corresponding to unmethylated cytosine residues in the target hypomethylation pattern. In some embodiments, the single-stranded nucleic acid decoy molecule set does not contain decoy molecules that exhibit G:T mismatches when hybridizing with a nucleic acid molecule or its complementary sequence (containing a sequence of converted nucleic acid corresponding to a hypomethylation pattern at a genomic locus). In some embodiments, the single-stranded nucleic acid decoy molecule set does not contain decoy molecules that exhibit G:T mismatches when hybridizing with a nucleic acid molecule or its complementary sequence (containing a sequence of converted nucleic acid corresponding to a hypermethylation pattern at a genomic locus). In some embodiments, the single-stranded nucleic acid decoy molecule set comprises decoy molecules that exhibit an A:C mismatch when hybridizing with a nucleic acid molecule or its complementary sequence (a sequence comprising a transformed nucleic acid sequence comprising a hypomethylation pattern corresponding to a genomic locus). In some embodiments, the single-stranded nucleic acid decoy molecule set comprises decoy molecules that exhibit an A:C mismatch when hybridizing with a nucleic acid molecule or its complementary sequence (a sequence comprising a transformed nucleic acid sequence comprising a hypermethylation pattern corresponding to a genomic locus).

[0047] In some embodiments of any of the methods for designing decoy sets provided herein, the nucleic acid decoy molecule further comprises one or more additional sequences and / or modifications. In some embodiments, the additional sequences comprise an adaptor sequence, a primer sequence, a barcode sequence, a unique molecular identifier sequence, and / or a universal tail at one or both ends. In some embodiments, the modification comprises a covalently linked compound or protein. In some embodiments, the compound is biotin.

[0048] In some embodiments, the method further includes designing a decoy set in any of the methods for designing decoy sets provided herein, and synthesizing the designed decoy molecules. Further aspects of this disclosure include decoy sets manufactured according to the methods of the foregoing embodiments.

[0049] It should be understood that all combinations of the foregoing concepts, as well as other concepts discussed in more detail below, are considered part of the inventive subject matter disclosed herein. Specifically, all combinations of the subject matter of the claims listed at the end of this disclosure are considered part of the inventive subject matter disclosed herein.

[0050] Incorporate by reference

[0051] All publications, patents, patent applications, and any other references mentioned in this specification are incorporated herein by full citation as if each individual publication, patent, or patent application were specifically and individually indicated to be incorporated herein by full citation. In the event of any conflict between the terminology used in this text and that used in the incorporated references, the terminology used herein shall prevail. Attached Figure Description

[0052] Various aspects of the disclosed methods, apparatus, and systems are specifically set forth in the appended claims. A better understanding of the features and advantages of the disclosed methods, apparatus, and systems will be obtained by referring to the following detailed description and accompanying drawings of exemplary embodiments, wherein:

[0053] Figure 1 A non-limiting exemplary workflow diagram is provided for current methods for detecting cancer-related methylation signals, including, for example, samples from patients with minimal residual disease (MRD) / early-stage cancer or treatment response monitoring (TRM) / advanced-stage cancer. This exemplary workflow begins with a cell-free DNA (cfDNA) sample, followed by end repair and adaptor ligation, cytosine transformation, library PCR, target capture, sequencing, determination of cancer hypermethylation and / or hypomethylation scores, and finally, cancer identity invocation and tumor score determination.

[0054] Figure 2 A schematic diagram is provided of an exemplary method for selectively capturing nucleic acid molecules using the single-stranded hypermethylation-specific decoy or the single-stranded hypomethylation-specific decoy described herein.

[0055] Figure 3 A schematic diagram is provided of an exemplary method for selectively capturing nucleic acid molecules using single-stranded hypermethylation-specific decoys or double-stranded hypermethylation-specific decoys as described herein.

[0056] Figure 4 A schematic diagram is provided of an exemplary method for selectively capturing nucleic acid molecules using single-stranded hypomethylation-specific decoys or double-stranded hypomethylation-specific decoys as described herein.

[0057] Figure 5 A schematic diagram is provided illustrating a non-limiting example of the design principles for allele-specific methyl enrichment baits.

[0058] Figure 6A To 6C provides a non-limiting example of using methyl allele-specific decoys to enhance the detection of cancer-related methylation signals. Figure 6AThe cancer hypermethylation score map is shown, which was determined from 292 CpG clusters known to be hypermethylated in cancer by cluster consistency methylation score (ccmf) from the target capture group. Figure 6A The data depicted in the text comes from and Figure 6C The same experiment was conducted, but the overall signal was shown for all 292 loci. Figure 6B The cancer hypomethylation score map is shown, which was determined from 80 CpG clusters known to be hypomethylated in cancer by double-stranded cluster consistency unmethylation score (dccuf) from the target capture group. Figure 6C This displays a heatmap of methylation scores for each locus in the target capture group, which contains CpG clusters known to be highly methylated in cancer. The heatmap is derived from […]. Figure 6A The same experiment was performed, but the enhanced enrichment induced by each hypermethylation-specific decoy at each locus is shown. Methylation scores are displayed in the heatmap (bottom section), as shown on the right side of the methylation scale (from 0 to 0.8).

[0059] Figure 7 A schematic diagram is provided illustrating a non-limiting example of an off-target capture type that may occur between a double-stranded allele-specific decoy and an unexpected amplicon.

[0060] Figure 8A To 8B provides data-free examples demonstrating that target-decoy duplexes with A:C mismatches have low thermal stability and can be screened out during post-hybridization washing. Figure 8A Box plots show the determined melting temperatures (Tm) of hybrids with different baits designed for positive (+) strands of DNA in the original sample from 500 randomly selected methylated loci. Figure 8B A graph showing the Tm of hybrids with different baits designed for the negative (-) strand of DNA in the original sample.

[0061] Figure 9A Figure 9B provides a schematic diagram illustrating a chain-selective decoy design. Figure 9A Non-limiting examples of single-stranded (ss) hypomethylation-specific decoys designed to have only an A:C mismatch with the amplicon corresponding to the hypermethylated region are provided. Figure 9B The text provides a non-limiting example comparing ss strand-specific bait design (far right) with double-stranded allele-specific bait (second column from the right).

[0062] Figure 10AUp to 10B provides non-limiting examples demonstrating that chain-selective methylation enrichment decoy designs enable further enrichment of data on cancer-related methylation signals. Each figure shows the cancer methylation score determined for the decoy type shown along the x-axis. Figure 10A The middle value represents the high methylation score; Figure 10B (Middle represents low methylation score). Detailed Implementation

[0063] This disclosure generally relates to nucleic acid decoys for selectively enriching methylation signals, and methods for designing and / or manufacturing such decoys. These can be used to enhance the detection of methylation signals, for example, to enhance the detection of methylation signals on CpG dinucleotide clusters known to be associated with diseases or conditions that are hypomethylated or hypermethylated. Therefore, methods for selectively enriching target methylation signals and / or sequencing target methylation signals using decoys are also described herein.

[0064] Previous methylation analysis methods involved calculating the methylation fraction at a specific locus (i.e., the methylation fraction of potential methylation sites, such as the proportion of methylated CpG sites to the total number of CpG sites) and required capturing transformed nucleic acid molecules representing each methylation state (e.g., hypermethylation and hypomethylation). In contrast, the decoys described herein are each designed to capture transformed nucleic acids corresponding to only one methylation state (e.g., only hypermethylation signal or only hypermethylation signal). The decoys described herein can be single-stranded or double-stranded and are designed to selectively hybridize with nucleic acid molecules containing a sequence corresponding to the target methylation pattern at the target genomic locus that has been transformed (e.g., by enzymatic nucleotide conversion or bisulfite nucleotide conversion) to the target nucleic acid pattern. Some decoys of this disclosure can be further designed to form one or more A:C mismatches and / or not form G:T mismatches upon hybridization with off-target nucleic acid molecules. For example, when the single-stranded hypomethylation-specific decoy of this disclosure hybridizes with a nucleic acid molecule containing a sequence corresponding to a hypermethylated allele corresponding to a target genomic locus, it can form one or more A:C mismatches and / or not form G:T mismatches, and when the single-stranded hypermethylation-specific decoy of this disclosure hybridizes with a nucleic acid molecule containing a sequence corresponding to a hypomethylated allele corresponding to a target genomic locus, it can form one or more A:C mismatches and / or not form G:T mismatches.

[0065] When performing target capture after constructing a next-generation sequencing (NGS) library from a cell-free DNA sample (see...) Figure 1For example, the nucleic acid decoys described herein can improve the detection sensitivity of hypomethylation or hypermethylation patterns. This can be, for example, including but not limited to, improving the detection sensitivity of hypomethylation or hypermethylation patterns associated with one or more diseases or conditions, such as treatment selection, treatment response, minimal residual disease (MRD), or early cancer detection methods, or monitoring treatment response to advanced diseases.

[0066] Aberrant methylation is characteristic of many cancers and can be detected in many different types of patient samples, including those containing cfDNA. In particular, detecting rare cancer-driven methylation patterns is a key challenge in cancer screening and minimal residual disease (MRD) monitoring. This disclosure specifically describes methods for detecting aberrant methylation (e.g., DNA methylation in CpG dinucleotide clusters) that effectively reduce background and increase the signal-to-noise ratio, thereby allowing the detection of very low-frequency tumor DNA in otherwise normal DNA samples, which may aid in the early detection and / or monitoring of cancer. The methods described in this disclosure can similarly aid in treatment response monitoring (TRM), for example, by improving the signal-to-noise ratio when tracking the amount of targeted methylation signal in response to treatment. Comprehensive genomic analysis (CGP) may also include data generated according to the methods described herein, such as, for example, data related to targeted methylation signals from, for example, solid tissue samples.

[0067] Compared to other methods, the nucleic acid decoy design described in this paper allows for improved detection sensitivity for hypomethylation or hypermethylation patterns, for example, by allowing the use of fewer reads (i.e., lower sequencing depth) compared to conventional decoy designs and related methods, while also reducing detection costs.

[0068] As described in this article, higher levels of abnormal molecules can be detected more efficiently than previous methods by enriching abnormal molecules from normal molecules in a target capture step prior to sequencing.

[0069] This article describes a decoy set for target capture and methods for designing such a decoy set, enabling allele-specific and / or chain-specific capture of methylation signals from genomic regions containing methylation signals (hypomethylation or hypermethylation) associated with diseases or conditions. Therefore, this article also describes methods for selectively capturing nucleic acid molecules using the decoy sets described herein.

[0070] This document describes various decoy designs. For example, the decoys described herein can be single-stranded or double-stranded, and can be hypomethylation-specific or hypermethylation-specific. Methods for designing decoys of this disclosure may include one or more of the following: i) identifying a target-specific methylation pattern (e.g., a target hypermethylation pattern or a target hypomethylation pattern) at a genomic locus; ii) determining the transformed nucleic acid sequence for each strand (e.g., the positive and negative strands) of the methylation pattern at the genomic locus and its reverse complementary sequence; and iii) designing nucleic acid decoy molecules that selectively hybridize with one or more of the transformed nucleic acid sequences of the methylation pattern at the genomic locus.

[0071] Methods using the decoys of this disclosure (such as, for example, in methods for selectively capturing nucleic acid molecules) may include one or more of the following: i) obtaining a sample of nucleic acid molecules from a subject to query for a target methylation pattern; ii) converting any methylation pattern present in the nucleic acid molecules from the subject into a nucleic acid pattern, such that the methylation pattern initially present in the sample becomes "encoded" or "fixed" as a nucleic acid pattern (allowing the target methylation pattern to be queried as the target nucleic acid pattern); iii) amplifying the converted nucleic acid molecules into an amplicon set; iv) hybridizing the decoy with the amplicon (during which the decoy selectively hybridizes with the target nucleic acid pattern if present); and v) removing nucleic acids that have not hybridized with the decoy. The specific design of the decoys described herein provides improved sensitivity and sequencing efficiency compared to previously available methods. As described herein, this overall scheme can be multiplexed and / or modified in a variety of ways.

[0072] Depending on the disease, condition, and / or genomic locus driving the query, the target methylation pattern may correspond to either a hypermethylation signal or a hypomethylation signal. In some cases, a single genomic locus may be associated with multiple different types of methylation states, depending on the disease or condition (e.g., hypermethylation in one disease but hypomethylation in another; a hypomethylation pattern in one disease but a different hypomethylation pattern in another; a hypermethylation pattern in one disease but a different hypermethylation pattern in another; etc.). However, each decoy or decoy set described herein is designed to enrich only one type of methylation signal: a single hypermethylation signal at a specific locus or a single hypomethylation signal at a specific locus, but not both hypomethylation and hypermethylation signals at the same locus. Therefore, for a decoy set designed to enrich one or more hypermethylation signals, the decoy can be further designed to exclude nucleic acid sequences that hybridize to nucleic acid patterns corresponding to hypomethylation signals at genomic loci. Accordingly, for decoy sets designed to enrich one or more hypomethylation signals, the decoys can be further designed to exclude nucleic acid sequences that hybridize with nucleic acid patterns that correspond to hypermethylation signals at genomic loci.

[0073] As described below, the decoy is a single-stranded or double-stranded nucleic acid molecule. Furthermore, the decoy is classified as "allele-specific" (also described herein as "methyl allele-specific") or "strand-selective" (also described herein as "strand-specific"). The strand-selective decoy discussed herein is single-stranded (and therefore, is also referred to herein synonymously, for example, a single-stranded decoy). The allele-specific decoy discussed herein is double-stranded. Both allele-specific and strand-selective decoys can be designed to enrich for hypermethylation or hypomethylation signals. Therefore, hypermethylation-specific decoys can be either allele-specific or strand-specific, and can be either double-stranded or single-stranded. Similarly, hypomethylation-specific decoys can be either allele-specific or strand-specific, and can be either double-stranded or single-stranded.

[0074] In some cases, nucleic acid decoys are single-stranded. This so-called “single-stranded,” “strand-selective,” or “strand-specific” methylation enrichment decoy design allows for the selective capture and enrichment from a Methyl-seq library of specific strands of DNA molecules (i.e., the strand present in the original sample along the 5' to 3' orientation; for example, the “positive” (+) strand (also called the “sense strand” or “coding strand” if in the context of a gene) or the “negative” (-) strand (i.e., the strand present in the original sample along the 3' to 5' orientation; also called the “antisense strand” or “non-coding strand” if in the context of a gene) containing hypermethylated or hypomethylated signals that can distinguish cancer or other disease samples from healthy samples. Using these single-stranded decoys involves hybridizing the single-stranded nucleic acid decoy with the amplicon set discussed above, such that at least a portion of the resulting hybrid includes a mismatch-free hybridization between: 1) the intact single-stranded nucleic acid decoy and 2) the target nucleic acid pattern.

[0075] In some cases, nucleic acid decoys are double-stranded. This so-called “methyl allele-specific” enrichment decoy design allows for the selective capture and enrichment of alleles with high or low methylation signals from mMethyl-seq libraries. These “allele-specific” double-stranded decoys are conceptually similar to the single-stranded decoys described above, except that they do not distinguish between the + / - DNA strands from the sample: each “allele-specific” decoy contains two strands that separate during the hybridization step, allowing each strand of the double-stranded decoy to hybridize separately with a different nucleic acid strand. The individual strands of the allele-specific decoy are complementary to each other, and each strand remains considered an “allele-specific” decoy upon separation from the complementary decoy strand, such as during and after hybridization with nucleic acid molecules containing the target nucleic acid pattern.

[0076] When using double-stranded decoys for hybridization, there is a greater chance of mismatches between the decoy and the amplicon, meaning that double-stranded decoys have slightly lower specificity than single-stranded decoys. However, as shown in this paper, both versions are improvements over previous decoy designs.

[0077] The method for designing the bait sets described herein represents an improvement over conventional bait designs used in methyl-seq. Conventional bait designs indiscriminately capture methylation signals without selectivity for alleles or chains. The novel bait designs described herein offer greater flexibility and selectivity in capturing both allele- and chain-specific methylation signals, effectively distinguishing between cancer and healthy samples, thereby improving assay sensitivity and reducing costs, for example, in the developing MRD / early cancer diagnostic assays.

[0078] I. General Technology

[0079] The techniques and procedures described or cited herein are generally well understood by those skilled in the art and are typically employed using conventional methodologies, such as those widely used as described in the following references: Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd Edition (2001), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Current Protocols in Molecular Biology (edited by F.M. Usubel et al., (2003)); Methods in Enzymology (Academic Press, Inc.): PCR 2: A Practical Approach (edited by M.J. MacPherson, B.D. Messers, and G.R. Taylor, (1995)), Harlow and Lane (edited by Harlow and Lane, (1988); Antibodies, A Laboratory Manual, and Animal Cell Culture (edited by R.R. Freshney, (1987)); Oligonucleotide Synthesis (edited by M.J. Gait, 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (JECellis, editor, 1998) Academic Press; Animal Cell Culture (RIFreshney), editor, 1987); Introduction to Cell andTissue Culture (JP Mather and PERoberts, 1998) Plenum Press; Cell andTissue Culture: Laboratory Procedures (A. Doyle, JBGriffiths and DGNewell, editors, 1993-8) J. Wiley and Sons; Handbook of Experimental Immunology (DMWeir and CCBlackwell (ed.); Gene Transfer Vectors for Mammalian Cells (JMMiller and MP Calos, ed., 1987); PCR: The Polymerase Chain Reaction (Mullis et al., ed., 1994); Current Protocols in Immunology (JEColigan et al., ed., 1991); Short Protocols in Molecular Biology (Wiley and Sons, 1999); Immunobiology (CAJaneway and P. Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: A Practical Approach (D. Catty., ed., IRL Press, 1988-1989); Monoclonal Antibodies: A Practical Approach (P. Shepherd and C. Dean, ed., Oxford University Press, 2000); Using Antibodies: A Laboratory Manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999); The Antibodies (M. Zanetti and JD Capra, eds., Harwood Academic Publishers, 1995); and Cancer: Principles and Practice of Oncology (VT DeVita et al., eds., JBLippincott Company, 1993).

[0080] II. Definition

[0081] Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains.

[0082] Unless the context clearly indicates otherwise, nouns without quantifiers as used in this specification and the appended claims mean one or more types. Thus, for example, reference to "molecule" optionally includes combinations of two or more such molecules, etc. Unless otherwise stated, any reference to "or" herein is intended to cover "and / or / or".

[0083] The term “abnormal methylation” is used herein to refer to a methylation pattern that is not normally present in the normal epigenetic characteristics of healthy cells. For example, the term may refer to an increase in methylation at sites that are normally not methylated in normal cells / tissues, or a decrease in methylation at sites that are normally methylated in normal cells / tissues. In some embodiments, in a particular type of tissue, abnormal methylation is characterized when the pattern and / or amount of methylation at one or more genomic loci of nucleic acids derived from the sample (e.g., tumor-derived nucleic acids) differs from the pattern and / or amount of methylation normally present at the corresponding one or more loci. As used herein, “abnormal methylation” includes both “hypermethylation” and “hypomethylation.” As used herein, “hypermethylation” refers to an abnormal methylation form in a particular type of tissue where the methylation at one or more genomic loci is increased compared to the methylation normally present at the corresponding one or more loci. As used herein, “hypomethylation” refers to an abnormal methylation form in a particular type of tissue where the methylation at one or more genomic loci is decreased compared to the methylation normally present at the corresponding one or more loci.

[0084] As used herein, the term "about" refers to the typical range of error for various values ​​that is readily known to those skilled in the art. References to "about" values ​​or parameters herein include (and describe) embodiments relating to that value or parameter itself.

[0085] Where a range of values ​​is provided, it should be understood that every intermediate value between the upper and lower limits of the range, as well as any other specified value or intermediate value within the specified range, is included within the scope of this disclosure. Where the specified range includes an upper or lower limit, the range excluding any of the included limits is also included in this disclosure.

[0086] As used herein, “administration” means the method of giving a subject (e.g., a patient) a dose of a compound (e.g., an antagonist) or a pharmaceutical composition (e.g., a pharmaceutical composition containing an antagonist). Administration can be performed by any suitable route, including parenteral, intrapulmonary, and intranasal administration, and, if local treatment is required, intralesional administration. Parenteral infusion includes, for example, intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Administration can be performed by any suitable route, such as by injection, such as intravenous or subcutaneous injection, depending in part on whether the administration is transient or prolonged. Various dosing schedules are considered herein, including but not limited to single or multiple administrations at various time points, bolus administration, and pulsatile infusion.

[0087] The terms “allelic frequency” and “allelic fraction” are used interchangeably in this document and refer to the fraction of a sequence read corresponding to a particular allele relative to the total number of sequence reads for a genomic locus.

[0088] As used herein, “amplification” generally refers to the process of producing multiple copies of the desired sequence. “Multiple copies” means at least two copies. “Copy” does not necessarily mean complete sequence complementarity or identity with the template sequence. For example, copies may include nucleotide analogs, such as deoxyinosine, intentional sequence alterations (e.g., sequence alterations introduced by primers containing sequences that hybridize to but are not complementary to the template), and / or sequence errors that occur during amplification.

[0089] The term “decoy” is used in this document synonymously with “nucleic acid decoy,” “decoy molecule,” and “target capture reagent,” and refers to one or more nucleic acid molecules designed according to the principles described herein for hybridization with a specific target nucleic acid pattern present in a transformed nucleic acid.

[0090] The terms “cancer” and “cancerous” refer to or describe a physiological condition in mammals that is typically characterized by uncontrolled cell growth. This definition includes benign, pre-malignant, and malignant cancers.

[0091] It should be understood that the aspects and embodiments of the invention described herein include “comprising the aspect and embodiments,” “consisting of the aspect and embodiments,” and “substantially consisting of the aspect and embodiments.” As used herein, the terms “comprising” (and any form or variation of “comprising”, such as “comprising multiple” and “comprising one”), “having” (and any form or variation of “having”, such as “having multiple” and “having one”), “including” (and any form or variation of “including”, such as “including multiple” and “including one”), or “containing” (and any form or variation of “containing”, such as “containing multiple” and “containing one”) are inclusive or open-ended and do not exclude additional, undescribed additives, components, integers, elements, or method steps.

[0092] As used herein, the term "simultaneous" refers to the administration of two or more therapeutic agents, wherein at least some of the administration overlaps in time. Therefore, simultaneous administration includes a dosing regimen in which one or more agents are continued after the discontinuation of one or more other agents.

[0093] As used herein, “control sample,” “control cell,” or “control tissue” refers to a sample, cell, tissue, standard, or level used for comparative purposes.

[0094] The term "CpG dinucleotide" is used herein to refer to a region of two or more DNA bases in which a cytosine nucleotide is followed by a guanine nucleotide along the 5'→3' direction, for example, 5'-C-phosphate-G-3'. In many genomes, CpG dinucleotides are often found in "clusters" or DNA regions containing multiple CpG dinucleotides (also known as "CpG islands"). Much or most DNA methylation in many genomes is present in CpG dinucleotides (where cytosine is methylated or hydroxymethylated).

[0095] The term "detection" includes any detection method, including direct and indirect detection.

[0096] The term “diagnosis” is used herein to refer to the identification or classification of a molecular or pathological state, disease, or condition (e.g., cancer). For example, “diagnosis” can refer to the identification of a specific type of cancer. “Diagnosis” can also refer to the classification of a specific cancer subtype, for example by histopathological criteria, or by molecular characteristics (e.g., a subtype characterized by the expression of a biomarker or combination of biomarkers (e.g., a specific gene or the protein encoded by said gene), or by abnormal levels and / or patterns of DNA methylation.

[0097] "Effective dose" refers to the amount of a therapeutic agent used to treat or prevent a disease or ailment in a mammal. In the case of cancer, an effective dose of a therapeutic agent can reduce the number of cancer cells; reduce the size of the primary tumor; inhibit (i.e., to some extent slow down and, in some embodiments, prevent) the invasion of cancer cells into peripheral organs; inhibit (i.e., to some extent slow down and, in some embodiments, prevent) tumor metastasis; inhibit tumor growth to some extent; and / or alleviate one or more symptoms associated with the ailment to some extent. In terms of the extent to which the drug can prevent growth and / or kill existing cancer cells, it can be cytoseptic and / or cytotoxic. For cancer therapies, in vivo efficacy can be measured, for example, by assessing duration of survival, time to disease progression (TTP), response rate (e.g., CR and PR), duration of response, and / or quality of life.

[0098] As used herein, the terms “one genomic locus” and “multiple genomic loci” include nuclear DNA and organelle DNA (such as mitochondrial DNA) present in the subject’s genome, as well as their transcripts and fragments.

[0099] As used herein, the terms “individual,” “patient,” or “subject” are used interchangeably and refer to any single animal requiring treatment, such as a mammal (including non-human animals, such as dogs, cats, horses, rabbits, zoo animals, cattle, pigs, sheep, and non-human primates). In some specific embodiments, the individual, patient, or subject herein is a human being.

[0100] "Individual response" or "response" may be assessed using any endpoint that indicates benefit to the individual, including but not limited to (1) inhibiting disease progression (e.g., cancer progression) to some extent, including slowing or completely blocking it; (2) reducing tumor size; (3) inhibiting (i.e., reducing, slowing or completely stopping) cancer cell infiltration into adjacent organs and / or tissues; (4) inhibiting (i.e., reducing, slowing or completely stopping) metastasis; (5) alleviating one or more symptoms associated with the disease or condition (e.g., cancer) to some extent; (6) increasing or prolonging survival, including overall survival and progression-free survival; and / or (7) reducing mortality at a given time point after treatment.

[0101] As used herein, "oligonucleotide" generally refers to a short, single-stranded polynucleotide with a length of (but not necessarily) less than about 250 nucleotides. Oligonucleotides can be synthetic. The terms "oligonucleotide" and "polynucleotide" are not mutually exclusive. The above description of polynucleotides applies equally and fully to oligonucleotides.

[0102] "Pharmaceutically acceptable carriers" refer to components in a pharmaceutical preparation that are non-toxic to the subjects, excluding the active ingredient. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.

[0103] The term "pharmaceutical formulation" refers to a formulation in which the bioactive ingredient contained therein is in a form in which the activity is effective and which does not contain any additional components that would have unacceptable toxicity to a subject to whom the formulation will be administered.

[0104] As used herein, “polymerase chain reaction” or “PCR” generally refers to a procedure in which trace amounts of specific nucleic acid, RNA, and / or DNA fragments are amplified, as described, for example, in U.S. Patent No. 4,683,195. Generally, sequence information at the ends or further out of the target region is required so that oligonucleotide primers can be designed; these primers are identical or similar in sequence to the opposite strand of the template to be amplified. The 5' terminal nucleotides of both primers may be congruent to the ends of the amplified material. PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genomic DNA, and cDNA transcribed from total cellular RNA, bacteriophage, or plasmid sequences, etc. See generally Mullis et al., Cold Spring Harbor Symp. Quant. Biol. 51:263 (1987) and Erlich, ed., PCR Technology (Stockton Press, New York, 1989). As used in this article, PCR is considered one, but not the only, instance of a nucleic acid polymerase reaction method for amplifying nucleic acid test samples. It includes using known nucleic acids (DNA or RNA) as primers and utilizing nucleic acid polymerases to amplify or generate specific nucleic acid fragments, or amplifying or generating specific nucleic acid fragments complementary to specific nucleic acids.

[0105] The terms “polynucleotide” or “nucleic acid” used interchangeably herein refer to a polymer of nucleotides of any length, including DNA and RNA. Nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and / or their analogues, or any substrate that can be incorporated into the polymer by DNA or RNA polymerases or by a synthetic reaction. Thus, for example, polynucleotides as defined herein include, but are not limited to, single-stranded and double-stranded DNA, DNA including single-stranded and double-stranded regions, single-stranded and double-stranded RNA, and RNA including single-stranded and double-stranded regions, and hybrid molecules comprising DNA and RNA, which may be single-stranded or more typically double-stranded or include single-stranded and double-stranded regions. Additionally, as used herein, the term “polynucleotide” refers to a triple-stranded region comprising RNA or DNA, or both RNA and DNA. The strands in such regions may originate from the same molecule or different molecules. The region may include all or some of the molecules, but more typically only some of the regions. One of the molecules with the triple-stranded region is typically an oligonucleotide. The term “polynucleotide” specifically includes cDNA.

[0106] Polynucleotides can contain modified nucleotides, such as methylated nucleotides and their analogues. If present, the nucleotide structure can be modified before or after polymer assembly. The nucleotide sequence can be broken down by non-nucleotide components. Polynucleotides can be further modified post-synthesized, such as by conjugation with tags. Other types of modifications include, for example, “capping”; replacing one or more naturally occurring nucleotides with analogues; internucleotide modifications, such as those with uncharged linkages (e.g., methylphosphonates, triphosphates, aminophosphates, carbamates, etc.) and those with charged linkages (e.g., thiophosphates, dithiophosphates, etc.); those containing side-hanging moieties (e.g., proteins (e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.)); those with intercalating agents (e.g., acridine, psoralen, etc.); those containing chelating agents (e.g., metals, radioactive metals, boron, oxidizing metals, etc.); those containing alkylating agents; those with modified linkages (e.g., α-anomeric nucleic acids); and unmodified forms of one or more polynucleotides. Furthermore, any of the hydroxyl groups typically present in sugars can be replaced, for example, by phosphonate groups, phosphate groups, protected by standard protecting groups, or activated to prepare additional linkages with additional nucleotides, or can be conjugated to a solid or semi-solid carrier. The OH groups at the 5' and 3' ends can be phosphorylated or partially replaced by amine or organic end-capping groups of 1 to 20 carbon atoms. Other hydroxyl groups can also be derived as standard protecting groups. Polynucleotides can also contain similar forms of ribose or deoxyribose known in the art, including, for example, 2'-O-methyl-, 2'-O-allyl-, 2'-fluoro-, or 2'-azido-ribose, carbocyclic sugar analogs, α-anomeric sugars, epimeric sugars (such as arabinose, xylose, or lythose), pyranoses, furans, sedoheptulose, acyclic analogs, and debased nucleoside analogs (such as methylribonucleosides). One or more phosphodiester bonds can be replaced by alternative linking groups. These alternative linking groups include, but are not limited to, the following embodiments: wherein the phosphate ester is linked by P(O)S (“thioester”), P(S)S (“dithioester”), (O)NR2 (“amid”), P(O)R, P(O)OR', CO, or CH2 (“methylacetal”), wherein each R or R' is independently H or a substituted or unsubstituted alkyl group (1 to 20 Cs), optionally containing an ether (-O-) linker, aryl, alkenyl, cycloalkyl, cycloalkenyl, or aralkyl. Not all links in a polynucleotide need to be identical. Polynucleotides may contain one or more different types of modifications and / or multiple modifications of the same type as described herein. The foregoing description applies to all polynucleotides mentioned herein, including RNA and DNA.

[0107] As used herein, the term "sample" refers to a composition obtained from or derived from a target subject and / or individual that contains, for example, cells and / or other molecular entities to be characterized and / or identified based on physical, biochemical, chemical, and / or physiological characteristics. For example, the phrase "disease sample" and variations thereof refer to any sample obtained from a target subject that is expected or known to contain cells and / or molecular entities to be characterized. Samples include, but are not limited to, tissue samples, primary or cultured cells or cell lines, cell supernatants, cell lysates, platelets, serum, plasma, vitreous fluid, lymph, synovial fluid, follicular fluid, semen, amniotic fluid, milk, whole blood, plasma, serum, blood-derived cells, urine, cerebrospinal fluid, saliva, sputum, tears, sweat, mucus, tumor lysates, and tissue culture media, tissue extracts (such as homogenized tissue), tumor tissue, cell extracts, and combinations thereof. In some cases, the sample is a whole blood sample, plasma sample, serum sample, or a combination thereof. In some embodiments, the sample is derived from a tumor (e.g., "tumor sample"), such as from a biopsy. In some embodiments, the sample is a formalin-fixed, paraffin-embedded (FFPE) sample.

[0108] As used herein, the term "group" refers to one or more groups. As used herein, the term "subgroup" within a subgroup of a group refers to a group smaller than the full "group". Note that, as used herein, "subgroup" is not necessarily synonymous with "part". As used herein, "part" refers to a group less than or equal to the full group.

[0109] As used in this article, the term “subgenomic region” (or “subgenomic sequence region”) refers to a portion of a genome sequence.

[0110] As used herein, the term “subject interval” refers to a subgenomic interval or an expressed subgenomic interval (e.g., a transcribed sequence of a subgenomic interval).

[0111] As used herein, “treatment” (and its grammatical variations, such as “treat” or “treating”) refers to a clinical intervention that attempts to alter the natural course of the disease in the individual being treated, and may be for prevention or during the course of clinicopathological progression. The desired effects of treatment include, but are not limited to, preventing the onset or recurrence of disease, alleviating symptoms, reducing any direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, improving or alleviating the disease state, and mitigating or improving prognosis.

[0112] As used herein, the term “tumor” refers to all proliferative cell growth and proliferation, whether malignant or benign, and all precancerous and cancerous cells and tissues. As mentioned herein, the terms “cancer,” “cancerous,” and “tumor” are not mutually exclusive. These terms refer to the presence of cells exhibiting typical characteristics of cancerous cells, such as uncontrolled proliferation, immortality, metastatic potential, rapid growth and proliferation rate, and certain characteristic morphological features. Cancer cells typically take the form of tumors, but such cells can exist alone in an animal or can be non-tumorigenic cancer cells, such as leukemia cells. These terms include solid tumors, soft tissue tumors, or metastatic lesions. As used herein, “tumor cell” refers to any tumor cell present in a tumor or its sample. Tumor cells can be distinguished from other cells that may be present in a tumor sample, such as stromal cells and tumor-infiltrating immune cells, using methods known in the art and / or described herein.

[0113] As used herein, the terms “variant sequence” or “variant” are used interchangeably and refer to a modified nucleic acid sequence relative to a corresponding “normal” or “wild-type” sequence, such as, for example, a transformed nucleic acid sequence corresponding to an aberrant methylation signal.

[0114] The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described. The description is presented to enable those skilled in the art to make and use the invention, and is provided in the context of the patent application and its claims. Various modifications to the described embodiments will be apparent to those skilled in the art, and the general principles herein can be applied to other embodiments. Therefore, the invention is not intended to be limited to the embodiments shown, but rather to be consistent with the widest scope consistent with the principles and features set forth herein.

[0115] III. DNA Methylation

[0116] DNA methylation is a type of epigenetic modification characterized by the addition of a methyl group to a DNA base, such as the addition of a methyl group to the C-5 position of cytosine. 5-Methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) are two major types of DNA methylation occurring in mammalian genomes and are commonly found in CpG environments (where a cytosine nucleotide is followed by a guanine nucleotide in the linear sequence of bases along its 5'->3' direction). However, other types of methylation, such as 3mC and 4mC, are also possible. Methylation in mammals primarily occurs at CpG sites, but can also occur at lower frequencies at non-CpG sites (e.g., CHG or CHH sites, where H represents A, T, or C).

[0117] During a typical workflow, such as detecting cancer-related methylation signals from MRD / early-stage cancer patient samples ( Figure 1 This creates various Methyl-seq library amplicones, each representing a unique DNA methylation pattern of a particular DNA fragment in the input DNA sample, depending on the methylation status of each CpG site in the original DNA molecule. Figure 5 (China).

[0118] This invention relates to an improved method for detecting the methylation status of target loci.

[0119] A. Targeted methylation mode

[0120] The methylation status of a genomic locus queried using the methods described herein can be referred to as the target methylation pattern at the genomic locus, or simply the target methylation pattern. A target methylation pattern represents the original genomic sequence of nucleic acids in a sample, and the epigenetic methylation status of any or all C residues present in the genomic sequence. Therefore, a target methylation pattern refers to the presence or absence of a methyl group at the C-5 position of cytosine within the original genomic context of the discussed locus in the sample. One or more target methylation patterns can be queried individually or in parallel using the methods described herein.

[0121] A target methylation pattern may include each or any of one or more 3mC, 4mC, 5mC, and / or 5hmC sites. A target methylation pattern may have one or more 5mC sites only. In some embodiments, a target methylation pattern may include methylation of every C residue at the queried genomic locus. Conversely, a target methylation pattern may not contain any methylated residues. For example, in some embodiments, a target methylation pattern may be so hypomethylated as to have no residues methylated in the target methylation pattern compared to a control methylation pattern—that is, according to the methods described herein, the phrase “target methylation pattern” includes, in addition to the presence of any degree of methylation, the absence of methylation at the genomic locus.

[0122] A targeted methylation pattern may include one or more CpG sites. In some embodiments, the targeted methylation pattern includes one CpG site. In some embodiments, the targeted methylation pattern includes more than one CpG site. In some embodiments, the targeted methylation pattern includes two CpG sites. In some embodiments, the targeted methylation pattern includes more than two CpG sites. In some embodiments, the targeted methylation pattern includes three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty CpG sites. In some embodiments, the targeted methylation pattern includes more than twenty CpG sites.

[0123] The target methylation pattern may have one or more non-CpG sites. In some embodiments, the target methylation pattern includes one CHG site. In some embodiments, the target methylation pattern includes more than one CHG site. In some embodiments, the target methylation pattern includes two CHG sites. In some embodiments, the target methylation pattern includes more than two CHG sites. In some embodiments, the target methylation pattern includes three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty CHG sites. In some embodiments, the target methylation pattern includes more than twenty CHG sites.

[0124] In some embodiments, the target methylation pattern includes one CHH site. In some embodiments, the target methylation pattern includes more than one CHH site. In some embodiments, the target methylation pattern includes two CHH sites. In some embodiments, the target methylation pattern includes more than two CHH sites. In some embodiments, the target methylation pattern includes three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty CHH sites. In some embodiments, the target methylation pattern includes more than twenty CHH sites.

[0125] The target methylation pattern can be compared to a different or “control” methylation pattern (e.g., not the target methylation pattern) at the same genomic locus. For example, the target methylation pattern can be compared to a previously known methylation pattern from one or more other samples and / or one or more other subjects. For example, such a previously known “control” methylation pattern may not be known to indicate a disease or condition. It may be known that the “control” methylation pattern does not indicate the specific disease or condition in question. Alternatively, it may be known that the “control” methylation pattern indicates one or more specific diseases or conditions. The target methylation pattern may be considered “abnormal” compared to another methylation pattern (such as any of the different or “control” methylation patterns described above). Conversely, the target methylation pattern may match a “control” methylation pattern and therefore is not abnormal compared to the “control” methylation pattern.

[0126] B. Target methylation signal

[0127] Target nucleic acid patterns are formed through the transformation of nucleic acids as described below. These target methylation patterns correspond to target methylation signals (also referred to herein as methylation features, target methylation features, aberrant methylation states, variant methylation states, variants, etc.). In other words, target methylation signals can be read or inferred from self-unmethylated transformed nucleic acid molecules (or their sequences). Thus, the transformed nucleic acids can emit signals indicating the methylation state of nucleic acid molecules in a subject's sample. Target methylation signals can be either hypermethylated or hypomethylated. One or more target methylation signals can be queried individually or in parallel using the methods described herein, each signal corresponding to a target methylation pattern.

[0128] C. Hypomethylation signaling

[0129] A locus is considered hypomethylated when it exhibits lower methylation at one or more nucleic acid residues than a “control” methylation pattern at the same locus. Therefore, in some embodiments, a target methylation pattern may correspond to a hypomethylation signal. In some embodiments, a hypomethylation signal at a genomic locus may indicate a disease or condition. Therefore, a target methylation pattern may correspond to a hypomethylation signal indicating a disease or condition. For example, in some embodiments, a target methylation pattern may lack one methylated CpG site compared to different methylation patterns at the same genomic locus that do not indicate a specific disease or condition, or compared to different methylation patterns at the same genomic locus that indicate one or more diseases or conditions. In some embodiments, a target methylation pattern may lack more than one methylated CpG site compared to different methylation patterns at the same genomic locus that do not indicate a specific disease or condition, or compared to different methylation patterns at the same genomic locus that indicate one or more diseases or conditions.

[0130] The nucleic acid decoys described in this article, designed to hybridize with target nucleic acid patterns transformed from target methylation patterns corresponding to hypomethylation signals, can be referred to synonymously in various ways, such as, for example, as hypomethylation-specific decoys, hypomethylation-specific nucleic acid decoys, low decoys, or low-decoys. Double-stranded hypomethylation-specific nucleic acid decoys can also be referred to, for example, as low-allele-specific double-stranded decoys or similar names.

[0131] D. Hypermethylation signaling

[0132] A locus is considered hypermethylated when it exhibits higher methylation at one or more nucleic acid residues than a “control” methylation pattern at the same locus. Therefore, in some embodiments, a target methylation pattern may correspond to a hypermethylation signal. In some embodiments, a hypermethylation signal at a genomic locus may indicate a disease or condition. For example, in some embodiments, a target methylation pattern may have another methylated CpG site compared to different methylation patterns at the same genomic locus that do not indicate a specific disease or condition, or a target methylation pattern may have another methylated CpG site compared to different methylation patterns at the same genomic locus that indicate one or more diseases or conditions. Similarly, in some embodiments, a target methylation pattern may have more than one methylated CpG site compared to different methylation patterns at the same genomic locus that do not indicate a specific disease or condition, or a target methylation pattern may have more than one methylated CpG site compared to different methylation patterns at the same genomic locus that indicate one or more diseases or conditions.

[0133] The nucleic acid decoys described in this article, designed to hybridize with target nucleic acid patterns transformed from target methylation patterns corresponding to hypermethylation signals, can be referred to synonymously in various ways, such as, for example, as hypermethylation-specific decoys, hypermethylation-specific nucleic acid decoys, high-decoys, or high-decoys. Double-stranded hypermethylation-specific nucleic acid decoys can also be referred to, for example, as high-allele-specific double-stranded decoys or similar names.

[0134] E. Target Nucleic Acid Model

[0135] During the transformation step discussed below, the target methylation pattern is converted into a target nucleic acid pattern. The target nucleic acid pattern corresponds to a genomic locus, the methylation status of which is queried in the methods described herein. Therefore, the transformed nucleic acid molecule contains a target nucleic acid pattern corresponding to the same genomic locus as the target methylation pattern. Information about the target methylation pattern is embedded in the nucleic acid sequence of the transformed nucleic acid molecule. That is, the original nucleic acid molecule extracted from the subject may contain actual methylated residues. However, during the transformation step, unmethylated cytosine residues are converted to thymine residues, while methylated cytosine residues remain cytosine. This means that the transformed nucleic acid molecule may or may not contain actual methylated residues, but when compared to the known genomic sequence, it still retains information about which residues in the original nucleic acid were methylated and which were not, respectively, in the form of which C4 residues were converted and which C5 residues were not converted. Therefore, the target nucleic acid pattern may correspond to or contain a target methylation signal (also described herein as a methylation feature or target methylation feature), but does not necessarily contain methylated residues. For example, a target nucleic acid pattern may contain or correspond to a hypomethylation feature or a hypermethylation feature (also described in this paper as a hypomethylation signal or a hypermethylation signal, respectively), without actually displaying the methylation pattern itself. In some cases, a target nucleic acid pattern may correspond to two adjacent genomic loci, each containing a different methylation state. For example, a target nucleic acid pattern may contain a sequence corresponding to a hypermethylated genomic locus adjacent to a hypomethylated genomic locus, and vice versa.

[0136] When the target methylation pattern is located at a double-stranded genomic locus (as shown in the figure) Figure 9B The high-methylation and low-methylation target genomic loci shown on the left), when converted into the target nucleic acid pattern, will produce four different nucleic acid strands (see figure for example). Figure 9B Amplicon shown in the second column from the left): (i) Positive strand of the transformed target nucleic acid pattern (in Figure 9B (i) Marked as “(+)”, corresponding to the positive strand of the target genome locus; (ii) the reverse complementary sequence of strand (i) (in) Figure 9B(iii) The negative strand of the transformed target nucleic acid pattern (in the middle marked "(+RC)"); Figure 9B The negative strand of the target genome locus is marked with "(-)"; and the reverse complementary sequence of strand (iii) is also marked with "(-)". Figure 9B (Marked as "(-RC)"). Each strand of the amplicon resulting from the transformation of the target methylation pattern at the genomic locus (e.g., each strand in strands (i)-(iv) listed above) is considered to correspond to the target methylation pattern and to the target genomic locus. Therefore, each nucleic acid resulting from the transformation of the target methylation pattern at the genomic locus is considered to be part of the target nucleic acid pattern. Furthermore, the reverse complementary sequence of each nucleic acid resulting from the transformation of the target methylation pattern at the genomic locus is also considered to be part of the target nucleic acid pattern.

[0137] When the target methylation pattern is located on a single-stranded locus (such as, for example, a locus on 5 mC RNA), conversion to the target nucleic acid pattern will produce two distinct nucleic acid strands: (i) the converted target nucleic acid pattern corresponding to the single-stranded target genomic locus; and (ii) the reverse complementary sequence of strand (i).

[0138] The methods described herein can be used to query one or more target nucleic acid patterns individually or in parallel. For example, if multiple different target methylation patterns are queried in parallel, multiple different target nucleic acid patterns may also exist in the transformed nucleic acid molecule.

[0139] The decoy design described in this article allows for accurate and precise inference of the methylation state of the original nucleic acid molecule from the nucleic acid sequence of the transformed nucleic acid.

[0140] F. Cytosine conversion

[0141] The methylation patterns in nucleic acid molecules from the subject's sample can then be converted into transformed nucleic acids via cytosine conversion (also referred to herein as "nucleotide conversion," "methylation conversion," or simply "conversion"). As part of this conversion, target methylation patterns that may be present in the nucleic acid molecules from the subject's sample are converted into target nucleic acid patterns corresponding to genomic loci. The methylation conversion reaction can include, for example, selectively converting unmethylated (also referred to herein as unmethylated) cytosine residues into uracil residues, or selectively converting methylated cytosine residues into uracil residues. The cytosine residues that have been converted to uracil residues are then further converted into thymine residues, for example, by amplifying the transformed nucleic acid. Therefore, the amplified transformed nucleic acid (containing, for example, thymine residues at positions in the nucleic acid molecule from the subject's sample where, for example, unmethylated cytosine residues are present) can also be referred to as transformed nucleic acids.

[0142] The transformation step translates methylation state, or methylation pattern, into a methylation signal because transformed nucleic acids may not retain actual methylated residues, but they do contain information about the methylation pattern present in the original nucleotide. Therefore, transformed nucleic acids represent methylation states because they contain patterns associated with those states.

[0143] Transformation can be performed using various methods known in the art, such as, for example, bisulfite reactions (see, for example, Li et al. (2011), “DNA Methylation Detection: Bisulfite Genomic Sequencing Analysis”, Methods Mol. Biol. 791:11-21), enzymatic transformation reactions, etc. For example, an enzymatic Methyl-seq kit from New England BioLabs (Ipswich, Massachusetts) can be used to enzymatically deaminize unmethylated cytosine with APOBEC to form uracil. This kit uses deca-undecapodimethylcytosine dioxygenase 2 (TET2) for pretreatment to oxidize 5-mC and 5-hmC, thereby better protecting methylated cytosine from APOBEC deamination. Liu et al. (2019) recently described a bisulfite-free, base-level resolution sequencing method for detecting 5mC and 5hmC, namely TET-assisted pyridineborane sequencing (TAPS). This method combines the deca- and decano-transmethylcytosine dioxygenase (TET)-mediated oxidation of 5mC and 5hmC to 5-carboxycytosine (5caC) and the reduction of 5caC to dihydrouracil (DHU) by pyridine borane. Subsequent PCR amplification converts DHU to thymine, thereby achieving the conversion of methylated cytosine to thymine (Liu et al. (2019), “Bisulfite-Free Direct Detection of 5-Methylcytosine and 5-Hydroxymethylcytosine at Base Resolution”, Nature Biotechnology, Vol. 37, pp. 424-429).In some embodiments, the transformation includes TET-assisted bisulfite treatment, TET-assisted pyridineborane treatment, oxybisulfite treatment, APOBEC treatment, and / or other DNA deaminase treatment (e.g., as described by Vaisvila et al. (2023), “Discovery of novel DNA cytosine deaminase activities enables a nondestructive single-enzyme methylation sequencing method for baseresolution high-coverage methylome mapping of cell-free and ultra-low input DNA”, bioRxiv, 2023.06.29.547047).

[0144] In some embodiments, the conversion includes enzymatic conversion. In some embodiments, the conversion includes bisulfite conversion. In some embodiments, the conversion includes a conversion of cytosine (C) to thymine (T). In some embodiments, the conversion converts unmethylated cytosine residues to thymine residues. In some embodiments, the conversion converts methylated cytosine residues to thymine residues.

[0145] In some embodiments, the conversion transforms unmethylated cytosine residues into uracil residues. In some embodiments, the conversion transforms methylated cytosine residues into uracil residues. In some embodiments, the conversion transforms methylated cytosine residues into dihydrouracil residues. In some embodiments, the conversion transforms unmethylated cytosine residues into dihydrouracil residues.

[0146] Bisulfite conversion or treatment refers to a biochemical process that converts unmethylated cytosine residues into uracil or thymine residues (e.g., deamination to uracil, followed by amplification to thymine during PCR), thereby retaining methylated cytosine residues (e.g., 5-methylcytosine, 5mC; or 5-hydroxymethylcytosine, 5hmC). Reagents for converting cytosine to uracil are known to those skilled in the art and include bisulfite reagents such as sodium bisulfite, potassium bisulfite, ammonium bisulfite, magnesium bisulfite, sodium metabisulfite, potassium metabisulfite, ammonium metabisulfite, magnesium metabisulfite, etc.

[0147] In some embodiments, the method of this disclosure includes treating multiple nucleic acids or nucleic acid fragments of this disclosure with enzymatic digestion and bisulfite treatment. The principle of this method is that DNA fragmentation is achieved not by sonication, but by combined enzymatic digestion with multiple endonucleases (MseI, Tsp509I, NlaIII, and Hpy CH4V), wherein the restriction sites of MseI, Tsp509I, NlaIII, and Hpy CH4V are TTAA, AATT, CATG, and TGCA, respectively. See, for example, Smiraglia DJ et al., Oncogene 2002; 21: 5414-5426. This is followed by, for example, bisulfite treatment as described herein.

[0148] Enzymatic methods for cytosine conversion are also known, such as enzymatic methyl sequencing (EM-seq). Such methods may be advantageous because they employ enzymes rather than bisulfites, which can damage and fragment DNA, leading to DNA loss and potential sequencing bias. For example, TET2 (a deca-dodecanoic translocation (Tet) family 2-methylcytosine dioxygenase) and T4-BGT (T4 phage β-glucosyltransferase) can be used to convert 5mC and 5hmC into products that cannot be deaminated by APOBEC3A (apolipoprotein B mRNA editing enzyme catalyzing polypeptide-like 3A), which is then deaminated using APOBEC3A by converting the unmodified cytosine to uracil. See, for example, Vaisvila, R. et al. (2021) Genome Res.31:1-10.

[0149] In some embodiments, the methods of this disclosure include treating multiple nucleic acids or nucleic acid fragments of this disclosure with TET-assisted bisulfite (e.g., TAB-seq). In the TAB-seq method, a β-glucosyltransferase (βGT) is used to convert 5hmC to β-glucosyl-5-hydroxymethylcytosine (5gmC), and a Tet enzyme (e.g., mTet1) is used to oxidize 5mC to 5-carboxycytosine (5caC). Subsequently, the nucleic acids can be treated with bisulfite. See, for example, Yu, M. et al. (2018) Methods Mol. Biol. 1708:645-663.

[0150] In some embodiments, the methods of this disclosure include treating multiple nucleic acids or nucleic acid fragments of this disclosure with TET-assisted pyridineborane (e.g., TAPS). In the TAPS method, TET methylcytosine dioxygenase is used to oxidize 5mC and 5hmC to 5caC, which is then reduced to dihydrouracil (DHU) via pyridineborane. DHU is converted to thymine during subsequent PCR. See, for example, Liu, Y. et al. (2019) Nat. Biotechnol. 37:424-429.

[0151] In some embodiments, the methods of this disclosure include treating multiple nucleic acids or nucleic acid fragments of this disclosure with bisulfite (e.g., oxBS). In the oxBS method, 5hmC is oxidized to 5-formylcytosine (5fC), which can be converted to uracil by the action of bisulfite. The sequencing results treated with bisulfite and oxBS can then be used to infer the 5hmC level from 5mC. See, for example, Booth, MJ et al. (2013) Nat. Protocols 8:1841-1851. This method can be extended at the genome-wide level in oxBS-seq; see, for example, Kirschner, K. et al. (2018) Methods Mol. Biol. 1708:665-678.

[0152] In some embodiments, the methods of this disclosure include treating a plurality of nucleic acids or nucleic acid fragments of this disclosure with APOBEC. Enzymatic reagents for converting cytosine to uracil, i.e., cytosine deaminases, include those of the APOBEC family, such as APOBEC-seq or APOBEC3A. Members of the APOBEC family are cytidine deaminases that convert cytosine to uracil while retaining 5-methylcytosine, i.e., without altering 5-methylcytosine. Such enzymes are described in US2013 / 0244237 and WO2018165366 and are commercially available (see, for example, NEBNext® Enzymatic Methyl-seq Kit, New England Biolabs). Non-restricted examples of APOBEC family proteins include APOBEC1, APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D, APOBEC3F, APOBEC3G, APOBEC3H, APOBEC4, and activation-induced (cytidine) deaminases.

[0153] G. Associated with disease or condition

[0154] Target methylation patterns can indicate or be associated with a disease or condition. Similarly, target methylation patterns can correspond to methylation signals (e.g., hypermethylation or hypomethylation signals) that indicate or are associated with a disease or condition (e.g., cancer). For example, a target methylation pattern can be a biomarker of a disease or condition, such as a cancer biomarker. A disease or condition can be any disease or condition known to be associated with at least one hypermethylation pattern and / or at least one hypomethylation pattern. Therefore, the presence of a disease or condition in a subject can be indicated or associated with at least one hypomethylation signal and / or at least one hypermethylation signal. In some embodiments, hypermethylation signals at genomic loci indicate a disease or condition. In some embodiments, hypomethylation signals at genomic loci indicate a disease or condition.

[0155] Exemplary diseases or conditions include, but are not limited to, cancer, hereditary conditions (such as, for example, Down syndrome and Fragile X syndrome), neurological disorders, or any other type of disease in which the detection of abnormal methylation states (e.g., one or more hypomethylation signals and / or one or more hypermethylation signals) is associated with the diagnosis, treatment, or prediction of the disease. For example, in some embodiments, the disease or condition includes tissue-specific markers, cancer, autoimmune diseases, infectious diseases, and / or the state of transplanted tissues or organs. In some embodiments, the disease or condition is a tissue-specific marker, cancer, an autoimmune disease, or a combination thereof. In some embodiments, the disease or condition is cancer.

[0156] In some embodiments, a condition can be a susceptibility to developing a disease or condition, such as a genetic susceptibility, or can indicate the likelihood of developing a disease or condition. For example, in some embodiments, a condition is the risk of developing cancer, or is associated with the risk of developing cancer. In some embodiments, a condition can be a genetic susceptibility to cancer (e.g., having a genetic mutation that increases their baseline risk of developing cancer). In some embodiments, a condition is the progression and / or recurrence of a disease or condition, such as, for example, the progression or recurrence of cancer or a tumor.

[0157] In some embodiments, the disease or condition is a hyperproliferative disease. In some embodiments, the hyperproliferative disease is cancer. In some embodiments, the cancer is a solid tumor or its metastatic form. In some embodiments, the cancer is a hematologic cancer, such as leukemia or lymphoma. In some embodiments, the disease or condition is not a hyperproliferative disease.

[0158] In some embodiments, the same methylation pattern may indicate or be associated with multiple different diseases or conditions. In some embodiments, multiple different methylation patterns may be associated with the same disease or condition.

[0159] In some embodiments, the methylation patterns described herein can be used as prognostic or diagnostic indicators associated with a sample. For example, in some cases, prognostic or diagnostic indicators may include indicators of the presence of a disease (e.g., cancer) in the sample, indicators of the probability of the presence of a disease (e.g., cancer) in the sample, indicators of the probability (i.e., risk factors) that a subject from which the sample originates will develop a disease (e.g., cancer), or indicators of the likelihood that a subject from which the sample originates will respond to a particular therapy or treatment.

[0160] In some embodiments, as described herein, a target methylation pattern associated with a hypermethylation or hypomethylation signal indicates responsiveness to treatment, such as, for example, cancer treatment. In some embodiments where a subject has cancer and the target methylation pattern is associated with a hypermethylation or hypomethylation signal indicating responsiveness to cancer treatment, the method described herein may further include predicting a subject's responsiveness to cancer treatment based at least in part on the presence or absence of a target methylation signal, such as a hypermethylation or hypomethylation signal at a locus known to be associated with responsiveness to treatment.

[0161] In some embodiments, the disease or condition is cancer. Many cancers exhibit severe epigenetic dysregulation, resulting in aberrant DNA methylation patterns, including hypermethylation and hypomethylation, which are distinctly different from healthy samples. These characteristics can be used to develop NGS-based cancer diagnostic assays for methylation analysis (Methyl-seq). Aberrant methylation is widespread in cancer and can be detected in many different types of patient samples, including those containing cfDNA. Detecting rare cancer-driving patterns is a key challenge for many liquid biopsy applications, including, for example, the detection and monitoring of minimal residual disease (MRD) and treatment response assays (TRM). Furthermore, epigenetic data can be an important component of comprehensive omics-level analysis of a subject or a group of subjects. Therefore, data generated according to the methods described herein can be included in comprehensive genome-wide analysis (CGP).

[0162] Some methylation patterns in cancer are associated with or predict a response to a particular treatment regimen or disease management strategy. For example, in glioblastoma, promoter methylation in the gene MGMT has been associated with better outcomes (Lalezari et al. (2013) Neuro Oncol 15:370-381). Methylation-based studies may lead to the discovery of new predictive biomarkers to guide therapy and drug development. Many patients with advanced cancer have high levels of cancer signaling in their cfDNA; however, some patients have low levels of cancer signaling in their cfDNA and can benefit from ultrasensitive detection of methylation levels, such as those described in this article. Furthermore, significantly reduced cancer signaling has been observed in serial cfDNA samples from patients with advanced cancer who have responded best to treatment (chemotherapy, immunotherapy, targeted therapy, or certain combinations) just weeks after treatment (see, for example, Davis, AA et al. (2020) Mol. Cancer Ther. 19:1486-1496; Hrebien, S. et al. (2019) Ann. Oncol. 30:945-952). Ultrasensitive detection of methylation levels may be useful, for example, for continuous monitoring of this patient subgroup and early detection of relapse.

[0163] Exemplary cancers include, but are not limited to: B-cell cancer (e.g., multiple myeloma), melanoma, breast cancer, lung cancer (such as non-small cell lung cancer or NSCLC), bronchial cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine or endometrial cancer, oral or pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, bile duct cancer, small intestine or appendix cancer, salivary gland cancer, thyroid cancer, adrenal cancer, osteosarcoma, chondrosarcoma, hematologic malignancies, adenocarcinoma, and inflammatory myofibroblastic tumors. Viagra cell tumor, gastrointestinal stromal tumor (GIST), colon cancer, multiple myeloma (MM), myelodysplastic syndrome (MDS), myelodysplastic disorder (MPD), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia vera, Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), soft tissue sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, osteoblastoma Sarcoma, chordoma, angiosarcoma, endothelial sarcoma, lymphangiosarcoma, lymphangioendothelial sarcoma, synovoma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, bladder cancer, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ventricular septum Hemangioma, pineal tumor, angioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, hepatocellular carcinoma, thyroid cancer, gastric cancer, head and neck cancer, small cell carcinoma, primary thrombocytosis, myeloid metaplasia of unknown cause, hypereosinophilic syndrome, systemic mastocytosis, common hypereosinophilic syndrome, chronic eosinophilic leukemia, neuroendocrine carcinoma, carcinoid tumor, etc.

[0164] In some embodiments of any of the methods provided herein, the cancer is carcinoma, sarcoma, lymphoma, leukemia, myeloma, germ cell carcinoma, or germ cell tumor. In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is a hematologic malignancy. In some embodiments, the cancer is B. Cellular cancer, melanoma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, bladder cancer, brain cancer, central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine cancer, endometrial cancer, oral cancer, pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, bile duct cancer, small intestine cancer, appendix cancer, salivary gland cancer, thyroid cancer, adrenal cancer, osteosarcoma, chondrosarcoma, hematologic malignancies, adenocarcinoma, inflammatory myofibroblastic tumor, gastrointestinal stromal tumor (GIST), colon cancer, multiple myeloma (MM), myelodysplastic syndrome (MDS), myeloproliferative disorders (MPD), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), erythroblastoma. Polycythemia vera, Hodgkin's lymphoma, non-Hodgkin's lymphoma (NHL), soft tissue sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, osteosarcoma, chordoma, angiosarcoma, endothelial sarcoma, lymphangiosarcoma, lymphangioendothelial sarcoma, synovoma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, medullary carcinoma, bronchial carcinoma, renal cell carcinoma, liver cancer, bile carcinoma, ductal carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, bladder cancer, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pineal tumor, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, follicular lymphoma, diffuse large B-cell lymphoma Mantle cell lymphoma, hepatocellular carcinoma, thyroid cancer, gastric cancer, head and neck cancer, small cell carcinoma, primary thrombocytosis, idiopathic myelomecosis, eosinophilic syndrome, systemic mastocytosis, common eosinophilia, chronic eosinophilic leukemia, neuroendocrine carcinoma or carcinoid tumor.

[0165] In some embodiments, the cancers are appendiceal adenocarcinoma, bladder adenocarcinoma, bladder urothelial (transitional cell) carcinoma, nonspecific breast cancer (NOS), breast cancer NOS, invasive ductal carcinoma (IDC) of the breast, invasive lobular carcinoma (ILC) of the breast, cervical squamous cell carcinoma (SCC), colonic adenocarcinoma (CRC), esophageal adenocarcinoma, esophageal cancer NOS, esophageal squamous cell carcinoma (SCC), intraocular melanoma, gallbladder adenocarcinoma, gastroesophageal junction adenocarcinoma, intrahepatic bile duct carcinoma, renal cancer NOS, hepatocellular carcinoma (HCC), lung cancer NOS, lung adenocarcinoma, large cell lung cancer, and non-small cell lung cancer (NSCLC). NOS, small cell undifferentiated carcinoma of the lung, squamous cell carcinoma of the lung (SCC), ovarian cancer NOS, pancreatic cancer NOS, pancreatic ductal adenocarcinoma, pancreatocholangiocarcinoma, prostate cancer NOS, prostate acinar adenocarcinoma, prostate ductal adenocarcinoma, rectal adenocarcinoma (CRC), skin melanoma, small intestinal adenocarcinoma, soft tissue sarcoma NOS, gastric adenocarcinoma NOS, unknown primary cancer NOS, unknown primary adenocarcinoma, unknown primary cancer (CUP) NOS, unknown primary neuroendocrine tumor, unknown primary squamous cell carcinoma (SCC) or endometrial adenocarcinoma NOS.

[0166] In some instances, cancers include acute lymphoblastic leukemia (Philadelphia chromosome positive), acute lymphoblastic leukemia (progenitor B cell), acute myeloid leukemia (FLT3+), acute myeloid leukemia (with IDH2 mutation), anaplastic large cell lymphoma, basal cell malignant epithelial tumor, B-cell chronic lymphocytic leukemia, bladder cancer, breast cancer (HER2 overexpression / amplification), breast cancer (HER2+), breast cancer (HR+, HER2-), cervical cancer, cholangiocarcinoma, chronic lymphocytic leukemia, chronic lymphocytic leukemia (17p deletion), chronic myeloid leukemia, chronic myeloid leukemia (Philadelphia chromosome positive), classical Hodgkin lymphoma, colorectal cancer, colorectal cancer (dMMR and MSI-H), colorectal cancer (KRAS wild-type), cryopyridine-associated periodic syndrome, cutaneous T-cell lymphoma, dermatofibrosarcoma protuberans, diffuse large B-cell lymphoma, fallopian tube cancer, follicular B-cell lymphoma. Cellular non-Hodgkin lymphoma, follicular lymphoma, gastric cancer, gastric cancer (HER2+), gastroesophageal junction (GEJ) adenocarcinoma, gastrointestinal stromal tumor, gastrointestinal stromal tumor (KIT+), giant cell tumor of bone, glioblastoma, granulomatous polyangiitis, squamous cell malignant epithelial tumor of the head and neck, hepatocellular malignant epithelial tumor, Hodgkin lymphoma, juvenile idiopathic arthritis, lupus erythematosus, mantle cell lymphoma, medullary thyroid carcinoma, melanoma, melanoma with BRAF V600 mutation, melanoma with BRAF V600E or V600K mutation, Merkel cell malignant epithelial tumor, multicentric Castleman's disease, multiple hematologic malignancies (including Philadelphia chromosome-positive ALL). (and CML), multiple myeloma, myelofibrosis, non-Hodgkin's lymphoma, unresectable subependymal giant cell astrocytoma associated with tuberous sclerosis, non-small cell lung cancer, non-small cell lung cancer (ALK+), non-small cell lung cancer (PD-L1+), non-small cell lung cancer (with ALK fusion or ROS1 gene alteration), non-small cell lung cancer (with BRAF V600E mutation).Non-small cell lung cancer (with EGFR exon 19 deletion or exon 21 substitution (L858R) mutation), non-small cell lung cancer (with EGFR T790M mutation), ovarian cancer, ovarian cancer (with BRCA mutation), pancreatic cancer, pancreatic neuroendocrine tumor, gastrointestinal neuroendocrine tumor or pulmonary neuroendocrine tumor, childhood neuroblastoma, peripheral T-cell lymphoma, peritoneal cancer, prostate cancer, malignant renal cell carcinoma, rheumatoid arthritis, small lymphocytic lymphoma, soft tissue sarcoma, solid tumor (MSI-H / dMMR), head and neck squamous cell carcinoma, squamous non-small cell lung cancer, thyroid cancer, malignant thyroid epithelial tumor, urothelial carcinoma, malignant urothelial epithelial tumor, or Waldenström macroglobulinemia. In some embodiments, the cancer is glioblastoma, breast cancer, bladder cancer, cervical cancer, colorectal cancer, hepatocellular carcinoma, lung cancer, ovarian cancer, esophageal cancer, pancreatic cancer, gastric cancer or prostate cancer. ,

[0167] In some cases, cancer is a blood malignancy (or precancerous lesion). As used in this article, a blood malignancy refers to a tumor of the hematopoietic or lymphatic tissues, such as a tumor affecting the blood, bone marrow, or lymph nodes. Exemplary hematologic malignancies include, but are not limited to, leukemia (e.g., acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), hairy cell leukemia, acute monocytic leukemia (AMoL), chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), or large granular lymphocytic leukemia), lymphoma (e.g., AIDS-related lymphoma, cutaneous T-cell lymphoma, Hodgkin lymphoma (e.g., classical Hodgkin lymphoma or nodular predominantly Hodgkin lymphoma), mycosis fungoides, non-Hodgkin lymphoma (e.g., B-cell non-Hodgkin lymphoma (e.g., Burkitt lymphoma, small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma)). Cellular lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B lymphoblastic lymphoma or mantle cell lymphoma) or T-cell non-Hodgkin lymphoma (mycosis fungoides, anaplastic large cell lymphoma or precursor T lymphoblastic lymphoma)), primary central nervous system lymphoma, Sézary syndrome, Waldenström macroglobulinemia), chronic myeloproliferative neoplasm, Langerhans cell histiocytosis, multiple myeloma / plasma cell tumor, myelodysplastic syndrome or myelodysplastic / myeloproliferative neoplasm.

[0168] In some embodiments, the disease or condition may be associated with one or more variants of one or more of the following genes: ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, ALOX12B, AMER1, APC, AR, ARAF, ARFRP1, ARID1A, ASXL1, ATM, ATR, ATRX, AURKA, AURKB, AXIN1, AXL, BAP1, BARD1, BCL2, BCL2L1, BCL2L2, BCL6, BCOR, BCORL1, BCR, BRAF, BRCA1, BRCA2, BRD4, BRIP1, BTG1, BTG2, BTK, CALR, CARD11, CASP8, CBF B. CBL, CCND1, CCND2, CCND3, CCNE1, CD22, CD274, CD70, CD74, CD79A, CD79B, CDC73, CDH1, CDK12, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEB PA, CHEK1, CHEK2, CIC, CREBBP, CRKL, CSF1R, CSF3R, CTCF, CTNNA1, CTNNB1, CUL3, CUL4A, CXCR4, CYP17A1, DAXX, DDR1, DDR2, DIS3, DNMT3A, DOT1L, EED, EGFR, EMSY (C11orf30), ​​EP300, EPHA3, EPHB1, EPHB4, ERBB2, ERBB3, ERBB4, ERCC4, ERG, ERRFI1, ESR1, ETV4, ETV5, ETV6, EWSR1, EZH2, EZR, FAM46C, FANCA, FANCC, FANCG, FANCL, F AS, FBXW7, FGF10, FGF12, FGF14, FGF19, FGF23, FGF3, FGF4, FGF6, FGFR1, FGFR2, FGFR3, FGFR4, FH, FLCN, FLT1, FLT3, FOXL2, FUBP1, GABRA6, GATA3, GATA4, GATA6, GID4(C17orf39), GNA11, GNA13, GNAQ, GNAS, GRM3, GSK3B, H3F3A, HDAC1, HGF, HNF1A, HRAS, HSD3B1, ID3, ID3, IDH, IDH12 KBKE、IKZF1、INPP4B、IRF2、IRF4、IRS2、JAK1、JAK2、JAK3、JUN、KDM5A、KDM5C、KDM6A、KDR、KEAP1、KELKLKL26 (MLL)、KMT2D(MLL2), KRAS, LTK, LYN, MAF, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAP3K13, MAPK1, MCL1, MDM2, MDM4, MED12, MEF2B, MEN1, MERTK, MET, MIT F, MKNK1, MLH1, MPL, MRE11A, MSH2, MSH3, MSH6, MST1R, MTAP, MTOR, MUTYH, MYB, MYC, MYCL, MYCN, MYD88, NBN, NF1, NF2, NFE2L2, NFKBIA, NKX2-1, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, NT5C2, NTRK1, NTRK2, NTRK3, NUTM1, P2RY8, PALB2, PARK2, PARP1, PARP2, PARP3, PAX5, PB RM1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PDK1, PIK3C2B, PIK3C2G, PIK3CA, PIK3CB, PIK3R1, PIM1, PMS2, POLD1, POLE, PPARG, PPP2R1A, P PP2R2A, PRDM1, PRKAR1A, PRKCI, PTCH1, PTEN, PTPN11, PTPRO, QKI, RAC1, RAD21, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RAF1, RARA, RB1, RBM10, REL, RET, RICTOR, RNF43, ROS1, RPTOR, RSPO2, SDC4, SDHA, SDHB, SDHC, SDHD, SETD2, SF3B1, SGK1, SLC34A2, SMAD2, SM AD4, SMARCA4, SMARCB1, SMO, SNCAIP, SOCS1, SOX2, SOX9, SPEN, SPOP, SRC, STAG2, STAT3, STK11, SUFU, SYK, TBX3, TEK, TERC, TERT, TET2, TGFBR2, TIPARP, TMPRSS2, TNFAIP3, TNFRSF14, TP53, TSC1, TSC2, TYRO3, U2AF1, VEGFA, VHL, WHSC1, WHSC1L1, WT1, XPO1, XRCC2, ZNF217 or ZNF703 loci or any combination thereof.

[0169] In some embodiments, the disease or condition may be associated with one or more variants of one or more of the following genes: ABL, ALK, ALL, B4GALNT1, BAFF, BCL2, BRAF, BRCA, BTK, CD19, CD20, CD3, CD30, CD319, CD38, CD52, CDK4, CDK6, CML, CRACC, CS1, CTLA-4, dMMR, EGFR, ERBB1, ERBB2, FGFR1-3. FLT3, GD2, HDAC, HER1, HER2, HR, IDH2, IL-1β, IL-6, IL-6R, JAK1, JAK2, JAK3, KIT, KRAS, MEK, MET, MSI-H, mTOR, PARP, PD-1, PDGFR, PDGFRα, PDGFRβ, PD-L1, PI3Kδ, PIGF, PTCH, RAF, RANKL, RET, ROS1, SLAMF7, VEGF, VEGFA, or VEGFB loci or any combination thereof.

[0170] In some cases, the disclosed methods for selectively capturing nucleic acid molecules can be used to select subjects (e.g., patients) for clinical trials based on methylation status detected at one or more loci (e.g., CpG sites). In some cases, patient selection for clinical trials based on the identification of aberrant methylation at, for example, one or more loci can accelerate the progress of targeted therapies and improve healthcare outcomes for treatment decisions.

[0171] IV. Decoy Design

[0172] This disclosure describes double-stranded and / or single-stranded nucleic acid decoys designed according to the principles described herein. As described herein, the decoys are designed to contain a target-specific capture sequence that selectively hybridizes with a nucleic acid sequence corresponding to only one methylation state (e.g., hypermethylation signal only or hypermethylation signal only) at a genomic locus, such that a given decoy designed according to the principles described herein, whether single-stranded or double-stranded, is designed to be specific to both genomic loci and methylation states. Thus, only one methylation state (hypermethylation only or hypomethylation only) is queried at each locus at a time, although multiple loci can be queried in parallel. Therefore, a suitable target genomic locus contains one or more potential methylation sites. Furthermore, once nucleotide transformation occurs, a suitable hypermethylated target genomic locus produces a transformed nucleic acid sequence that is not identical to the transformed nucleic acid sequence produced by the hypomethylated version of the same genomic locus. Similarly, a suitable hypomethylated target genomic locus produces a transformed nucleic acid sequence that is not identical to the transformed nucleic acid sequence produced by the hypermethylated version of the same genomic locus.

[0173] The methods described herein involve at least one nucleic acid decoy designed according to the principles described herein. The exact nucleotide sequence of the nucleic acid decoy (whether designed to be hypomethylation-specific or hypermethylation-specific, and whether single-stranded or double-stranded) depends on the sequence of the genomic locus being queried, such that at least a portion of the decoy selectively hybridizes with the target nucleic acid pattern. Furthermore, the decoys of the present invention can be modified and / or extended, for example, beyond the region that selectively hybridizes with the target nucleic acid pattern, as described in subsequent sections herein.

[0174] A decoy molecule is considered to selectively hybridize with a given nucleic acid molecule when at least one target-specific capture sequence of the decoy hybridizes without mismatch along the length of the target locus for which the decoy is designed (i.e., it is perfectly complementary along the length of the target nucleic acid pattern). For example, if a decoy is designed with a 100 bp target-specific capture sequence corresponding to a 100 bp target nucleic acid pattern, then the decoy selectively hybridizes with the nucleic acid molecule when the entire 100 bp of the decoy's target-specific capture sequence hybridizes without mismatch. A decoy molecule is considered to selectively hybridize with a given nucleic acid molecule when the mismatch ratio of its hybridization with the decoy is less than the mismatch ratio of its hybridization with a non-target nucleic acid molecule. For example, for a hypomethylation-specific decoy, the decoy is considered to selectively hybridize with a nucleic acid molecule when the mismatch ratio of its hybridization with the nucleic acid molecule is less than the mismatch ratio of its hybridization with a nucleic acid molecule corresponding to a hypermethylation pattern at the same genomic locus. Accordingly, when the mismatch ratio of hybridization between a high methylation-specific decoy and a nucleic acid molecule is less than the mismatch ratio of hybridization between a nucleic acid molecule with a low methylation pattern corresponding to the same genomic locus, it can be considered that the decoy selectively hybridizes with that nucleic acid molecule.

[0175] When at least one decoy molecule in a decoy set selectively hybridizes with a given nucleic acid molecule, the decoy set can be considered to selectively hybridize with that nucleic acid molecule. Therefore, for example, as described above, when at least one target-specific capture sequence of at least one decoy molecule in a decoy set hybridizes with a given nucleic acid molecule without mismatch in length at the target locus designed for it, or with fewer mismatches compared to off-target sequences, the decoy set can be considered to selectively hybridize with that given nucleic acid molecule.

[0176] Decoys that selectively hybridize with nucleic acid sequences, at least under stringent washing conditions, will not effectively hybridize with other sequences (such as non-target sequences). Therefore, non-selective hybridization events can be washed away in washing steps, such as those described herein. For example, a nucleic acid decoy that selectively hybridizes with a target nucleic acid pattern containing a high methylation signature at a genomic locus will not hybridize with nucleic acid patterns containing a low methylation signature or “normal” methylation signature at the same genomic locus, or will only hybridize at a lower melting temperature (Tm). Similarly, a nucleic acid decoy that selectively hybridizes with a target nucleic acid pattern containing a low methylation signature at a genomic locus will not hybridize with nucleic acid patterns containing a high methylation signature or “normal” methylation signature at the same genomic locus, or will only hybridize at a lower melting temperature (Tm).

[0177] In some embodiments, the hybrid will contain a target nucleic acid pattern and a decoy, wherein the target nucleic acid pattern perfectly hybridizes with all or part of the decoy such that there are no mismatched residues within the hybridization region. For example, a hybrid containing perfect hybridization between the decoy and the target nucleic acid pattern will have complementary (e.g., A:T and G:C) pairings along its entire length any portion of the decoy designed to be complementary to the target nucleic acid and any portion of the target nucleic acid intended to be captured by the decoy, and there will be no protrusions or any mismatched bases. However, in some embodiments, other sequences may hybridize and contain one or more mismatched nucleic acids. For example, if a hybridization region exists that is not between the decoy and the corresponding target nucleic acid pattern, that region may contain one or more mismatches.

[0178] The decoys associated with the methods described herein can be "allele-specific" (also described herein as "methyl allele-specific") nucleic acid decoys or "strand-specific" (also described herein as "single-strand" and "strand-selective") nucleic acid decoys. Unlike conventional decoys, each of the decoys described herein is designed to hybridize with a nucleotide-transformed version of a specific target methylation pattern: a target hypermethylation pattern or a target hypomethylation pattern, but not with both a target hypomethylation pattern and a target hypomethylation pattern. In other words, each decoy is designed to hybridize with the target nucleic acid pattern described herein.

[0179] When a decoy is designed to hybridize with a target nucleic acid pattern in a nucleic acid molecule transformed from a target methylation pattern corresponding to a hypermethylation signal, the decoy can be called, for example, a hypermethylation-specific decoy. Conversely, when a decoy is designed to hybridize with a target nucleic acid pattern in a nucleic acid molecule transformed from a target methylation pattern corresponding to a hypomethylation signal, the decoy can be called, for example, a hypomethylation-specific decoy. Therefore, a hypermethylation-specific allele-specific decoy will hybridize with the transformed nucleic acid of either strand corresponding to a hypermethylated allele at a target genomic locus; correspondingly, a hypomethylation-specific allele-specific decoy will hybridize with the transformed nucleic acid of either strand corresponding to a hypomethylated allele at a target genomic locus. However, the hypermethylation-specific chain decoy hybridizes only with transformed nucleic acids corresponding to the amplicon strand of the hypermethylated allele at the target genomic locus (e.g., corresponding to one of the following: the + strand of the + amplicon corresponding to the + strand of the + amplicon; the reverse complementary sequence (RC) of the + strand of the + amplicon; the - strand of the - amplicon corresponding to the - strand of the - amplicon at the hypermethylated genomic locus; or the RC of the - strand of the - amplicon). Conversely, the hypomethylation-specific chain decoy hybridizes only with transformed nucleic acids corresponding to the amplicon strand of the hypomethylated allele at the target genomic locus (e.g., corresponding to one of the following: the + strand of the + amplicon corresponding to the + strand of the + amplicon; the reverse complementary sequence (RC) of the + strand of the + amplicon; the - strand of the - amplicon corresponding to the - strand of the - amplicon at the hypomethylated genomic locus; or the RC of the - strand of the - amplicon).

[0180] A. Design principles of allele-specific baits

[0181] The allele-specific methyl enrichment decoys described herein enhance the detection of methylation signals (e.g., hypermethylation or hypomethylation) associated with diseases or conditions such as cancer. Current methods for detecting minimal residual disease (MRD) / early cancer based on the detection of cancer-related methylation signals have low sensitivity. As described herein, cancer-related methylation signals can be selectively enriched by using allele-specific methyl enrichment decoys, for example, in target capture followed by next-generation sequencing (NGS). These allele-specific decoys improve the sensitivity of MRD / early cancer detection assays by enhancing the detection of cancer-related methylation signals from cfDNA samples from MRD / early cancer patients, although the decoys described herein are not limited to MRD applications. For example, the decoys described herein can also be used for applications such as, at least, TRM / advanced cancer patient ctDNA samples and / or as part of a comprehensive genome-wide analysis (CGP).

[0182] Current methods for detecting cancer-related methylation signals from MRD / early-stage cancer patient samples employ workflows such as starting with cfDNA samples, followed by end repair and adaptor ligation, cytosine transformation, library PCR, target capture, sequencing, determination of cancer hypermethylation and / or hypomethylation scores, and finally, cancer identity retrieval and tumor score determination. Figure 1 During methyl-seq library construction, cytosine transformation and library PCR steps can produce variations in the library sequence depending on the methylation status of the original DNA molecules in the sample. For example, methylation of cytosine in the CpG environment of the original DNA molecules from the sample can protect cytosine bases from transformation and maintain their identity in NGS sequencing; unmethylated cytosine in the CpG or CH environment (where H is any base other than G) is converted to uracil and subsequently sequenced as thymine bases in NGS sequencing.

[0183] Traditional targeted methylation sequencing involves capturing both hypermethylated and hypomethylated DNA fragments from a given genomic locus with similar efficiencies. In conventional methods, for the same genomic region, decoys designed to match transformed hypermethylated sequences and decoys designed to match transformed hypomethylated sequences are mixed in a hybridization reaction. In contrast, the single allele-specific decoy set described herein is either hypomethylation-specific or hypermethylation-specific, such that decoys in a single decoy set selectively hybridize with target nucleic acid patterns transformed from target methylation patterns corresponding to hypomethylation signals or target methylation patterns corresponding to hypermethylation signals, respectively, but not with either.

[0184] The allele-specific baits described in this article are double-stranded, for example, Figure 9B The Fold-80 base penalty in [the study / analysis] was measured. Therefore, allele-specific bait sets, as described herein, contain an even number of strands. Figure 9B As shown in the column labeled "Methyl allele-specific bait", an allele-specific bait set designed for a target methylation pattern (hypermethylation-specific bait or hypomethylation-specific bait) at a double-stranded genomic locus can, for example, contain the following four different sequences for hybridization with the amplicon (i.e., four different target-specific capture sequences in the same bait set): (i) a strand containing a sequence corresponding to the positive strand of the transformed target nucleic acid pattern (in Figure 9B (i) Marked as “(+)”); (ii) The reverse complementary sequence of chain (i) (in Figure 9B(iii) A strand containing a sequence of the negative strand corresponding to the transformed target nucleic acid pattern (in the middle marked "(+RC)"); Figure 9B (i) marked as “(-)”); and (iv) the reverse complementary sequence of chain (iii) (in Figure 9B The symbol “(-RC)” indicates that hybridization with an allele-specific bait set may include hybridization with, for example, a bait containing four different sequences to hybridize with the target nucleic acid pattern. Therefore, each of the four sequences (i)-(iv) listed above is designed to hybridize without mismatch with the amplicon sequence corresponding to the target (i.e., one of the four strands of the target nucleic acid pattern). The bait set can be said to selectively hybridize with the target nucleic acid pattern when at least one of the sequences (i)-(iv) in the bait set hybridizes without mismatch with the nucleic acid sequence of the target nucleic acid pattern. In some embodiments, the bait set can be said to selectively hybridize with the target nucleic acid pattern as long as the number of mismatches is less than the number of mismatches present in the non-target hybrid.

[0185] Different decoy molecules within the same decoy set can contain each of the different target-specific capture sequences, such that a given decoy set can contain decoy molecules that correspond to the same genomic locus but have different target-specific capture sequences.

[0186] In some embodiments, sequences (i) and (ii) listed above are present in allele-specific bait sets. That is, in some embodiments, double-stranded bait sets may target only the + strand of the target genomic locus. In some embodiments, sequences (iii) and (iv) listed above are present in allele-specific bait sets. That is, in some embodiments, double-stranded bait sets may target only the - strand of the target genomic locus. In some embodiments, sequences (i), (ii), (iii), and (iv) listed above are present in allele-specific bait sets. That is, in some embodiments, double-stranded bait sets may target both the + and - strands of the target genomic locus. In some embodiments, bait sets targeting only the + strand of the target genomic locus or only the - strand of the target genomic locus may exhibit reduced capture efficiency compared to bait sets targeting both the + and - strands of the target genomic locus.

[0187] The embodiments described herein may use hypermethylation-specific allele-specific decoys. These embodiments include, for example, selectively capturing nucleic acid molecules from a sample from a subject using a method involving: converting unmethylated cytosine (C) in one or more nucleic acid molecules to uracil (U), or converting methylated C in one or more nucleic acid molecules to U, to form transformed nucleic acid molecules; amplifying the transformed nucleic acid molecules into an amplicon set; hybridizing the nucleic acid decoy set with the amplicon set to form multiple hybrids, wherein the nucleic acid decoy set selectively hybridizes with a target nucleic acid pattern, wherein the target nucleic acid pattern corresponds to a target methylation pattern at a genomic locus in the pre-transformed nucleic acid molecule, wherein the target methylation pattern corresponds to a hypermethylation signal indicating a disease or condition, and wherein the nucleic acid decoy is double-stranded; and separating the multiple hybrids from nucleic acid molecules that have not hybridized with the decoy. In some such embodiments, the nucleic acid decoy set does not contain nucleic acid decoys that selectively hybridize with nucleic acid patterns corresponding to hypomethylation signals at genomic loci.

[0188] The embodiments described herein may use hypomethylation-specific allele-specific decoys. These embodiments include, for example, selectively capturing nucleic acid molecules from a sample from a subject using a method involving: converting unmethylated cytosine (C) in one or more nucleic acid molecules to uracil (U), or converting methylated C in one or more nucleic acid molecules to U, to form transformed nucleic acid molecules; amplifying the transformed nucleic acid molecules into an amplicon set; hybridizing the nucleic acid decoy set with the amplicon set to form multiple hybrids, wherein the nucleic acid decoy set selectively hybridizes with a target nucleic acid pattern corresponding to a target methylation pattern at a genomic locus in the pre-transformed nucleic acid molecule, wherein the target methylation pattern is associated with a hypomethylation signal indicating a disease or condition, and wherein the nucleic acid decoy is double-stranded; and separating the multiple hybrids from nucleic acid molecules that have not hybridized with the decoy. In some such embodiments, the nucleic acid decoy set does not contain nucleic acid decoys that selectively hybridize with nucleic acid patterns corresponding to hypermethylation signals at genomic loci.

[0189] B. Design principles of single-chain decoys

[0190] Compared to the allele-specific double-stranded decoys described above, the single-stranded (ss) chain-specific methyl enrichment decoys described herein enable further enrichment of methylation signals. The single-stranded, chain-specific decoys described herein reduce off-target binding by being designed to: 1) query only one strand at a time (e.g., e.g., Figure 9B The decoys shown in the rightmost column), and optionally also 2) facilitate the selection of potential off-target A:C mismatches rather than potential off-target G:T mismatches (such as, for example, Figure 9A(The bait shown).

[0191] As mentioned above and as Figure 9B The column labeled "Methyl-Allele-Specific Decoy" shows a double-stranded methylation allele-specific decoy set designed for target methylation patterns at double-stranded genomic loci. This decoy set can contain four different target-specific capture sequences from the same decoy set: (i) a strand containing a sequence corresponding to the positive strand of the transformed target nucleic acid pattern (in...). Figure 9B (i) Marked as “(+)”); (ii) The reverse complementary sequence of chain (i) (in Figure 9B (iii) A strand containing a sequence of the negative strand corresponding to the transformed target nucleic acid pattern (in the middle marked "(+RC)"); Figure 9B (i) marked as “(-)”); and (iv) the reverse complementary sequence of chain (iii) (in Figure 9B In contrast, the single-chain or "chain-selective" decoy set described in this paper contains only one of the four different target-specific capture sequences mentioned above.

[0192] While the aforementioned double-stranded allele-specific decoys represent an improvement over traditional methods, they may still lead to off-target capture of unintended amplicones due to off-target binding, such as between hypermethylated targets and double-stranded hypomethylated specific decoys, or between hypomethylated targets and double-stranded hypermethylated specific decoys (see example...). Figure 7 (The general schemes listed herein). These off-target binding events form a target-decoy duplex characterized by an adenine / cytosine mismatch (A:C; also referred to herein as A / C) or a guanine / thymine mismatch (G:T; also referred to herein as G / T), depending on the orientation (positive or negative) of the corresponding strands of the original DNA molecule. Figure 7 ).

[0193] The single-stranded or "strand-selective" decoy sets described in this article can be optimized through further refinement of the single-stranded decoy design as described below to reduce off-target binding. Due to the similarity between highly methylated and hypomethylated DNA sequences after cytosine transformation, there may be relatively few mismatches between the decoys and unintended targets, meaning that targets with unintended methylation states can still be enriched. Figure 7 For example, a decoy designed for hypomethylation specificity can hybridize with a "mismatch" sequence from a hypermethylated target region, containing a mismatch of several nucleotides, and vice versa. When a low-allele-specific double-stranded decoy undergoes off-target cross-binding with a hypermethylated amplicon, or vice versa, an A:C or G:T mismatch is formed. Figure 7 The chain-specific decoys disclosed in this paper can be further designed to avoid such mismatches.

[0194] To design such chain-specific decoys that avoid these mismatches, the four different target-specific capture sequences can be divided into two groups based on the mismatch state of the unexpected hybridization: A:C mismatch group and G:T mismatch group (see, for example, along...). Figure 9B The strands labeled "AC" and "GT" on the right). The optimized single-stranded decoy set described herein to avoid G:T mismatches can include either of the "A:C" mismatched strands. Then, for each target region, one or both of the two A:C mismatched DNA strands can be generated (e.g., by synthesis) as strand-selective (single-stranded) methyl enrichment decoys (see [link to documentation]). Figure 9A ).

[0195] Compared to hybrids with G:T mismatches, nucleic acid hybrids with A:C mismatches have a lower melting temperature (Tm). Therefore, off-target hybrids containing A:C mismatches can be preferentially depleted during post-hybridization washing. Thus, the chain-selective decoys designed to form only A:C mismatches with sequences corresponding to unexpected methylation signals at target loci, as described herein, can provide further enhanced selectivity in methyl target capture. Therefore, for further optimization of chain-selective decoy design, off-target A:C mismatches are superior to off-target G:T mismatches.

[0196] Therefore, the single-chain, chain-specific decoy of the present invention can be designed to query only a single chain at a time, without considering mismatches. This may be similar to, for example... Figure 7 The general scheme is listed, but each chain of low-bait and high-bait schemes shown is considered a separate bait, such that each bait is considered a single chain (e.g., as...). Figure 9B(As shown in the far right column), and in which complementary decoy chains are not included together in the same reaction. For example, in the embodiments described herein involving querying a single-stranded target nucleic acid pattern corresponding to a target genomic locus, a highly methylation-specific single-stranded decoy can be used. For example, this might require using methods involving the selective capture of nucleic acid molecules from samples from a subject by: converting unmethylated cytosine (C) in one or more nucleic acid molecules to uracil (U), or converting methylated C in one or more nucleic acid molecules to U, to form a transformed nucleic acid molecule; amplifying the transformed nucleic acid molecule into an amplicon set; hybridizing the nucleic acid decoy set with the amplicon set to form a plurality of hybrids, wherein at least a portion of the hybrids contain nucleic acid molecules containing a target nucleic acid pattern corresponding to a target methylation pattern at a genomic locus in the pre-transformed nucleic acid molecule, wherein the target methylation pattern corresponds to a hypermethylation signal indicating a disease or condition, wherein the nucleic acid decoy set selectively hybridizes with the target nucleic acid pattern at the genomic locus, and wherein the nucleic acid decoy set is single-stranded; and separating the plurality of hybrids from nucleic acid molecules that have not hybridized with the decoy. In some such embodiments, the nucleic acid decoy set may not contain a nucleic acid decoy that selectively hybridizes with a nucleic acid pattern corresponding to a hypomethylation signal at a genomic locus (e.g., off-target binding). However, in some embodiments, one or more A:C mismatches and / or G:T mismatches may exist between the decoy nucleic acid and the off-target nucleic acid, which still allows the decoy to hybridize with the off-target nucleic acid, potentially leading to erroneous signals. Furthermore, highly methylation-specific single-stranded decoys can be designed to selectively hybridize (e.g., on-target binding) with a target nucleic acid pattern at a genomic locus, where complementarity is slightly imperfect (e.g., one or at most a few mismatches), such that although the complementarity of the hybridization region between the decoy and the target nucleic acid pattern does not necessarily have to be 100%, the nucleic acid molecule containing the target nucleic acid pattern is still selectively captured relative to other (e.g., off-target) sequences.

[0197] Similarly, in the embodiments described herein involving querying a single-stranded target nucleic acid pattern corresponding to a target genomic locus, the hypomethylation-specific single-stranded decoy of the present invention can be used. For example, this might include selectively capturing nucleic acid molecules from a sample from a subject using methods involving: converting unmethylated cytosine (C) in one or more nucleic acid molecules to uracil (U), or converting methylated C in one or more nucleic acid molecules to U, to form a transformed nucleic acid molecule; amplifying the transformed nucleic acid molecule into an amplicon set; hybridizing the nucleic acid decoy set with the amplicon set to form a plurality of hybrids, wherein at least a portion of the hybrids contain nucleic acid molecules containing a target nucleic acid pattern corresponding to a target methylation pattern at a genomic locus in the untransformed nucleic acid molecule, wherein the target methylation pattern corresponds to a hypomethylation signal indicating a disease or condition, wherein the nucleic acid decoy set selectively hybridizes with the target nucleic acid pattern at the genomic locus, and wherein the nucleic acid decoy set is single-stranded; and separating the plurality of hybrids from nucleic acid molecules that have not hybridized with the decoy. In some such embodiments, the nucleic acid decoy set may not contain nucleic acid decoys that selectively hybridize (e.g., off-target binding) with nucleic acid patterns corresponding to hypermethylation signals at genomic loci. However, similar to the above, in some embodiments, one or more A:C mismatches and / or G:T mismatches may exist between the decoy nucleic acid and the off-target nucleic acid, which still allows the decoy to hybridize with the off-target nucleic acid, potentially leading to erroneous signals. Furthermore, hypomethylation-specific single-stranded decoys can be designed to selectively hybridize (e.g., on-target binding) with target nucleic acid patterns at genomic loci, where complementarity is slightly imperfect (e.g., one or at most a few mismatches), such that although the complementarity of the hybridization region between the decoy and the target nucleic acid pattern does not necessarily have to be 100%, the nucleic acid molecule containing the target nucleic acid pattern is still selectively captured relative to other (e.g., off-target) sequences.

[0198] CA:C mismatch, chain stabilization, and decoy modification

[0199] Alternatively, the single-stranded nucleic acid decoys of the present invention (whether designed for high or low methylation specificity) can be designed to be perfectly complementary to the target nucleic acid pattern (i.e., no mismatch hybridization), but allow hybridization with one or more off-target A:C mismatches, while disallowing hybridization with off-target G:T mismatches (e.g., as shown in the image). Figure 9A As shown, along the ss decoy, exemplary A:C mismatch residues are marked with an asterisk. Figure 9B In the context of the exemplary schematic diagram shown, for example, this might require using the rightmost single-chain decoy labeled "AC," but not the rightmost decoy labeled "GT." Figure 9BIn the middle, chain-specific decoys of A:C and G:T subtypes are marked along the left side (these are nucleic acid sequences that hybridize with transformed nucleic acid sequences corresponding to non-target methylation patterns at the same genomic locus and have A:C or G:T mismatches, respectively).

[0200] In a pool of mixed hybrids where some hybrids contain mismatches and others do not, the hybrids containing mismatches can be preferentially depleted by washing based on the respective melting temperatures of the mismatched and non-mismatched hybrids. For example, as... Figure 8B As shown and discussed in the examples below, the hybrid between the decoy and the off-target strand with an A:C mismatch (see example...) Figure 8B The Tm value of the second image from the left in the middle is lower than that of the hybrid between the decoy and the off-target strand with G:T mismatch (see example...). Figure 8B (In the rightmost figure), both have Tm values ​​lower than those of the perfectly matched target hybrid (see example...). Figure 8B The leftmost image and the second image from the right; in Figure 8B In the diagram, the leftmost dataset corresponds to a high-specificity decoy that hybridizes to the reverse complementary sequence of the strand corresponding to the hypermethylated DNA strand in the original sample, showing a perfect match for G:C binding. The second dataset from the left corresponds to a high-specificity decoy that hybridizes to the reverse complementary sequence of the strand corresponding to the hypomethylated DNA strand in the original sample, showing an A:C mismatch. The second dataset from the right corresponds to a low-specificity decoy that hybridizes to the reverse complementary sequence of the strand corresponding to the hypomethylated DNA strand in the original sample, showing a perfect match for A:T binding. The rightmost dataset corresponds to a low-specificity decoy that hybridizes to the reverse complementary sequence of the strand corresponding to the hypermethylated DNA strand in the original sample, showing a G:T mismatch. (The whisker extends to 1.5 times the interquartile range).

[0201] Therefore, while accepting off-target mismatches in decoy design might seem counterproductive, the intentional A:C mismatches described herein offer a surprising advantage in further improving the signal-to-noise ratio by allowing the depletion of off-target A:C mismatched hybrids via washing at one or more temperatures below the Tm of perfectly matched hybrids but above the Tm of A:C mismatched hybrids. At these temperatures, perfectly matched (on-target) hybrids will remain annealed, but off-target hybrids with A:C mismatches will dehybridize, thus preferentially depleting them. This has the potential to further enrich a hybrid library targeting one or more specific nucleic acid patterns.

[0202] For example, in embodiments described herein involving querying a single-stranded target nucleic acid pattern corresponding to a target genomic locus, the single-stranded nucleic acid decoy of the present invention can be used. This may require methods involving selectively capturing nucleic acid molecules by: converting a target methylation pattern at a genomic locus in a nucleic acid molecule from a sample of a subject to a target nucleic acid pattern corresponding to the genomic locus to form a converted nucleic acid molecule; amplifying the converted nucleic acid molecule into an amplicon set; and hybridizing the single-stranded nucleic acid decoy set with the amplicon set to form multiple hybrids. The multiple hybrids may include, for example, at least a first partial hybrid and a second partial hybrid. In some embodiments, the first partial hybrid of the multiple hybrids comprises a hybrid between a decoy that hybridizes with each other without mismatches (or with fewer mismatches compared to off-target hybrids) and a nucleic acid strand from an amplicon, while the second partial hybrid comprises a hybrid between a decoy that hybridizes with each other and has an A:C mismatch (but not a G:T mismatch) and a nucleic acid strand from an amplicon. For example, the hybrid in the first part of the hybrid can be between: i) a single-stranded nucleic acid decoy from a single-stranded nucleic acid decoy group and ii) a nucleic acid molecule containing the target nucleic acid pattern, wherein i) and ii) hybridize with each other at least on the target nucleic acid pattern without mismatch (or with fewer mismatches compared to off-target hybrids). Conversely, the hybrid in the second part of the hybrid can be between: i) a single-stranded nucleic acid decoy from a single-stranded nucleic acid decoy group and ii) a nucleic acid molecule that does not contain the target nucleic acid pattern (e.g., from an off-target amplicon), wherein i) and ii) hybridize with each other and have one or more A:C mismatches. In some embodiments, the hybrid in the second part of the hybrid contains more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more than 20 A:C mismatches. In some embodiments, the hybrids in the second portion of the hybrid contain 5 or fewer, 10 or fewer, 15 or fewer, 20 or fewer, 25 or fewer, or 30 or fewer A:C mismatches. In some embodiments, the hybrids in the second portion of the hybrid contain 20 or fewer A:C mismatches.

[0203] When at least a portion of a plurality of hybrids comprises single-stranded nucleic acid decoys from a single-stranded nucleic acid decoy set that hybridize with each other without mismatches (or with fewer mismatches compared to off-target hybrids) and nucleic acid molecules containing the target nucleic acid pattern (e.g., the first portion of the hybrids discussed above), the plurality of hybrids can be separated from the nucleic acid molecules that have not hybridized with the decoys via one or more washing steps, and the first portion of the hybrids and the second portion of the hybrids can also be separated from each other. In these embodiments, the target methylation pattern may correspond to a hypermethylation signal indicating a disease or condition, or a hypomethylation signal indicating a disease or condition.

[0204] The washing step for removing hybrids containing A:C mismatches enriches a library of hybrids containing target nucleic acid patterns that bind to the decoy and are mismatch-free (or have fewer mismatches compared to off-target hybrids). During such washing, nucleic acid molecules that do not hybridize with the decoy and nucleic acid molecules in the hybrids discussed in the second part above are depleted from, for example, the substrate. Thus, in some embodiments, one or more washes may include exposing the hybrids to one or more temperatures below the Tm of hybrids containing decoys that hybridize with the target nucleic acid patterns and are mismatch-free (or have fewer mismatches compared to off-target hybrids), but above the Tm of hybrids containing A:C mismatches, such that hybrids containing A:C mismatches unwind while hybrids without mismatches remain intact, thereby allowing hybrid sequences with A:C mismatches, along with any other unhybridized nucleic acids, to be washed away, thereby removing or depleting hybrids containing A:C mismatches.

[0205] In some embodiments, none of the multiple hybrids contains a G:T mismatch. For example, in some embodiments, neither the first and second hybrids discussed above contain a G:T mismatch. In some embodiments, some hybrids (e.g., one or more portions of a hybrid) contain one or more G:T mismatches. In some embodiments, a hybrid contains more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more than 20 A:C mismatches. In some embodiments, a hybrid contains 5 or fewer, 10 or fewer, 15 or fewer, 20 or fewer, 25 or fewer, or 30 or fewer A:C mismatches. In some embodiments, a hybrid contains 20 or fewer A:C mismatches.

[0206] Therefore, certain aspects of the present invention relate to determining one or more melting temperatures (Tm) of hybridized nucleic acids. Various methods for determining Tm are known in the art. For example, the methods described herein may involve determining the Tm value of a first hybrid comprising a decoy that hybridizes with a target nucleic acid pattern without mismatches (or with fewer mismatches compared to off-target hybrids), such as, for example, a highly specific decoy that hybridizes with the reverse complementary sequence of a strand corresponding to a hypermethylated DNA strand in the original sample without mismatches (or with fewer mismatches compared to off-target hybrids). In some embodiments, the methods described herein may further involve determining a second Tm of a second hybrid comprising a decoy and an off-target nucleic acid, wherein the hybridization region between the decoys contains one or more mismatched nucleic acids, such as, for example, one or more A:C and / or one or more G:T mismatches. For example, in some embodiments, the methods described herein may include determining the Tm of a hybrid comprising a high-specificity decoy that hybridizes to the reverse complementary sequence of a strand corresponding to a hypomethylated DNA strand in the original sample and has an A:C mismatch, and / or determining the Tm value of a hybrid comprising a low-specificity decoy (e.g., a sequence of reverse complementary sequences of a strand corresponding to a hypomethylated DNA strand in the original sample) that hybridizes to the reverse complementary sequence of a strand corresponding to a hypomethylated DNA strand in the original sample. Figure 8A As shown, the leftmost dataset corresponds to a high-specificity decoy that hybridizes to the reverse complementary sequence of the strand corresponding to the hypermethylated DNA strand in the original sample, showing a perfect match for G:C binding. The second dataset from the left corresponds to a high-specificity decoy that hybridizes to the reverse complementary sequence of the strand corresponding to the hypomethylated DNA strand in the original sample, showing an A:C mismatch. The second dataset from the right corresponds to a low-specificity decoy that hybridizes to the reverse complementary sequence of the strand corresponding to the hypomethylated DNA strand in the original sample, showing a perfect match for A:T binding. The rightmost dataset corresponds to a low-specificity decoy that hybridizes to the reverse complementary sequence of the strand corresponding to the hypermethylated DNA strand in the original sample, showing a G:T mismatch. (The whisker extends to 1.5 times the interquartile range).

[0207] For example, in some embodiments comprising a first hybrid containing a decoy that hybridizes with each other with nucleic acid chains from the amplicon without mismatch and a second hybrid containing a decoy that hybridizes with each other with nucleic acid chains from the amplicon and has an A:C mismatch, the method may further include separating the first hybrid from the second hybrid.

[0208] In some embodiments, separating the first hybrid from the second hybrid and / or separating multiple hybrids from nucleic acid molecules that have not hybridized with the decoy includes one or more washing steps. In some embodiments, the separation of the first hybrid from the second hybrid and the separation of multiple hybrids from nucleic acid molecules that have not hybridized with the decoy can be performed simultaneously in a single washing step. In some embodiments, the separation of the first hybrid from the second hybrid and the separation of multiple hybrids from nucleic acid molecules that have not hybridized with the decoy can be performed sequentially in more than one washing step. Different washing steps can be performed at the same temperature. Alternatively, different washing steps can be performed at different temperatures. In some embodiments, the temperature of the washing step is set based on a determined Tm of the hybrid. In some embodiments, the temperature of the washing step is set above the determined Tm of the hybrid, such as, for example, above the Tm of a hybrid containing one or more A:C mismatches. In some embodiments, the temperature of the washing step is set below the determined Tm of the hybrid, such as, for example, below the Tm of a hybrid between the decoy and the target nucleic acid pattern. In some embodiments, the temperature of the washing step is set below the determined Tm of a hybrid between a single-stranded decoy and the target nucleic acid pattern that hybridizes with each other and has no mismatches. In some embodiments, the temperature of the washing step is set below the Tm for determining hybrids between single-stranded decoys and target nucleic acid patterns that hybridize with each other and have fewer mismatches than hybrids containing decoys and off-target sequences.

[0209] In some embodiments, the hybrid is attached to the substrate prior to one or more washing steps, such that unhybridized or dehybridized nucleic acid molecules are depleted from the substrate during the washing steps. Exemplary ways of attaching the hybrid to the substrate may include, for example, biotinylating the bait and coating the substrate (such as, for example, beads) with streptavidin.

[0210] In some embodiments, the decoy may be longer than the target nucleic acid pattern, such that only a portion of the decoy is complementary to the target nucleic acid pattern. The non-complementary portion of the decoy to the target nucleic acid pattern may contain other sequences, such as, for example, one or more synthetic adaptors, primer recognition sequences, and / or barcodes (e.g., amplification primers, sequencing adaptors, flow cell adaptors, substrate adaptors, sample barcodes or indexes, and / or unique molecular identifier sequences). In some embodiments, the decoy molecule may further include a generic tail at one or both ends. Other potential properties or modifications of the decoy molecule will be described in the Target Capture Reagents section below.

[0211] In some embodiments, a nucleic acid decoy set may include multiple redundant target-specific capture sequences, such as, for example, different sequences complementary to different portions of the same target nucleic acid pattern. For example, each individual decoy in a multi-redundant decoy set may contain one of a variety of different target-specific capture sequences present in the set. Target-specific capture sequences may partially overlap at the same target locus or correspond to different portions of the same target locus. Such multi-redundant decoy sets can reduce hybridization bias by increasing coverage, depending on the hybridization efficiency with the target nucleic acid pattern. For example, a multi-redundant decoy set may have 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 different or semi-overlapping sequences corresponding to the same target binding sequence. In some embodiments, a multi-redundant decoy set may have 2, 3, or 5 different or semi-overlapping sequences corresponding to the same target binding sequence.

[0212] V. Methods for selectively capturing nucleic acid molecules

[0213] The present invention further includes a method for selectively capturing nucleic acid molecules using the decoy molecules described herein. For example, in some embodiments, the method described herein involves hybridizing a nucleic acid molecule with one or more nucleic acid decoys designed according to the principles described herein. This hybridization can be performed in the target capture step of a Methyl-Seq workflow (such as, for example, in...). Figure 1 The exemplary workflow shown is performed under conditions suitable for hybridization, wherein multiple nucleic acid molecules are able to hybridize with the decoy nucleic acid, and then the multiple hybrids are separated from the nucleic acid molecules that have not hybridized with the decoy.

[0214] Figure 2 One implementation of a single-stranded nucleic acid decoy designed according to the principles described herein is provided as a non-limiting example of the step in method 200 for selectively capturing nucleic acid molecules from a sample from a subject (such as, for example, a human subject). Figure 2 As shown, one or more unmethylated cytosine residues (C) or one or more methylated C residues in a nucleic acid molecule are converted to uracil residues (U) to form a transformed nucleic acid molecule. In some cases, the transformation includes enzymatic transformation and / or bisulfite transformation. In some cases, the transformation includes TET-assisted bisulfite treatment, TET-assisted pyridineborane treatment, oxidized bisulfite treatment, APOBEC treatment, and / or other DNA deaminase treatment.

[0215] In some cases, before step 202, one or more adaptors (such as, for example, amplification primers, flow cell adaptor sequences, substrate adaptor sequences, and / or sample index sequences) are ligated to one or more nucleic acid molecules. In some cases, between steps 202 and 204, one or more adaptors are ligated to one or more nucleic acid molecules.

[0216] The transformed nucleic acid molecules are amplified 204 times to form an amplicon set. In some embodiments, the amplification includes polymerase chain reaction (PCR) amplification, non-PCR amplification, or isothermal amplification.

[0217] The amplicon is hybridized 206 times with a single-stranded nucleic acid decoy set to form multiple hybrids, wherein at least a portion of the hybrids contains a target nucleic acid pattern corresponding to a target methylation pattern at a genomic locus in the nucleic acid molecule prior to transformation. In some cases, the target methylation pattern corresponds to a hypermethylation signal indicating a disease or condition. In some cases, the target methylation pattern corresponds to a hypomethylation signal indicating a disease or condition. In some cases, the disease or condition is cancer. In some cases, the first portion of the multiple hybrids contains a single-stranded nucleic acid decoy from the single-stranded nucleic acid decoy set that hybridizes with each other without mismatch and a nucleic acid molecule containing the target nucleic acid pattern. In some cases, the decoy set is hypermethylation specific. In some cases, the decoy set is hypomethylation specific. In some cases, the hybrids in the multiple hybrids do not contain a guanine / thymine (G:T) mismatch between a hypomethylation-specific decoy and a nucleic acid molecule containing a sequence corresponding to a hypermethylated version of a genomic locus. In some cases, the hybrids in multiple hybrids do not contain guanine / thymine (G:T) mismatches between a hypermethylation-specific decoy and a nucleic acid molecule containing a hypomethylated version of a sequence corresponding to a genomic locus. In some cases, a second hybrid in multiple hybrids contains a single-stranded nucleic acid decoy from a single-stranded nucleic acid decoy group and a nucleic acid molecule that does not contain the target nucleic acid pattern, wherein the hybrid in the second hybrid contains one or more adenine / cytosine (A:C) mismatches. For example, for a hypomethylation-specific decoy group, an exemplary second hybrid may contain a single-stranded nucleic acid decoy from a single-stranded nucleic acid decoy group that hybridizes with a nucleic acid molecule containing a hypermethylated version of a sequence corresponding to a genomic locus and has one or more A:C mismatches. For a hypermethylation-specific decoy group, an exemplary second hybrid may contain a single-stranded nucleic acid decoy from a single-stranded nucleic acid decoy group that hybridizes with a nucleic acid molecule containing a hypomethylated version of a sequence corresponding to a genomic locus and has one or more A:C mismatches.

[0218] 208. Multiple hybrids are separated from nucleic acid molecules that have not hybridized with the decoy. In some cases, the separation includes one or more washing steps, in which the nucleic acid molecules that have not hybridized with the decoy are depleted. In some cases, hybrids containing incomplete hybridization (such as hybrids containing one or more mismatches) are depleted in one or more washing steps. For example, a second hybrid may be depleted. In some cases, one or more washing steps occur at a temperature below the melting temperature (Tm) of a hybrid containing nucleic acid decoys that have hybridized with each other without mismatches and nucleic acid molecules containing the target nucleic acid pattern.

[0219] Figure 3 One embodiment of a hypermethylation-specific nucleic acid decoy designed according to the principles described herein is provided as a non-limiting example of the step in method 300 for selectively capturing nucleic acid molecules from a sample from a subject (such as, for example, a human subject), the decoy being a single-stranded hypermethylation-specific decoy or a double-stranded hypermethylation-specific decoy. Figure 3 As shown, one or more unmethylated cytosine residues (C) or one or more methylated C residues in a nucleic acid molecule are converted to uracil residues (U) to form a converted nucleic acid molecule.

[0220] In some cases, the transformation includes enzymatic transformation and / or bisulfite transformation. In other cases, the transformation includes TET-assisted bisulfite treatment, TET-assisted pyridineborane treatment, oxidized bisulfite treatment, APOBEC treatment, and / or other DNA deaminase treatment.

[0221] In some cases, before step 302, one or more adaptors (such as, for example, amplification primers, flow cell adaptor sequences, substrate adaptor sequences, and / or sample index sequences) are ligated to one or more nucleic acid molecules. In some cases, between steps 302 and 304, one or more adaptors are ligated to one or more nucleic acid molecules.

[0222] The transformed nucleic acid molecules are amplified 304 times to form an amplicon set. In some embodiments, the amplification includes polymerase chain reaction (PCR) amplification, non-PCR amplification, or isothermal amplification.

[0223] The amplicon is hybridized with a set of hypermethylation-specific nucleic acid decoys 306 to form multiple hybrids, wherein the set of hypermethylation-specific nucleic acid decoys selectively hybridizes with a target nucleic acid pattern corresponding to a target methylation pattern at a genomic locus in the pre-transformed nucleic acid molecule, wherein the target methylation pattern corresponds to a hypermethylation signal. In some cases, the hypermethylation signal indicates a disease or condition, such as, for example, cancer. In some cases, the disease or condition is cancer. In some cases, the hypermethylation-specific nucleic acid decoy is single-stranded. In some cases, the hypermethylation-specific nucleic acid decoy is double-stranded. In cases involving double-stranded decoys, a hybrid containing at least one strand of the double-stranded decoy is considered to contain the decoy. For example, a hybrid containing an amplicon strand hybridized with a single strand from a double-stranded decoy is considered to contain the decoy. In some cases, a first portion of the multiple hybrids contains a hypermethylation-specific nucleic acid decoy from the set of hypermethylation-specific nucleic acid decoys that hybridize with each other without mismatch and a nucleic acid molecule containing the target nucleic acid pattern. In some cases, a second hybrid in a plurality of hybrids comprises a hypermethylation-specific nucleic acid decoy from a hypermethylation-specific nucleic acid decoy set and a nucleic acid molecule that does not contain the target nucleic acid pattern, wherein the hybrid in the second hybrid contains one or more mismatches. For example, an exemplary second hybrid may comprise a hypermethylation-specific nucleic acid decoy from a hypermethylation-specific nucleic acid decoy set that hybridizes with a nucleic acid molecule containing a low-methylation version of a sequence corresponding to a genomic locus and has one or more mismatches.

[0224] 308. Multiple hybrids are separated from nucleic acid molecules that have not hybridized with the decoy. In some cases, the separation includes one or more washing steps, in which the nucleic acid molecules that have not hybridized with the decoy are depleted. In some cases, hybrids containing incomplete hybridization (such as hybrids containing one or more mismatches) are depleted in one or more washing steps. For example, a second hybrid may be depleted. In some cases, one or more washing steps occur at a temperature below the melting temperature (Tm) of a hybrid containing nucleic acid decoys that have hybridized with each other without mismatches and nucleic acid molecules containing the target nucleic acid pattern.

[0225] Figure 4 One embodiment of a hypomethylation-specific nucleic acid decoy designed according to the principles described herein is provided as a non-limiting example of the step in method 400 for selectively capturing nucleic acid molecules from a sample from a subject (such as, for example, a human subject), the decoy being a single-stranded hypomethylation-specific decoy or a double-stranded hypomethylation-specific decoy. Figure 4 As shown, one or more unmethylated cytosine residues (C) or one or more methylated C residues in a nucleic acid molecule are converted to uracil residues (U) to form a converted nucleic acid molecule.

[0226] In some cases, the transformation includes enzymatic transformation and / or bisulfite transformation. In other cases, the transformation includes TET-assisted bisulfite treatment, TET-assisted pyridineborane treatment, oxidized bisulfite treatment, APOBEC treatment, and / or other DNA deaminase treatment.

[0227] In some cases, before step 402, one or more adaptors (such as, for example, amplification primers, flow cell adaptor sequences, substrate adaptor sequences, and / or sample index sequences) are ligated to one or more nucleic acid molecules. In some cases, between steps 402 and 404, one or more adaptors are ligated to one or more nucleic acid molecules.

[0228] The transformed nucleic acid molecules are amplified 404 times to form an amplicon set. In some embodiments, the amplification includes polymerase chain reaction (PCR) amplification, non-PCR amplification, or isothermal amplification.

[0229] The amplicon is hybridized 406 times with a set of hypomethylation-specific nucleic acid decoys to form multiple hybrids, wherein the set of hypomethylation-specific nucleic acid decoys selectively hybridizes with a target nucleic acid pattern corresponding to a target methylation pattern at a genomic locus in the pre-transformed nucleic acid molecule, wherein the target methylation pattern corresponds to a hypomethylation signal. In some cases, the hypomethylation signal indicates a disease or condition, such as, for example, cancer. In some cases, the disease or condition is cancer. In some cases, the hypomethylation-specific nucleic acid decoy is single-stranded. In some cases, the hypomethylation-specific nucleic acid decoy is double-stranded. In cases involving double-stranded decoys, a hybrid containing at least one strand of the double-stranded decoy is considered to contain the decoy. For example, a hybrid containing an amplicon strand hybridized with a single strand from a double-stranded decoy is considered to contain the decoy. In some cases, a first portion of the multiple hybrids contains a hypomethylation-specific nucleic acid decoy from the set of hypomethylation-specific nucleic acid decoys that hybridize with each other without mismatch and a nucleic acid molecule containing the target nucleic acid pattern. In some cases, a second hybrid in a plurality of hybrids comprises a hypomethylation-specific nucleic acid decoy from a hypomethylation-specific nucleic acid decoy set and a nucleic acid molecule that does not contain the target nucleic acid pattern, wherein the hybrid in the second hybrid contains one or more mismatches. For example, an exemplary second hybrid may comprise a hypomethylation-specific nucleic acid decoy from a hypomethylation-specific nucleic acid decoy set that hybridizes with a nucleic acid molecule containing a sequence corresponding to a hypermethylated version of a genomic locus and has one or more mismatches.

[0230] 408. Multiple hybrids are separated from nucleic acid molecules that have not hybridized with the decoy. In some cases, the separation includes one or more washing steps, wherein the nucleic acid molecules that have not hybridized with the decoy are depleted. In some cases, hybrids containing incomplete hybridization (such as hybrids containing one or more mismatches) are depleted in one or more washing steps. For example, a second hybrid may be depleted. In some cases, one or more washing steps occur at a temperature below the melting temperature (Tm) of a hybrid containing nucleic acid decoys that have hybridized with each other without mismatches and nucleic acid molecules containing the target nucleic acid pattern.

[0231] VI. Combinations of different baits

[0232] Some aspects of the invention relate to combinations of different decoys. For example, in some embodiments, different decoys (e.g., corresponding to different target nucleic acid sequences, and / or decoys with different characteristics, such as different numbers of strands, different lengths, and / or other various modifications discussed above) are combined, for example, in the same group and / or the same vial. For example, these different decoys may target the same locus or multiple different loci, and / or may be single-stranded or double-stranded, or a combination thereof.

[0233] A. Different decoys targeting the same gene locus

[0234] For example, different decoys targeting the same locus may each be specific to different degrees or patterns of methylation on the same genomic sequence. For instance, for a single genomic region, there may be multiple different potentially hypermethylated alleles or multiple different potentially hypomethylated alleles, resulting in multiple potentially different hypermethylated features or multiple potentially different hypomethylated features in a transformed nucleic acid molecule corresponding to a given genomic locus. Different decoys can be used to investigate each different potentially hypomethylated allele.

[0235] For example, in some embodiments, multiple hypermethylation-specific decoy sets, such as second, third, fourth, or more hypermethylation-specific decoy sets, may be used together, each hybridizing with different target nucleic acid patterns transformed from different hypermethylation signatures at the same genomic locus. In such embodiments, the selectivity of one decoy set within the multiple decoys for its intended target depends on the sequence differences between the transformed nucleic acid sequences corresponding to different alleles.

[0236] For example, in the context of a hypermethylation-specific decoy, a sample may contain multiple different hypermethylated alleles at a single genomic locus. For example, multiple copies of the same genomic locus having multiple different target hypermethylation patterns may be present in a single sample from the same subject, and / or in one or more samples from one or more subjects. In some embodiments, one or more of the multiple different target hypermethylation patterns at the same genomic locus may, for example, correspond to a hypermethylation signal indicating a disease or condition. In some embodiments, different target hypermethylation patterns at the same genomic locus may correspond to one or more hypermethylation signals indicating one or more different diseases or conditions.

[0237] Similarly, in the context of a hypomethylation-specific decoy, a sample may contain multiple distinct hypomethylated alleles at a single genomic locus. For example, multiple copies of the same genomic locus having multiple distinct target hypomethylation patterns may be present in a single sample from the same subject, and / or in one or more samples from one or more subjects. In some embodiments, one or more of the multiple distinct target hypomethylation patterns at the same genomic locus may, for example, correspond to a hypomethylation signal indicating a disease or condition. In some embodiments, distinct target hypomethylation patterns at the same genomic locus may correspond to one or more hypomethylation signals indicating one or more distinct diseases or conditions.

[0238] Therefore, in some embodiments, multiple target methylation patterns at a single genomic locus can be converted into multiple target nucleic acid patterns corresponding to the same genomic locus to form multiple different converted nucleic acid molecules. In such embodiments, the method may further include: amplifying multiple different nucleic acid patterns into multiple amplicon sets; hybridizing multiple nucleic acid decoy sets with multiple amplicon sets to form multiple hybrids, wherein the multiple nucleic acid decoy sets contain multiple different decoy sets, wherein the different decoy sets selectively hybridize with different target nucleic acid patterns at the genomic locus; and separating the multiple hybrids from nucleic acid molecules that have not hybridized with the decoys.

[0239] In some embodiments, only one decoy is present at each genomic locus. In some embodiments, multiple decoys are present at each genomic locus, such as, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 decoys at each genomic locus. In some embodiments, different decoys targeting the same locus are all hypermethylation-specific decoys. In some embodiments, different decoys targeting the same locus are all hypomethylation-specific decoys.

[0240] B. Different decoys targeting different gene loci

[0241] Alternatively or concurrently, multiple different decoys can be used to query different loci in parallel. While multiple decoys targeting the same locus may be either hypermethylation-specific or hypomethylation-specific, decoys targeting different loci may, for example, be hypermethylation-specific at a first locus and hypomethylation-specific at a second locus. Furthermore, multiple decoys targeting the same locus may be mixed with one or more different decoys targeting one or more different loci. For example, in some embodiments, one or more hypomethylation-specific decoys targeting locus "A" and one or more hypermethylation-specific decoys targeting locus "B" may be present.

[0242] Provided the sequences of the transformed nucleic acid molecules corresponding to each locus are sufficiently different to allow selective binding between the decoy and its intended target, any number of different loci can be targeted in parallel with different decoys. In some embodiments, the methylation status of only one genomic locus is queried. In some embodiments, multiple genomic loci can be queried in parallel, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 different genomic loci. In some embodiments, the different decoys targeting different loci are all hypermethylation-specific decoys. In some embodiments, the different decoys targeting different loci are all hypomethylation-specific decoys. In some embodiments, one or more loci are queried using only hypermethylation-specific decoys, and one or more other loci are queried using only hypomethylation-specific decoys. In some embodiments, one locus is targeted by multiple different decoys (such as, for example, as described above), and another locus is targeted by multiple other different decoys, such that, for example, there are different decoys targeting the same locus, and other different decoys targeting different loci in parallel (e.g., multiple loci, each with different possible alleles, each allele being targeted by a different decoy).

[0243] The method of the present invention involving parallel querying of multiple loci may include, for example: converting multiple target methylation patterns (such as, for example, a first target methylation pattern and second, third, fourth or more target methylation patterns) at different genomic loci in a nucleic acid molecule from a sample of a subject into multiple target nucleic acid patterns at multiple genomic loci; and hybridizing multiple sets of nucleic acid decoys with amplicon sets, wherein each of the multiple sets of nucleic acid decoys selectively hybridizes with a target nucleic acid pattern among the multiple target nucleic acid patterns. In some embodiments, any or all of the first, second, third, fourth or more target methylation patterns are associated with a hypermethylation signal indicating a disease or condition. In some embodiments, any or all of the first, second, third, fourth or more target methylation patterns are associated with a hypomethylation signal indicating a disease or condition. In some embodiments, one or more genomic loci associated with different target methylation patterns are associated with a hypomethylation signal indicating a disease or condition, and / or one or more different genomic loci associated with other different target methylation patterns are associated with a hypermethylation signal indicating a disease or condition. In some embodiments, the diseases and / or conditions associated with different target methylation patterns are the same across loci. In other embodiments, the diseases and / or conditions associated with different target methylation patterns are different across loci.

[0244] Group C

[0245] Any of the different bait designs and / or combinations of different baits described above can be combined into, for example, groups. For instance, within a group, a first bait group designed to capture a high-methylation signature corresponding to an allele at one genomic locus can be used in the first part of the group; a second bait group designed to capture a low-methylation signature corresponding to another allele at another genomic locus or another allele at the same genomic locus can be used in the second part of the group; and a third bait group designed to capture both alleles can be used in the third part of the group.

[0246] Within a panel, different decoys can be used to query methylation states associated with different diseases or conditions. For example, a panel using the decoys of this invention could be a screening panel for different types of cancer. In some embodiments, the panel can be designed to focus only on hypermethylation signals or only on hypomethylation signals. In some such embodiments, the portion of the panel that queries both hypermethylation and hypomethylation signals can be quantified and / or normalized. For example, a disease or condition-specific panel could include, for example, three regions: one region with only a high-decoy, one region with only a low-decoy, and a normalized control that captures both, thereby allowing for fine-tuned quantification. The normalized control region of the panel can be further adjusted, for example, based on one or more target genomic loci. For example, adjustment could include selecting genomic regions with different methylation levels in non-disease states.

[0247] VII. Target loci

[0248] One or more target loci (also discussed herein as genomic loci with a target methylation pattern) are selected such that one or more decoys designed according to this disclosure can selectively hybridize with a target nucleic acid pattern corresponding to the one or more genomic loci. According to this disclosure, the decoys can be designed to hybridize with a target nucleic acid pattern corresponding to any genomic locus with a target methylation pattern. In some embodiments, the genomic locus does not contain a CpG (cytosine residue and guanine residue separated by a single phosphate ester group) site. In some embodiments, the genomic locus contains one CpG site. In some embodiments, the genomic locus contains two CpG sites. In some embodiments, the genomic locus contains more than two CpG sites. In some embodiments, the genomic locus contains 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more than 20 CpG sites.

[0249] In some embodiments, the target locus comprises a coding sequence, such as, for example, a gene or a fragment thereof. In some embodiments, the target locus comprises a non-coding sequence. In some embodiments, the target locus comprises an intragene region or a fragment thereof. In some embodiments, the target locus comprises an intergene region or a fragment thereof. In some embodiments, the target locus comprises a regulatory region or a fragment thereof. In some embodiments, the target locus comprises a non-coding sequence or a fragment thereof (e.g., a promoter sequence, an enhancer sequence, a 5' untranslated region (5' UTR), a 3' untranslated region (3' UTR) or a fragment thereof), an exon sequence or a fragment thereof, an intron sequence or a fragment thereof, or a combination of any of the foregoing.

[0250] The methods described herein may be used in combination with or as part of methods for evaluating multiple or a set of subject intervals (e.g., target nucleic acid patterns) from, for example, a group of loci (e.g., CpG sites), as described herein.

[0251] In some cases, the genomic loci assessed by the disclosed methods include multiple genes, for example, those in aberrant methylation forms, which are associated with diseases or conditions that affect cell division, growth, or survival, or with cancer (e.g., the cancer described herein).

[0252] In some cases, the set of loci (e.g., CpG sites) assessed by the disclosed methods includes at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, or more than 100 loci.

[0253] In some cases, the selected locus (also referred to herein as a target locus, target sequence, genomic locus, target genomic locus, genomic locus containing a target methylation pattern, etc.) or a fragment thereof may include a subject region of the subject's genome containing non-coding sequences, coding sequences, intragenic regions, or intergenic regions. For example, a subject region may include a non-coding sequence or a fragment thereof (e.g., promoter sequence, enhancer sequence, 5' untranslated region (5' UTR), 3' untranslated region (3' UTR) or a fragment thereof), a coding sequence or a fragment thereof, an exon sequence or a fragment thereof, an intron sequence or a fragment thereof.

[0254] In some embodiments, all CpG sites at a genomic locus are methylated in the target methylation pattern. In some embodiments, none of the CpG sites at a genomic locus are methylated in the target methylation pattern. In some embodiments, a subset of CpG sites at a genomic locus are methylated in the target methylation pattern. In some embodiments, the majority of CpG sites at a genomic locus are methylated in the target methylation pattern. In some embodiments, a minority of CpG sites at a genomic locus are methylated in the target methylation pattern. In some embodiments, the target methylation pattern comprises an equal number of methylated CpG sites and unmethylated CpG sites.

[0255] In some embodiments, the target methylation pattern corresponding to a genomic locus does not contain methylated CpG sites. In some embodiments, the target methylation pattern contains one methylated CpG site. In some embodiments, the target methylation pattern contains two methylated CpG sites. In some embodiments, the target methylation pattern contains more than two methylated CpG sites. In some embodiments, the target methylation pattern contains 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more methylated CpG sites.

[0256] In some embodiments, the target locus may be located within a subgenomic region. In some embodiments, more than one target locus may be located within a subgenomic region. In some embodiments, the target locus may comprise a subgenomic region. In some embodiments, the target locus may comprise more than one subgenomic region.

[0257] In some embodiments, one or more of the decoy designs disclosed herein are used to query the methylation state of more than one locus in parallel. In some embodiments, one or more of the decoy designs disclosed herein are used to query multiple methylation states of a single locus in parallel.

[0258] In some embodiments, sequencing reads generated using the methods disclosed herein overlap with one or more loci within one or more subgenomic regions of a sample. In some embodiments, sequencing reads generated using the methods disclosed herein overlap with ten or more loci within one or more subgenomic regions of a sample. In some embodiments, sequencing reads generated using the methods disclosed herein overlap with 10 to 20 loci within one or more subgenomic regions of a sample. In some embodiments, sequencing reads generated using the methods disclosed herein overlap with more than 20, more than 50, more than 100, more than 200, more than 300, more than 500, more than 1,000, more than 5,000, more than 10,000, more than 20,000, more than 50,000, or more than 100,000 loci within one or more subgenomic regions of a sample. In some embodiments, loci within one or more subgenomic regions of a sample that overlap with sequencing reads generated using the methods disclosed herein contain more than two CpG sites.

[0259] In some embodiments, one or more target loci include ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, ALOX12B, AMER1, APC, AR, ARAF, ARFRP1, ARID1A, ASXL1, ATM, ATR, ATRX, AURKA, AURKB, AXIN1, AXL, BAP1, BARD1, BCL2, BCL2L1, BCL2L2, BCL6, BCOR, BCORL1, BCR, BRAF, BRCA1, BRCA2, BRD4, BRIP1, BTG1, BTG2, BTK, CALR, CARD11, CASP8, CBFB, CBL, CCND 1. CCND2, CCND3, CCNE1, CD22, CD274, CD70, CD74, CD79A, CD79B, CDC73, CDH1, CDK12, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEBPA, CH EK1, CHEK2, CIC, CREBBP, CRKL, CSF1R, CSF3R, CTCF, CTNNA1, CTNNB1, CUL3, CUL4A, CXCR4, CYP17A1, DAXX, DDR1, DDR2, DIS3, DNMT3A, DOT1L, EED, EGFR, EMSY (C11orf30), ​​EP300, EPHA3, EPHB1, EPHB4, ERBB2, ERBB3, ERBB4, ERCC4, ERG, ERRFI1, ESR1, ETV4, ETV5, ETV6, EWSR1, EZH2, EZR, FAM46C, FANCA, FANCC, FANCG, FANCL, F AS, FBXW7, FGF10, FGF12, FGF14, FGF19, FGF23, FGF3, FGF4, FGF6, FGFR1, FGFR2, FGFR3, FGFR4, FH, FLCN, FLT1, FLT3, FOXL2, FUBP1, GABRA6, GATA3, GATA4, GATA6, GID4 (C17orf39), GNA11, GNA13, GNAQ, GNAS, GRM3, GSK3B, H3F3A, HDAC1, HGF, HNF1A, HRAS, HSD3B1, ID3, IDH1, IDH2, IGF1R, I KBKE, IKZF1, INPP4B, IRF2, IRF4, IRS2, JAK1, JAK2, JAK3, JUN, KDM5A, KDM5C, KDM6A, KDR, KEAP1, KEL, KIT, KLHL6, KMT2A (MLL), KMT2D(MLL2), KRAS, LTK, LYN, MAF, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAP3K13, MAPK1, MCL1, MDM2, MDM4, MED12, MEF2B, MEN1, MERTK, MET, MITF, MKNK1, MLH1, MPL, MRE11A, MSH2, MSH3, MSH6, MST1R, MTAP, MTOR, MUTYH, MYB, MYC, MYCL, MYCN, MYD88, NBN, NF1, NF2, NFE2L2, NFKBIA, NKX2-1, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, NT5C2, NTRK1, NTRK2, NTRK3, NUTM1, P2RY8, PALB2, PARK2, PARP1, PARP2, PARP3, PAX5, PBRM1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PDK1, PIK3C2B, PIK3C2G, PIK3CA, PIK3CB, PIK3R1, PIM1, PMS2, POLD1, POLE, PPARG, PPP2R1A, PPP2R2A, PRDM1, PRKAR1A, PRKCI, PTCH1, PTEN, PTPN11, PTPRO, QKI, RAC1, RAD21, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RAF1, RARA, RB1, RBM10, REL, RET, RICTOR, RNF43, ROS1, RPTOR, RSPO2, SDC4, SDHA, SDHB, SDHC, SDHD, SETD2, SF3B1, SGK1, SLC34A2, SMAD2, SMAD4, SMARCA4, SMARCB1, SMO, SNCAIP, SOCS1, SOX2, SOX9, SPEN, SPOP, SRC, STAG2, STAT3, STK11, SUFU, SYK, TBX3, TEK, TERC, TERT, TET2, TGFBR2, TIPARP, TMPRSS2, TNFAIP3, TNFRSF14, TP53, TSC1, TSC2, TYRO3, U2AF1, VEGFA, VHL, WHSC1, WHSC1L1, WT1, XPO1, XRCC2, ZNF217, ZNF703, or any combination thereof.

[0260] In some embodiments, one or more target loci include ABL, ALK, ALL, B4GALNT1, BAFF, BCL2, BRAF, BRCA, BTK, CD19, CD20, CD3, CD30, CD319, CD38, CD52, CDK4, CDK6, CML, CRACC, CS1, CTLA-4, dMMR, EGFR, ERBB1, ERBB2, FGFR1-3, FLT3, GD2, HDAC, HER1, HER2, HR, IDH2, IL-1β, IL-6, IL-6R, JAK1, JAK2, JAK3, KIT, KRAS, MEK, MET, MSI-H, mTOR, PARP, PD-1, PDGFR, PDGFRα, PDGFRβ, PD-L1, PI3Kδ, PIGF, PTCH, RAF, RANKL, RET, ROS1, SLAMF7, VEGF, VEGFA, and VEGFB. Or any combination thereof.

[0261] VIII. Objects

[0262] In some embodiments, the method includes obtaining a sample from a subject, such as an individual. In some embodiments, one or more samples are obtained from one or more subjects. In some embodiments, multiple samples are obtained from one subject. In some embodiments, multiple samples are obtained from more than one subject. In some embodiments, more than one sample is obtained from one subject. In some embodiments, the subject is a bacterial, plant, fungal, or animal subject. In some embodiments, the subject is an animal subject, such as, for example, a mammalian subject, such as a human subject. In some embodiments, the subject is an adult. In some embodiments, the subject is a child. In some embodiments, the subject is a pregnant subject. In some embodiments, the subject is a fetus. In some embodiments, the sample is obtained from multiple subjects simultaneously, such as, for example, from a pregnant woman and one or more fetuses simultaneously, such as, for example, from a blood sample collected from a pregnant woman.

[0263] In some cases, samples are obtained (e.g., collected) from subjects who have a condition or disease (e.g., hyperproliferative disorders or non-cancerous indications) or are suspected of having a condition or disease (e.g., patients). In some embodiments, the subject may have, have had, or be suspected of having any of the diseases or conditions disclosed herein and / or any disease or condition known or suspected to be associated with one or more aberrant methylation states. In some embodiments, the subject is monitored for a disease or condition, such as, for example, the progression or recovery of the disease or condition.

[0264] In some cases, the subject is at risk of developing a disease or condition. For example, in some cases, the subject has a genetic predisposition to the disease or condition (e.g., having gene mutations and / or abnormal methylation states that increase his or her baseline risk of developing cancer or the condition). In some cases, the subject has been exposed to environmental disturbances that increase his or her risk of developing a disease or condition (e.g., radiation or chemicals). In some cases, the subject needs to be monitored for the development of the disease or condition. In some cases, the subject needs to be monitored for the progression or regression of the disease or condition, such as after receiving a therapy or treatment for the disease or condition. In some cases, the subject needs to be monitored for the recurrence of the disease or condition. In some cases, the subject needs to be monitored for minimal residual disease (MRD). In some cases, the subject is undergoing treatment response monitoring (TRM). In some cases, subjects undergoing MRD monitoring have relatively low tumor scores (e.g., from early disease progression and / or shortly after surgery). In some cases, subjects undergoing TRM have relatively high tumor fractions (e.g., from advanced disease). In some cases, the subject has received or is receiving treatment for the disease or condition. In other cases, the patient has not received any treatment or therapy for the disease or condition.

[0265] In some cases, samples are obtained from subjects who have cancer. In some cases, the cancer is a solid tumor or its metastatic form. In some cases, the cancer is a blood cancer, such as leukemia or lymphoma. In some cases, the subject is at risk of developing cancer. For example, in some cases, the subject has a genetic predisposition to cancer (e.g., having gene mutations and / or abnormal methylation states that increase his or her baseline risk of developing cancer). In some cases, the subject has been exposed to environmental disturbances that increase his or her risk of developing cancer (e.g., radiation or chemicals). In some cases, the subject needs to be monitored for cancer development. In some cases, the subject needs to be monitored for cancer progression or regression, for example, after receiving treatment with anticancer therapy (or anti-cancer treatment). In some cases, the subject needs to be monitored for cancer recurrence. In some cases, the subject needs to be monitored for minimal residual disease (MRD). In some cases, the subject has received or is receiving treatment for cancer. In some cases, the subject needs to undergo treatment response monitoring (TRM). In some cases, the subject is a participant in a comprehensive genomic analysis (CGP) or requires a comprehensive genomic analysis (CGP). In some cases, the subjects had not yet received treatment with anticancer therapies (or anticancer treatments).

[0266] In some cases, the subject (e.g., a patient) is receiving or has previously received treatment with one or more targeted therapies. In some cases, such as for patients who have previously received targeted therapy, a post-targeted therapy sample (e.g., a specimen) is obtained (e.g., collected). In some cases, the post-targeted therapy sample is a sample obtained after the targeted therapy has been completed.

[0267] In some cases, the patient has not previously received treatment with targeted therapy. In some cases, for example, for patients who have not previously received treatment with targeted therapy, the sample includes excisions, such as the original excision or excisions after recurrence (e.g., after disease recurrence following treatment).

[0268] IX. Sample

[0269] The nucleic acid molecules used according to the methods described herein can be provided as one sample or multiple samples. For example, a single sample can be collected from a single subject. Alternatively, more than one sample can be collected from a single subject, or more than one sample can be collected from more than one subject. In some embodiments, multiple samples are collected from the same subject over time. In some embodiments, multiple samples are collected from different body sites of the same subject.

[0270] Therefore, in some embodiments, the methods of this disclosure include obtaining one or more samples from one or more subjects. The samples may be derived from one or more subjects, such as any of the subjects described above, or a combination thereof. The samples may contain nucleic acids containing targeted methylation patterns at one or more genomic loci as described above. The nucleic acid molecules may be derived from double-stranded nucleic acid molecules (e.g., DNA double-stranded molecules, such as cell-free DNA double-stranded molecules) or single-stranded nucleic acid molecules (e.g., single-stranded cfDNA molecules or RNA molecules). Double-stranded or single-stranded nucleic acid molecules may be naturally occurring and can be isolated according to the methods described herein.

[0271] The disclosed methods can be used with any of a variety of samples. For example, in some cases, the sample may include a tissue biopsy sample, a liquid biopsy sample, or a normal control. In some cases, the sample may be a liquid biopsy sample and may include blood, plasma, cerebrospinal fluid, sputum, feces, urine, or saliva. In some cases, the sample may be a liquid biopsy sample and may include circulating tumor cells (CTCs). In some cases, the sample may be a liquid biopsy sample and may contain cfDNA, circulating tumor DNA (ctDNA), or any combination thereof.

[0272] In some embodiments, the sample is or comprises biological tissue or fluid. The sample may contain compounds that do not naturally mix with tissues in nature, such as preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics, etc. In one embodiment, the sample is preserved as a frozen sample or a formaldehyde or paraformaldehyde-fixed, paraffin-embedded (FFPE) tissue preparation. For example, the sample may be embedded in a matrix, such as an FFPE block or a frozen sample. In another embodiment, the sample is blood or a blood component sample. In yet another embodiment, the sample is a bone marrow aspirate sample. In another embodiment, the sample comprises cfDNA, such as tumor cfDNA or cellular cfDNA. Not wishing to be bound by theory, it is believed that in some embodiments, cfDNA is DNA derived from apoptotic or necrotic cells. Typically, cfDNA is bound by proteins (e.g., histones) and protected by nucleases. cfDNA can be used as a biomarker, for example, for invasive prenatal testing (NIPT), organ transplantation, cardiomyopathy, microbiome, and cancer. In another embodiment, the sample comprises circulating tumor DNA (ctDNA). Without being bound by theory, it is believed that in some embodiments, ctDNA is cfDNA with genetic or epigenetic alterations (e.g., somatic alterations or methylation characteristics) that can distinguish tumor cells from non-tumor cells. In another embodiment, the sample contains circulating tumor cells (CTCs). Without being bound by theory, it is believed that in some embodiments, CTCs are cells shed from primary or metastatic tumors into the circulation. In some embodiments, CTCs undergo apoptosis and are a source of ctDNA in the blood / lymph.

[0273] In some embodiments, the sample may contain fetal DNA (e.g., from invasive or non-invasive prenatal testing). For example, the sample may be obtained using invasive amniocentesis, chorionic villus sampling (cVS), or fetal cord sampling techniques, or non-invasively using cfDNA samples (containing a mixture of maternal and fetal cfDNA).

[0274] Samples may contain cfDNA. Some cfDNA molecules are free-floating double-stranded DNA molecules (dsDNA or double-stranded DNA) or single-stranded DNA molecules present in the bloodstream, often as a result of apoptosis or necrosis, particularly in the context of disease. These degraded linear DNA fragments are typically about 50 to 300 base pairs in length. Most commonly, cfDNA is used for cancer screening in the early stages of disease progression by analyzing its sequence to identify cancer-related mutations. cfDNA may also contain methylated residues that reflect its methylation state, including aberrant methylation states, reflecting its genomic background.

[0275] The sample may contain circulating tumor DNA (ctDNA). In some embodiments, the sample contains tumor cells and / or tumor nucleic acids. In some embodiments, the method includes extracting a mixture of polynucleotides from the sample, wherein the polynucleotide mixture is derived from tumor cells and / or tumor nucleic acids. In some embodiments, the sample further contains non-tumor cells.

[0276] In some embodiments, the sample contains a tumor nucleic acid fraction of less than 1%, less than 0.5%, less than 0.1%, or less than 0.05% of the total nucleic acid. In some embodiments, the sample contains a tumor nucleic acid fraction of at least 0.01%, at least 0.05%, or at least 0.1% of the total nucleic acid. In some embodiments, the sample contains a maximum of 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, or 0.03% of the total nucleic acid. Or 0.02%, with the independently selectable lower limit being 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, or 1% of the total nucleic acid, where the upper limit is greater than the lower limit. Advantageously, as demonstrated herein, the method of this disclosure allows for the robust and ultrasensitive detection of trace amounts of aberrant methylation levels of tumor nucleic acids in otherwise normal nucleic acids.

[0277] In some cases, the nucleic acid molecules extracted from the sample may include a mixture of tumor nucleic acid molecules and non-tumor nucleic acid molecules. In some cases, the tumor nucleic acid molecules may be derived from the tumor portion of a heterogeneous tissue biopsy sample, and the non-tumor nucleic acid molecules may be derived from the normal portion of the heterogeneous tissue biopsy sample. In some cases, the sample may contain a liquid biopsy sample, and the tumor nucleic acid molecules may be derived from the circulating tumor DNA (ctDNA) fraction of the liquid biopsy sample, while the non-tumor nucleic acid molecules may be derived from the non-tumor cfDNA fraction of the liquid biopsy sample. In some embodiments, the sample contains cfDNA, circulating tumor DNA (ctDNA), or a combination of both.

[0278] In some embodiments, nucleic acid molecules from a sample are fragmented. For example, in some embodiments, the method further includes subjecting multiple nucleic acids to fragmentation before sequencing multiple polynucleotides or providing multiple sequence reads. Prior to NGS methods, various DNA fragmentation techniques have been used in the art. In some embodiments, nucleic acid fragmentation is performed by atomization, where compressed gas is used to mechanically shear the nucleic acid through a small opening. In some embodiments, nucleic acid fragmentation is performed by sonication, where ultrasound is used to shear the nucleic acid. In some embodiments, nucleic acids are enzymatically fragmented, for example, by digesting the nucleic acid into fragments using one or more enzymes. For example, some commercially available enzyme kits contain a mixture of two enzymes: one that randomly generates dsDNA nicks, and another that recognizes the nick site and cuts the opposite strand, thereby generating dsDNA breaks.

[0279] A. Nucleic acid extraction and processing

[0280] DNA or RNA can be extracted from tissue samples, biopsy samples, blood samples, or other bodily fluid samples using any of a variety of techniques known to those skilled in the art (see, for example, Example 1 of International Patent Application Publication No. WO 2012 / 092426; Tan et al. (2009), “DNA, RNA, and Protein Extraction: The Past and The Present”, J. Biomed. Biotech. 2009:574398; technical literature for the Maxwell® 16 LEV BloodDNA Kit (Promega Corporation, Madison, Wisconsin); and the Maxwell 16 Buccal Swab LEV DNA Purification Kit Technical Manual (Promega Literature #TM333, January 1, 2011, Promega Corporation, Madison, Wisconsin)). Protocols for RNA isolation are disclosed, for example, in the Maxwell® 16 Total RNA Purification Kit Technical Bulletin (Promega Literature #TB351, August 2009, Promega Corporation, Madison, Wisconsin).

[0281] For example, a typical DNA extraction procedure includes: (i) collecting a fluid, cell, or tissue sample from which DNA is to be extracted; (ii) disrupting the cell membrane (i.e., cell lysis) if necessary to release DNA and other cytoplasmic components; (iii) treating the liquid sample or the lysed sample with a concentrated salt solution to precipitate proteins, lipids, and RNA, followed by centrifugation to separate the precipitated proteins, lipids, and RNA; and (iv) purifying the DNA from the supernatant to remove detergents, proteins, salts, or other reagents used during the cell membrane lysis step.

[0282] Cell membrane disruption can be achieved using various mechanical shearing techniques (e.g., by passing through a French press or fine needle) or ultrasonic disruption techniques. The cell lysis step typically involves using detergents and surfactants to dissolve lipids in the cell and nuclear membranes. In some cases, the lysis step may further include using proteases to break down proteins and / or using RNases to digest RNA in the sample.

[0283] Examples of suitable techniques for DNA purification include, but are not limited to, (i) precipitation in ice-cold ethanol or isopropanol followed by centrifugation (DNA precipitation can be enhanced by increasing ionic strength, for example by adding sodium acetate); (ii) phenol-chloroform extraction followed by centrifugation to separate the aqueous phase containing nucleic acids from the organic phase containing denatured proteins; and (iii) solid-phase chromatography, in which nucleic acids are adsorbed onto a solid phase (e.g., silica or others), depending on the pH and salt concentration of the buffer.

[0284] In some cases, cellular proteins and histones bound to DNA can be removed prior to the DNA precipitation step by adding proteases, precipitating the proteins with sodium acetate or ammonium acetate, or by extraction with a phenol-chloroform mixture.

[0285] In some cases, DNA can be extracted using any of a variety of suitable commercial DNA extraction and purification kits. Some examples include, but are not limited to, the QIAamp (for isolating genomic DNA from human samples) and DNAeasy (for isolating genomic DNA from animal or plant samples) kits from Qiagen (Germantown, Maryland) or the Maxwell® and ReliaPrep™ series kits from Promega (Madison, Wisconsin).

[0286] As mentioned above, in some cases, the sample may include formalin-fixed (also known as formaldehyde-fixed or paraformaldehyde-fixed) paraffin-embedded (FFPE) tissue preparations. For example, an FFPE sample may be a tissue sample embedded in a matrix, such as an FFPE block. Methods for isolating nucleic acids (e.g., DNA) from paraffin-embedded (FFPE) tissues fixed in formaldehyde or paraformaldehyde are disclosed in, for example, Cronin et al., (2004) Am J Pathol. 164(1):35–42; Masuda et al., (1999) Nucleic Acids Res. 27(22):4436–4443; Spetht et al., (2001) Am J Pathol. 158(2):419–429; Ambion RecoverAll™ Total Nucleic Acid Isolation Protocol (Ambion, catalog number AM1975, September 2008); the Maxwell® 16 FFPE Plus LEV DNA Purification Kit Technical Manual (Promega Literature #TM349, February 2011); the EZNA® FFPE DNA Kit Handbook (OMEGA). Bio-Tek, Norcross, Georgia, Product Nos. D3399-00, D3399-01, and D3399-02, June 2009; and the QIAamp® DNA FFPE Tissue Handbook (Qiagen, Catalog No. 37625, October 2007). For example, the RecoverAll™ Total Nucleic Acid Isolation Kit uses xylene to dissolve paraffin-embedded samples at elevated temperatures and captures nucleic acids using a glass fiber filter. The Maxwell® 16 FFPE Plus LEV DNA Purification Kit, used with the Maxwell® 16 Instrument, is for purifying genomic DNA from 1 µm to 10 µm sections of FFPE tissue. DNA is purified using silica-coated paramagnetic particles (PMPs) and eluted at low elution volumes. The EZNA® FFPE DNA Kit uses a spinning column and buffer system to isolate genomic DNA. The QIAamp® DNA FFPE Tissue Kit uses QIAamp® DNA Micro technology to purify genomic and mitochondrial DNA.

[0287] In some cases, the disclosed method may further include determining or acquiring a yield value of nucleic acids extracted from a sample and comparing the determined value with a reference value. In some cases, the disclosed method may further include determining or acquiring a value of the size (or average size) of nucleic acid fragments in the sample and comparing the determined or acquired value with a reference value, such as the size (or average size) of at least 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 base pairs (bp). In some cases, one or more parameters described herein may be adjusted or selected in response to this determination.

[0288] After separation, nucleic acids are typically dissolved in a weakly alkaline buffer such as Tris-EDTA (TE) buffer or in ultrapure water. In some cases, the separated nucleic acids (e.g., genomic DNA) can be fragmented or cleaved using any of a variety of techniques known to those skilled in the art. For example, genomic DNA can be fragmented using physical cleavage methods, enzymatic cleavage methods, chemical cleavage methods, and other methods known to those skilled in the art. Methods for DNA cleavage are described in Example 4 of International Patent Application Publication No. WO 2012 / 092426. In some cases, alternative methods to DNA cleavage can be used to avoid the ligation step during library preparation.

[0289] B. Library Preparation

[0290] In some cases, nucleic acids isolated from a sample can be used to construct libraries (e.g., nucleic acid libraries as described herein). Exemplary methods for library preparation can be found, for example, in the examples below. Other exemplary methods for library preparation can be found in the methods described in WO2023129965A2 (the contents of which are incorporated herein by reference in their entirety), wherein an additional primer extension step is added after adaptor ligation and before cytosine transformation to synthesize a transformation-resistant DNA copy that retains the genomic sequence of the original DNA molecule in the input cfDNA material.

[0291] Various types of libraries can be used in the methods described herein. For example, both methyl-seq and single-workflow libraries can be used for hybrid capture reactions with methyl enrichment decoys to enrich signals from regions of cancer containing aberrant methylation signals.

[0292] In some cases, nucleic acids are fragmented using any of the methods described above, optionally with end-strand damage repair, and optionally ligated to synthetic adaptors, primers and / or barcodes (e.g., amplification primers, sequencing adaptors, flow cell adaptors, substrate adaptors, sample barcodes or indexes and / or unique molecular identifier sequences), size-selected (e.g., by preparative gel electrophoresis), and / or amplified (e.g., using PCR, non-PCR amplification techniques, or isothermal amplification techniques). In some cases, fragmented and adaptor-ligated nucleic acid assemblies are used without explicit size selection or amplification before hybridization-based selection of the target sequence. In some cases, nucleic acids are amplified using any of a variety of specific or non-specific nucleic acid amplification methods known to those skilled in the art. In some cases, nucleic acids are amplified, for example, by whole-genome amplification methods (such as randomly induced strand displacement amplification). Examples of nucleic acid library preparation techniques for next-generation sequencing are described, for example, in van Dijk et al. (2014), Exp. Cell Research 322:12–20, and Illumina’s Genomic DNA Sample Preparation Kit.

[0293] In some cases, the resulting nucleic acid library may contain all or substantially all of the genome's complexity. The term "substantially all" in this context refers to the possibility, in practice, of some unnecessary loss of genomic complexity during the initial steps of the procedure. The methods described herein are also useful where the nucleic acid library includes a portion of the genome (e.g., where genomic complexity is reduced by design). In some cases, any selected portion of the genome may be used in the methods described herein. For example, in some embodiments, an entire exome or a sub-exome is isolated. In some cases, the library may comprise at least 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, or 5% of the genomic DNA. In some cases, the library may consist of cDNA copies comprising at least 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, or 5% of the genomic DNA. In some cases, the amount of nucleic acid used to generate a nucleic acid library may be less than 5 micrograms, less than 1 microgram, less than 500 ng, less than 200 ng, less than 100 ng, less than 50 ng, less than 10 ng, less than 5 ng, or less than 1 ng.

[0294] In some cases, a library (e.g., a nucleic acid library) comprises a collection of nucleic acid molecules. As described herein, the nucleic acid molecules in a library may include target nucleic acid molecules (e.g., tumor nucleic acid molecules, reference nucleic acid molecules, and / or control nucleic acid molecules; also referred to herein as first, second, and / or third nucleic acid molecules, respectively). The nucleic acid molecules in a library may originate from a single subject or individual. In some cases, a library may include nucleic acid molecules derived from more than one subject (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, or more subjects). For example, two or more libraries from different subjects may be combined to form a library having nucleic acid molecules from more than one subject (wherein the nucleic acid molecules derived from each subject are optionally linked to a unique sample barcode corresponding to a specific subject). In some cases, the subject is a person who has cancer or a tumor or is at risk of developing cancer or a tumor.

[0295] In some cases, a library (or a portion thereof) may include one or more subgenomic regions. In some cases, a subgenomic region may be a single nucleotide position, for example, a nucleotide position where an aberrant methylation state is associated (positively or negatively) with a disease or condition (such as, for example, tumor). In some cases, a subgenomic region includes more than one nucleotide position. Such examples include sequences with lengths of at least 2, 5, 10, 50, 100, 150, 250, or more than 250 nucleotide positions. A subgenomic region may contain, for example, one or more complete genes (or portions thereof), one or more exons or coding sequences (or portions thereof), one or more introns (or portions thereof), one or more microsatellite regions (or portions thereof), or any combination thereof. A subgenomic region may contain all or part of a naturally occurring nucleic acid molecule (e.g., a genomic DNA molecule). For example, a subgenomic region may correspond to a segment of genomic DNA for which a sequencing reaction is performed. In some cases, a subgenomic region is a continuous sequence from a genomic source. In some cases, subgenomic regions include discontinuous sequences within the genome; for example, subgenomic regions in cDNA may include exon-exon connections formed due to splicing. In some cases, subgenomic regions include tumor nucleic acid molecules. In some cases, subgenomic regions include non-tumor nucleic acid molecules.

[0296] C. End-stage repair

[0297] In some embodiments, nucleic acid molecules in the sample may further undergo end repair, for example as part of a Methyl-Seq workflow. End repair of nucleic acid molecules involves phosphorylation of the 5' end of the nucleic acid molecule. This process can be performed using a polynucleotide kinase. The polynucleotide kinase preferably lacks exonuclease activity (e.g., 5' to 3' exonuclease activity), thereby avoiding any passivation of the nucleic acid molecule ends. T4 polynucleotide kinase and Thermo PNK are exemplary polynucleotide kinases that can be used for this process.

[0298] X. Connector Sub-connection

[0299] In some embodiments, the method described herein further includes ligating one or more adaptors to one or more nucleic acid molecules. Suitable adaptors include, but are not limited to, amplification primers, flow cell adaptor sequences, substrate adaptor sequences, or sample index sequences. Such adaptor ligation can be performed before or after the cytosine transformation step. For example, in some embodiments, the adaptor can be ligated to an untransformed nucleic acid molecule (e.g., before the transformation step). Alternatively, in some embodiments, the adaptor can be ligated to a transformed nucleic acid molecule. In some embodiments, the adaptor is ligated to the transformed nucleic acid molecule before amplification.

[0300] XI. Amplification

[0301] In some embodiments, the method further includes amplifying the transformed nucleic acid molecules into an amplicon set prior to bait hybridization. This can be achieved by various methods known in the art, such as, for example, by polymerase chain reaction (PCR) amplification, non-PCR amplification, and / or isothermal amplification. In some embodiments, the amplification step is performed by PCR. A variety of PCR techniques suitable for NGS are known in the art. PCR amplification can also be used to convert uracil residues or other cytosine conversion products into thymine residues. In some embodiments, PCR amplification is performed using deoxyribonucleotides containing thymine.

[0302] XII. Target Capture

[0303] The decoys disclosed herein can be used, for example, in the target capture step of Methyl-Seq library preparation. Therefore, the methods described herein may further include one or more target capture steps. Target capture is performed prior to sequencing multiple polynucleotides or providing multiple sequence reads and involves selectively capturing one or more nucleic acid molecules using one or more of the decoys described herein. For example, this may include selectively enriching multiple nucleic acids or nucleic acid fragments corresponding to genomic loci containing two or more CpG dinucleotide clusters to produce an enriched sample by selectively capturing nucleic acid molecules using one or more of the decoys described herein.

[0304] Target capture using the methods described herein involves hybridizing nucleic acid molecules with one or more nucleic acid decoys as described herein. This is performed under suitable hybridization conditions, where multiple nucleic acid molecules are capable of hybridizing with the decoy nucleic acids. After hybridization, the multiple hybrids are separated from the nucleic acid molecules that have not hybridized with the decoys. Separation can be achieved in various ways, such as, for example, separating the multiple nucleic acid molecules that have hybridized with the decoy nucleic acids. After separation, the separated or otherwise isolated multiple nucleic acid molecules that have hybridized with the decoy molecules are sequenced by NGS.

[0305] For example, one or more decoys described herein can be used to hybridize with, for example, a target genomic locus or fragment thereof containing a cluster of two or more CpG dinucleotides. For a general discussion of previously available decoy designs, see, for example, Graham, BI et al., Twist Fast Hybridization targeted methylation sequencing: a tunable target enrichment solution for methylation detection [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; April 10–15 and May 17–21, 2021. Pennsylvania (Philadelphia): AACR; Cancer Res 2021;81(13_Supplement):Abstract nr 2098.

[0306] In some embodiments, a hybrid capture method is used. Further details about this and other hybrid capture processes can be found in U.S. Patent No. 9,340,830; Frampton, GM et al. (2013) Nat. Biotech. 31:1023-1031; and Montesion, M. et al., Cancer Discovery (2021) 11(2):282-92.

[0307] A. Target capture reagent

[0308] The methods described herein may include contacting a nucleic acid library with multiple decoys to select and capture multiple specific target sequences (e.g., gene sequences or fragments thereof) for analysis. In some cases, the decoy (i.e., a molecule that can bind to the target molecule and thereby allow capture of the target molecule, also described herein as an enrichment decoy) is used to select a target region to be analyzed. For example, the target capture agent may be a decoy molecule, such as a nucleic acid molecule (e.g., a single-stranded or double-stranded DNA molecule, a single-stranded RNA molecule, or an RNA-DNA duplex), which can hybridize (i.e., complement) with the target molecule and thereby allow capture of the target nucleic acid. In some cases, the target capture agent (e.g., a decoy molecule (or decoy sequence)) is a capturing oligonucleotide (or a capturing decoy). In some cases, the target nucleic acid is a genomic DNA molecule, an RNA molecule, a cDNA molecule derived from an RNA molecule, a microsatellite DNA sequence, etc. In some cases, the target capture agent is suitable for solution-phase hybridization with the target. In some cases, the target capture agent is suitable for solid-phase hybridization with the target. In some cases, target capture reagents are suitable for both solution-phase and solid-phase hybridization with targets. The design and construction of conventional target capture reagents are described in more detail, for example, in International Patent Application Publication No. WO2020 / 236941, the entire contents of which are incorporated herein by reference; the design of decoys according to the methods described herein is described in detail in the preceding sections.

[0309] The methods described herein optimize sequencing of a large number of genomic loci (e.g., genes or gene products (e.g., mRNA, such as 5mC in RNA sequenced via RNA bisulfite, microsatellite loci, etc.) from samples (e.g., cancer tissue samples, liquid biopsy samples, etc.) from one or more subjects by appropriately selecting and designing target capture reagents (e.g., according to one or more of the decoy design strategies described herein) to select target nucleic acid molecules to be sequenced. In some cases, the target capture reagent can hybridize with a specific target locus (e.g., a specific target locus or a fragment thereof). In some cases, the target capture reagent can hybridize with a specific group of target loci (e.g., a specific group of loci or a fragment thereof). In some cases, multiple target capture reagents, including mixtures of target-specific and / or group-specific target capture reagents, can be used.

[0310] In some cases, the number of target capture agents (e.g., decoy molecules) in multiple target capture agents (e.g., decoy sets) that contact the nucleic acid library to capture multiple target sequences for nucleic acid sequencing is greater than 10, greater than 50, greater than 100, greater than 200, greater than 300, greater than 400, greater than 500, greater than 600, greater than 700, greater than 800, greater than 900, greater than 1,000, greater than 1,250, greater than 1,500, greater than 1,750, greater than 2,000, greater than 3,000, greater than 4,000, greater than 5,000, greater than 10,000, greater than 25,000, or greater than 50,000.

[0311] In some cases, the total length of the decoy molecule can be between approximately 70 and 300 nucleotides. In one case, the decoy molecule length is approximately 100 to 300 nucleotides, 110 to 200 nucleotides, or 120 to 170 nucleotides. In addition to those mentioned above, the methods described herein may also use intermediate decoy molecule lengths of less than approximately 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, or 300 nucleotides.

[0312] In some cases, each decoy sequence may include: (i) a target-specific capture sequence (e.g., a highly methylated or hypomethylated specific decoy corresponding to a locus or microsatellite locus-specific complementary sequence, depending on the decoy design disclosed herein), (ii) an adaptor, primer, barcode, and / or unique molecular identifier sequence, and (iii) a generic tail at one or both ends. As used herein, the terms “target-capturing reagent” or “decoy” may refer to a target-specific target-capturing sequence or the entire target-capturing reagent oligonucleotide including a target-specific target-capturing sequence.

[0313] In some cases, the target-specific capture sequence in the target capture reagent is approximately 40 to 1000 nucleotides in length. In others, it is approximately 70 to 300 nucleotides in length. In still others, it is approximately 100 to 200 nucleotides in length. In yet another case, it is approximately 120 to 170 nucleotides in length, typically 120 nucleotides. In addition to those mentioned above, intermediate lengths may also be used in the methods described herein, such as target-specific sequences of lengths of about 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 300, 400, 500, 600, 700, 800, and 900 nucleotides, as well as target-specific sequences of lengths between the above lengths.

[0314] In some cases, the decoy molecule contains multiple target-specific capture sequences corresponding to multiple adjacent genomic loci. In other cases, the decoy molecule contains multiple different target-specific capture sequences, such as, for example, each sequence corresponding to a hypermethylation signal at a different adjacent genomic locus, or each sequence corresponding to a hypomethylation signal at a different adjacent genomic locus.

[0315] In some cases, target-capturing agents can be designed to select subject regions containing one or more rearrangements, such as introns containing genomic rearrangements. In such cases, the target-capturing agent is designed to mask repetitive sequences to improve selection efficiency. In those cases where the rearrangements have known conjugation sequences, complementary target-capturing agents can be designed to recognize conjugation sequences to improve selection efficiency.

[0316] In some cases, the disclosed methods may include the use of target capture reagents designed to capture two or more different target classes, each with a different target capture reagent design strategy. In some cases, the hybridization-based capture methods and target capture reagent compositions disclosed herein can provide capture and uniform coverage of a set of target sequences while minimizing coverage of genomic sequences outside the set of sequences that are targets. In some cases, the target sequences may include the entire exome of genomic DNA or a selected subset thereof. In some cases, the target sequences may include, for example, large chromosomal regions (e.g., entire chromosome arms). The methods and compositions disclosed herein provide different target capture reagents for achieving different sequencing depths and coverage patterns against complex sets of target nucleic acid sequences.

[0317] Typically, DNA molecules are used as target capture reagent sequences, although RNA molecules can also be used. In some cases, as described herein, the DNA molecule target capture reagent can be single-stranded DNA (ssDNA) or double-stranded DNA (dsDNA). In some cases, RNA-DNA duplexes are more stable than DNA-DNA duplexes and therefore offer potentially better nucleic acid capture.

[0318] In some cases, the disclosed methods include providing a selected set of nucleic acid molecules captured from one or more nucleic acid libraries (e.g., library captures). For example, the method may include: providing one or more nucleic acid libraries, each containing multiple nucleic acid molecules (e.g., multiple target nucleic acid molecules and / or reference nucleic acid molecules) extracted from one or more samples from one or more subjects; contacting the one or more libraries (e.g., in a solution-based hybridization reaction) with one, two, three, four, five, or more than five of a plurality of target capture reagents (e.g., one or more decoys designed according to the principles described herein) to form a hybridization mixture containing multiple target capture reagent / nucleic acid molecule hybrids; separating the multiple target capture reagent / nucleic acid molecule hybrids from the hybridization mixture, for example, by contacting the hybridization mixture with a binding entity that allows separation of the multiple target capture reagent / nucleic acid molecule hybrids from the hybridization mixture, thereby providing library captures (e.g., selected or enriched subgroups of nucleic acid molecules from the one or more libraries). For example, in some embodiments, separation may be achieved using biotinylated decoys and streptavidin-coated beads.

[0319] In some cases, the disclosed method may further include amplifying the library capture (e.g., by performing PCR). In other cases, the library capture is not amplified.

[0320] In some cases, target capture reagents may be part of a kit, which may optionally include instructions, standards, buffers, enzymes, or other reagents.

[0321] B. Hybridization conditions

[0322] As described above, the methods disclosed herein may include the step of contacting a library (e.g., a nucleic acid library) with a plurality of target capture reagents to provide a selected library target nucleic acid sequence (i.e., a library capture). The contact step may be performed, for example, in solution-based hybridization. In some cases, the method includes repeating the hybridization step to perform one or more additional rounds of solution-based hybridization. In some cases, the method further includes performing one or more additional rounds of solution-based hybridization with the same or different sets of target capture reagents.

[0323] In some cases, solid supports (e.g., arrays) are used to achieve the contact step. Suitable solid supports for hybridization are described, for example, in Albert, TJ et al. (2007) Nat. Methods 4(11):903-5; Hodges, E. et al. (2007) Nat. Genet. 39(12):1522-7; and Okou, DT et al. (2007) Nat. Methods 4(11):907-9, the entire contents of which are incorporated herein by reference.

[0324] Hybridization methods adaptable to use in the methods described herein are described in the art, for example, as in International Patent Application Publication No. WO 2012 / 092426. Methods for hybridizing target capture reagents with multiple target nucleic acids are described in more detail in, for example, International Patent Application Publication No. WO 2020 / 236941, the entire contents of which are incorporated herein by reference.

[0325] Hybridization conditions can include one or more conditions with varying degrees of stringency. For example, hybridization conditions can include one or more temperatures below the washing step temperature. Hybridization conditions can also include one or more temperatures above the washing step temperature.

[0326] In some cases, hybridization conditions include a prehybridization mixture containing one or more baits as described herein, one or more blocking agents (e.g., one or two commercially available blocking agents, such as, for example, human Cot-1 DNA and / or cleaved salmon sperm), a blocking agent solution, and / or a methyl enhancer. In some cases, the prehybridization mixture is freeze-dried. In some cases, the freeze-dried prehybridization mixture is resuspended in the hybridization mixture. In some cases, a hybridization enhancer is added to the resuspended hybridization mixture. In some cases, the prehybridization mixture and / or the hybridization mixture is denatured. Denaturation includes incubation at a temperature above the bait's Tm (e.g., at least about 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, or up to about 99°C) for a duration sufficient to denature the bait (e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 minutes, or longer). For example, denaturation may include incubation at 95°C for 5 minutes.

[0327] In some cases, hybridization conditions include incubating the target in the library at, for example, about 50°C, 55°C, 60°C, 65°C, 70°C, or 75°C for, for, for, for, for, for, for, for, for, approximately 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 5.25, 5.5, 5.75, 5, 5.25, 5.5, 5.75, 6, 6.25, 6.5, 6.75, 7, 7.25, 7.5, 7.75, 8 hours or longer.

[0328] In some cases, the washing step includes applying a washing buffer. In some cases, the method includes a first washing step and a second washing step. In some cases, the method includes a third washing step. In some cases, the method includes more than three washing steps. In some cases, the washing step includes incubation at a temperature below the Tm of the hybrid containing the decoy and target and without mismatches. In some cases, the washing step includes incubation at a temperature below the Tm of the hybrid containing the decoy, which has fewer mismatches than the hybrid containing the decoy and off-target sequences. In some cases, the washing step includes incubation at, for example, about 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, or 70°C. In some cases, the washing step occurs at a temperature higher than that of subsequent washing steps. For example, in some cases, the first washing step includes incubation at about 65°C, and the second washing step includes incubation at about 48°C.

[0329] XIII. Sequencing

[0330] The methods described herein may further include sequencing nucleic acid molecules in a plurality of hybrids. For example, in some embodiments, the method may include sequencing hybrid nucleic acid molecules that have hybridized with a decoy. In some embodiments, sequencing occurs after one or more washing steps, wherein nucleic acid molecules that have not bound to the decoy and / or nucleic acid molecules that have bound to the decoy but have incomplete hybridization (i.e., contain one or more mismatched residues) are depleted. In some embodiments, after hybridization with one or more nucleic acid decoys, the method may further include: i) separating a first portion of a plurality of hybrids from a second portion of a plurality of hybrids, wherein the first portion of the hybrid contains a hybrid between a nucleic acid decoy and a nucleic acid molecule containing a target nucleic acid pattern, and the second portion of the hybrid contains a hybrid between a nucleic acid decoy and a nucleic acid molecule that does not contain a target nucleic acid pattern, wherein the hybrid in the second portion of the hybrid contains one or more adenine / cytosine (A:C) mismatches; ii) including ligating the hybrid to a substrate and washing the substrate, wherein the nucleic acid molecules in the second portion of the hybrid are depleted; and iii) sequencing the plurality of nucleic acid molecules in the second portion of the hybrid after depleting the nucleic acid molecules in the second portion of the hybrid.

[0331] In some embodiments, the plurality of sequence reads disclosed herein are obtained from next-generation sequencing (NGS).

[0332] NGS methods are known in the art and described, for example, in Metzker, M. (2010) Nature Biotechnology Reviews 11:31-46. Next-generation sequencing platforms include, for example, Roche / 454's Genome Sequencing (GS) FLX system, Illumina / Solexa's Genome Analyzer (GA), Illumina's HiSeq2500, HiSeq 3000, HiSeq 4000, and NovaSeq 6000 sequencing systems, Life / APG's Supported Oligonucleotide Ligation Detection (SOLiD) system, Polonator's G.007 system, Helicos BioSciences' HeliScope gene sequencing system, and Pacific Biosciences' PacBio RS system. NGS technology may include one or more steps, such as template preparation, sequencing and imaging, and data analysis. Methods for template preparation may include steps such as randomly breaking nucleic acids (e.g., genomic DNA) into smaller sizes and generating sequencing templates (e.g., fragment templates or paired templates). Spatially separated templates can be attached or fixed to solid surfaces or supports, allowing for a large number of sequencing reactions to occur simultaneously. Template types that can be used for NGS reactions include, for example, clonal amplification templates derived from single DNA molecules and single DNA molecule templates. Exemplary sequencing and imaging steps for NGS include, for example, cycle reversible termination (CRT), ligation sequencing (SBL), single-molecule addition (pyrosequencing), and real-time sequencing. Once NGS reads have been generated, they can be aligned to known reference sequences or assembled de novo. For example, genetic variations, such as single nucleotide polymorphisms and structural variants, in a sample (e.g., a tumor sample) can be identified by aligning NGS reads to a reference sequence (e.g., a wild-type sequence). Sequence alignment methods for NGS are described, for example, in Trapnell, C. and Salzberg SL Nature Biotech., 2009, 27:455-457. Examples of de novo assembly are described, for example, in Warren R. et al., Bioinformatics, 2007, 23:500-501; Butler J. et al., Genome Res., 2008, 18:810-820; and Zerbino DR and Birney E., Genome Res., 2008, 18:821-829.Sequence alignment or assembly can be performed using read data from one or more NGS platforms, for example, a mix of Roche / 454 and Illumina / Solexa read data. In some embodiments, NGS is performed according to, for example, Frampton, GM et al. (2013) Nat. Biotech. 31:1023-1031; and / or Montesion, M. et al., Cancer Discovery (2021) 11(2):282-92.

[0333] In some embodiments, sequencing includes using massively parallel sequencing (MPS) technologies (such as, for example, next-generation sequencing (NGS) and / or using a next-generation sequencer), whole genome sequencing, whole exome sequencing, targeted sequencing, direct sequencing, or Sanger sequencing technologies.

[0334] In some embodiments, sequencing produces multiple sequence reads, wherein one or more reads overlap with one or more loci (e.g., at least 10 loci, and even up to or more than tens of thousands of loci) within one or more subgenomic regions in the sample. In some embodiments, each of the one or more loci contains at least 10 loci, and each locus contains more than two CpG sites.

[0335] In some embodiments, the multiple sequence reads disclosed herein are obtained from next-generation sequencing (NGS). In some embodiments, sequencing includes bisulfite sequencing, whole-genome bisulfite sequencing (WGBS), APOBEC-seq, methyl-CpG-binding domain (MBD) protein capture, methyl-DNA immunoprecipitation (MeDIP-seq), methylation-sensitive restriction endonuclease sequencing (MSRE / MRE-Seq or Methyl-Seq), oxidized bisulfite sequencing (oxBS-Seq), degenerate representative bisulfite sequencing (RRBS), or Tet-assisted bisulfite sequencing (TAB-Seq).

[0336] NGS methods are known in the art and are described, for example, in Metzker, M. (2010) Nature Biotechnology Reviews 11:31-46. NGS technology may include one or more steps, such as template preparation, sequencing and imaging, and data analysis. Methods for template preparation may include steps such as randomly breaking nucleic acids (e.g., genomic DNA) into smaller sizes and generating sequencing templates (e.g., fragment templates or paired templates). Spatially separated templates may be attached or immobilized to a solid surface or support, allowing for a large number of sequencing reactions to occur simultaneously. Template types that can be used for NGS reactions include, for example, clonal amplification templates derived from a single DNA molecule and single DNA molecule templates. Exemplary sequencing and imaging steps of NGS include, for example, cycle reversible termination (CRT), ligation sequencing (SBL), single-molecule addition (pyrosequencing), and real-time sequencing.

[0337] Once NGS reads have been generated, they can be aligned with known reference sequences or assembled de novo. For example, NGS reads can be aligned with reference sequences (e.g., wild-type sequences and / or nucleic acid sequences in which methylation information is embedded via transformation from control or wild-type sequences with known methylation states) to identify genetic variations (such as single nucleotide polymorphisms and structural variants) and / or epigenetic variation signals (such as signals of aberrant methylation states) in a sample (e.g., tumor samples). Sequence alignment methods for NGS are described, for example, in Trapnell, C. and Salzberg S.L. Nature Biotech., 2009, 27:455-457. Examples of de novo assembly are described, for example, in Warren R. et al., Bioinformatics, 2007, 23:500-501; Butler J. et al., Genome Res., 2008, 18:810-820; and Zerbino DR and Birney E., Genome Res., 2008, 18:821-829. Sequence alignment or assembly can be performed using reads from one or more NGS platforms. In some embodiments, NGS is performed according to, for example, Frampton, GM et al. (2013) Nat. Biotech. 31:1023-1031; and / or Montesion, M. et al., Cancer Discovery (2021) 11(2):282-92.

[0338] In some embodiments, multiple sequence reads are obtained by sequencing the nucleic acids captured through hybridization with the decoy molecule. In some embodiments, multiple sequence reads are obtained by whole-exome sequencing of the nucleic acids captured through hybridization with the decoy molecule. In some embodiments, multiple sequence reads are obtained by next-generation sequencing (NGS) of the nucleic acids captured through hybridization with the decoy molecule.

[0339] In some embodiments, the plurality of sequence reads disclosed herein includes paired-end sequence reads. In some embodiments, the coherent methylation pattern and / or CCF is determined based on paired-end sequence reads corresponding to one or more clusters. In some embodiments, the coherent unmethylation pattern and / or CCUF is determined based on paired-end sequence reads corresponding to one or more clusters. Generally, paired-end sequencing methodologies are described, for example, in WO2007 / 010252, WO2007 / 091077, and WO03 / 74734. This method utilizes paired sequencing of double-stranded polynucleotide templates, which produces the sequential determination of nucleotide sequences in two distinct and independent regions of the polynucleotide template. The paired-end approach allows for the acquisition of two linked or paired reads of sequence information from each double-stranded template on a clustered array, rather than just a single sequencing read as can be obtained by other methods. Paired-end sequencing techniques can particularly utilize clustered arrays typically formed by solid-phase amplification, such as those described in WO03 / 74734. For example, target nucleic acid molecules containing adaptors are immobilized to a solid vector at the 5' end of each strand via bridge amplification, forming a dense cluster of double-stranded DNA. Since the 5' ends of both strands are immobilized, sequencing primers are then hybridized to the free 3' ends, and sequencing is performed. The adaptor sequence can be inserted between the target sequences to allow up to four reads per double strand, as described in WO2007 / 091077. In further improvements to this methodology, specific strands can be cleaved in a controlled manner, as described in WO2007 / 010252. Therefore, the timing of sequencing reads on each strand can be controlled, allowing for sequential determination of nucleotide sequences in two distinct and independent regions on the complementary strand of the double-stranded template. See, for example, U.S. Patent No. 10,174,372.

[0340] In some embodiments, the plurality of sequence reads includes unpaired sequence reads.

[0341] In some embodiments, the method of this disclosure further includes, before determining the co-methylation pattern and CCF: demultiplexing sequence reads from multiple sequence reads. In some embodiments, the method of this disclosure further includes, before determining the co-methylation pattern and CCF: aligning the sequence reads from multiple sequence reads to a reference genome (e.g., a human reference genome). In some embodiments, the alignment is a three-letter alignment with a human reference genome. In some embodiments, the method of this disclosure further includes, before determining the co-methylation pattern and CCF: excluding sequence reads from multiple sequence reads that have failed to undergo cytosine conversion. In some embodiments, the method of this disclosure further includes, before determining the co-methylation pattern and CCF: excluding sequence reads that have a base other than cytosine or thymine at the first position of at least one of the CpG dinucleotides. For example, these may be due to sequencing errors or mutations (somatic or germline mutations). In some embodiments, the method of this disclosure further includes, before determining the co-methylation pattern and CCF: excluding sequence reads with a base quality below a threshold base quality. In some embodiments, two overlapping paired-end sequence reads are used to determine the base call at the cytosine position within the CpG dinucleotide.

[0342] A.Methyl-Seq

[0343] In some embodiments, the methods disclosed herein involve one or more steps of a Methyl-seq workflow (also known as NGS (Next-Generation Sequencing)) for methylation analysis. An exemplary Methyl-seq workflow may include a chemical process (e.g., bisulfite or enzymatic process) that converts unmethylated cytosine to thymine while preserving the integrity of methylated cytosine during NGS library construction. Therefore, the DNA methylation state of the original DNA molecules in the input material can be inferred and compared to identify aberrant methylation states, such as, for example, healthy samples versus cancer samples. Figure 1 The exemplary methyl-seq workflow for cancer identity invocation and tumor score determination is shown from left to right. The methods described herein can be used to determine methylation scores and detect aberrant methylation states, not only associated with cancer but also for any DNA sequence with potentially hypermethylated or hypomethylated states, such as hypomethylated or hypermethylated signals associated with any other disease or condition. Therefore, the methods described herein can also be used in other workflows involving the selective detection of targeted methylation patterns from a sample.

[0344] like Figure 1As shown, an exemplary Methyl-Seq workflow begins with a sample, such as a cfDNA sample. For example, the sample undergoes end repair and adaptor ligation, cytosine transformation, library PCR, target capture, and sequencing. Adaptor ligation can be performed before or after transformation. For example, in some embodiments, the adaptor is ligated to an untransformed molecule. However, in some embodiments, the adaptor can alternatively be ligated to a transformed molecule. After sequencing, hypomethylation and / or hypermethylation scores are determined, and diagnostics are performed, such as, for example, cancer detection calls and / or tumor score calculations.

[0345] Some Methyl-seq methods rely on library construction and adaptor ligation, followed by standard bisulfite conversion and sequencing (e.g., WGBS). Alternatively, bisulfite treatment can be performed before adaptor ligation (see, for example, Miura, F. et al., Amplification-free whole-genome bisulfite sequencing by post-bisulfite adaptor tagging, Nucleic Acids Res., 40, e136F (2012)). Recent techniques utilize other cytosine conversion methods, such as enzymatic methods, to reduce the DNA damage caused by bisulfite, for example, bisulfite in commercially available Methyl-seq kits. Library amplification, quantification, and sequencing steps typically follow bisulfite conversion. In some embodiments, nucleic acids are extracted from the sample prior to Methyl-seq. In some embodiments, the nucleic acids are subjected to fragmentation, repair, and adaptor ligation prior to Methyl-seq. As previously mentioned, cytosine conversion can be performed before or after adaptor ligation. In some embodiments, DNA repair is performed after cytosine conversion. PCR amplification (typically at least two cycles) is performed after cytosine conversion to convert uracil residues (generated from previously unmethylated cytosine) into thymine, and is accomplished using a polymerase capable of reading uracil (excluding polymerases with proofreading and repair activities). In some embodiments, fragments are enriched for the desired length prior to sequencing.

[0346] The remainder of this document will discuss further exemplary details of the various steps of the Methyl-Seq workflow that can be used as part of this invention.

[0347] XIV. Methylation Score

[0348] In some embodiments involving one or more of the nucleic acid decoys disclosed herein, methylation scores are determined post-sequencing. For example, one or more hypermethylation scores and / or one or more hypomethylation scores may be determined for a genomic locus corresponding to any of the decoys used. The methylation scores of this disclosure correlate sequencing data generated from transformed nucleic acid molecules hybridized with decoys with methylation patterns present in samples from the subject, for example, by comparing, for example, the C and T residue patterns in the transformed nucleic acid sequence hybridized with the decoy to known genomic sequences (e.g., non-transformed genomic DNA from the same genomic locus, optionally from the same subject). Such comparisons may be made, for example, by means of alignment tools. Examples of alignment tools optimized for aligning sequence reads of transformed DNA include, but are not limited to, NovoAlign (Novocraft Technologies, Selangor, Malaysia) and the Bismark tool (Krueger et al. (2011), “Bismark: A Flexible Aligner and Methylation Caller for Bisulfite-Seq Applications”, Bioinformatics 27(11):1571-1572).

[0349] In some embodiments, determining the methylation score includes, for example, determining the ratio of sequencing reads corresponding to the transformed nucleic acid molecule hybridized with the decoy to the total sequencing reads. In some embodiments, for example, determining the methylation score includes, for example, quantifying and / or normalizing hypermethylation and / or hypomethylation signals based on a normalized region on a group, wherein the normalized region contains a mixed decoy (i.e., a mixture of hypermethylation specificity and hypomethylation specificity).

[0350] In some embodiments, determining a methylation score includes generating (e.g., via a processor) a cluster consistency score (CCF) for clusters (e.g., clusters of two or more CpG dinucleotides), where the CCF represents the fraction of a sequence read corresponding to a cluster that displays a consistent methylation pattern out of the total number of sequence reads from multiple sequence reads corresponding to the cluster; detecting one or more of the methylation or demethylation levels of the cluster based on the CCF; and generating a genomic and / or epigenetic profile for the subject based at least in part on the detected methylation level, the detected demethylation level, or both.

[0351] In some embodiments, the method includes (e.g., via a sequencer) sequencing a plurality of nucleic acid fragments to obtain a plurality of sequence reads, wherein the plurality of nucleic acid fragments have undergone cytosine transformation and wherein the plurality of nucleic acid fragments correspond to genomic loci containing clusters of two or more CpG dinucleotides; (e.g., via a processor) determining a coherent methylation pattern of the clusters, wherein the coherent methylation pattern represents each CpG dinucleotide in the cluster that is methylated in at least one sequence read from the plurality of sequence reads based on cytosine transformation; and (e.g., via a processor) generating a cluster coherence score (CCF) of the clusters, wherein the CCF represents the fraction of the sequence reads corresponding to the cluster that exhibit a coherent methylation pattern out of the total number of sequence reads corresponding to the cluster from the plurality of sequence reads.

[0352] In other embodiments, the method includes (e.g., via a sequencer) sequencing multiple nucleic acid fragments to obtain multiple sequence reads, wherein the multiple nucleic acid fragments have undergone cytosine conversion and wherein the multiple nucleic acid fragments correspond to genomic loci containing clusters of two or more CpG dinucleotides; (e.g., via a processor) determining a consistent unmethylation pattern of the clusters, wherein the consistent unmethylation pattern represents each CpG dinucleotide in the cluster for which methylation was not detected in at least one sequence read from the multiple sequence reads based on cytosine conversion; and (e.g., via a processor) generating a cluster consistent unmethylation fraction (CCUF) of the clusters, wherein the CCUF represents the fraction of sequence reads corresponding to the cluster that exhibit a consistent unmethylation pattern out of the total number of sequence reads corresponding to the cluster from the multiple sequence reads. Those skilled in the art will understand that the methods disclosed herein for measuring methylation (e.g., CCMF) can also be applied to measuring unmethylated or unmethylated sites (e.g., CCUF). It should be understood that cluster consistent methylation fraction, cluster consistent unmethylation fraction, or both may generally be referred to as cluster consistency fraction (CCF).

[0353] Other aspects of this disclosure relate to methods for detecting a disease or condition (e.g., cancer) in an individual, including detecting methylation levels (e.g., methylation levels of clusters of two or more CpG dinucleotides) according to any of the methods of this disclosure. In some embodiments, the method includes (e.g., by a sequencer) sequencing a plurality of nucleic acid fragments to obtain a plurality of sequence reads, wherein the plurality of nucleic acid fragments are obtained from a sample from an individual and have subsequently undergone cytosine conversion, and wherein the plurality of nucleic acid fragments correspond to genomic loci containing clusters of two or more CpG dinucleotides; (e.g., by a processor) determining a coherent methylation pattern of the clusters, wherein the coherent methylation pattern represents each CpG dinucleotide in the cluster that is methylated in at least one sequence read from the plurality of sequence reads based on cytosine conversion; and (e.g., by a processor) generating a cluster coherence score (CCF) of the clusters, wherein the CCF represents the fraction of sequence reads corresponding to the cluster that exhibit a coherent methylation pattern out of the total number of sequence reads corresponding to the cluster from the plurality of sequence reads. In some embodiments, a CCF at or above a threshold or reference value indicates the presence of a disease or condition in an individual and identifies the individual as having a disease or condition. In some embodiments, a CCF below a threshold or reference value does not indicate the presence of a disease or condition in an individual and identifies the individual as not having a disease or condition. In some embodiments, the method may be useful, for example, in screening for diseases or conditions (e.g., in a new diagnosis in an individual who has not previously been diagnosed with cancer or the same type of cancer) or in monitoring for relapse or minimal residual disease in an individual (e.g., in an individual who has previously been diagnosed with cancer and has achieved remission).

[0354] Other aspects of this disclosure relate to methods for screening individuals suspected of having a disease or condition (e.g., cancer), which include detecting methylation levels (e.g., methylation levels of clusters of two or more CpG dinucleotides) according to any of the methods of this disclosure. In some embodiments, the method includes (e.g., by a sequencer) sequencing a plurality of nucleic acid fragments to obtain a plurality of sequence reads, wherein the plurality of nucleic acid fragments are obtained from a sample from an individual and have subsequently undergone cytosine conversion, and wherein the plurality of nucleic acid fragments correspond to genomic loci containing clusters of two or more CpG dinucleotides; (e.g., by a processor) determining a coherent methylation pattern of the clusters, wherein the coherent methylation pattern represents each CpG dinucleotide in the cluster that is methylated in at least one sequence read from the plurality of sequence reads based on cytosine conversion; and (e.g., by a processor) generating a cluster coherence score (CCF) of the clusters, wherein the CCF represents the fraction of sequence reads corresponding to the cluster that exhibit a coherent methylation pattern out of the total number of sequence reads corresponding to the cluster from the plurality of sequence reads. In some embodiments, a CCF at or above a threshold or reference value indicates the presence of a disease or condition in an individual and identifies the individual as likely to have the disease or condition. In some embodiments, a CCF below a threshold or reference value does not indicate the presence of a disease or condition in an individual and identifies the individual as likely not to have the disease or condition. In some embodiments, the method may be useful, for example, in screening for diseases or conditions (e.g., in a new diagnosis in an individual who has not previously been diagnosed with cancer or the same type of cancer) or in monitoring for relapse or minimal residual disease in an individual (e.g., in an individual who has previously been diagnosed with cancer and has achieved remission).

[0355] Other aspects of this disclosure relate to methods for determining the prognosis of an individual suffering from a disease or condition (e.g., cancer), including detecting methylation levels (e.g., methylation levels of clusters of two or more CpG dinucleotides) according to any of the methods of this disclosure. In some embodiments, the method includes (e.g., by a sequencer) sequencing a plurality of nucleic acid fragments to obtain a plurality of sequence reads, wherein the plurality of nucleic acid fragments are obtained from a sample from an individual and have subsequently undergone cytosine conversion, and wherein the plurality of nucleic acid fragments correspond to genomic loci containing clusters of two or more CpG dinucleotides; (e.g., by a processor) determining a coherent methylation pattern of the clusters, wherein the coherent methylation pattern represents each CpG dinucleotide in the cluster that is methylated in at least one sequence read from the plurality of sequence reads based on cytosine conversion; and (e.g., by a processor) generating a cluster coherence score (CCF) of the clusters, wherein the CCF represents the fraction of sequence reads corresponding to the cluster that exhibit a coherent methylation pattern out of the total number of sequence reads corresponding to the cluster from the plurality of sequence reads. In some embodiments, a CCF at or above a threshold or reference value indicates the presence of a disease or condition in an individual and at least partially determines the individual's prognosis. In some embodiments, a CCF below a threshold or reference value does not indicate the presence of a disease or condition in an individual and at least partially determines the individual's prognosis. In some embodiments, a CCF at or above a threshold or reference value corresponds to a worse prognosis for an individual compared to an individual with a CCF below a threshold or reference value.

[0356] Other aspects of this disclosure relate to methods for predicting the survival of an individual with a disease or condition (e.g., cancer), including detecting methylation levels (e.g., methylation levels of clusters of two or more CpG dinucleotides) according to any of the methods of this disclosure. In some embodiments, the method includes (e.g., by a sequencer) sequencing a plurality of nucleic acid fragments to obtain a plurality of sequence reads, wherein the plurality of nucleic acid fragments are obtained from a sample from an individual and have subsequently undergone cytosine conversion, and wherein the plurality of nucleic acid fragments correspond to genomic loci containing clusters of two or more CpG dinucleotides; (e.g., by a processor) determining a coherent methylation pattern of the clusters, wherein the coherent methylation pattern represents each CpG dinucleotide in the cluster that is methylated in at least one sequence read from the plurality of sequence reads based on cytosine conversion; and (e.g., by a processor) generating a cluster coherence score (CCF) of the clusters, wherein the CCF represents the fraction of sequence reads corresponding to the cluster that exhibit a coherent methylation pattern out of the total number of sequence reads corresponding to the cluster from the plurality of sequence reads. In some embodiments, a CCF at or above a threshold or reference value indicates the presence of a disease or condition in an individual and at least partially predicts the individual's survival. In some embodiments, a CCF below a threshold or reference value does not indicate the presence of a disease or condition in an individual and at least partially predicts the individual's survival. In some embodiments, a CCF at or above a threshold or reference value corresponds to a shorter survival time for an individual compared to an individual with a CCF below a threshold or reference value. In some embodiments, a methylation level detected in a sample above a threshold or reference value predicts a lower survival rate for an individual compared to an individual whose sample has a methylation level below a threshold or reference value.

[0357] A. Mutation Call

[0358] In addition to calculating methylation scores, the methods disclosed herein may also involve mutation calls. A base call refers to the raw output of a sequencing device, such as a defined nucleotide sequence in an oligonucleotide molecule. A mutation call is the process of selecting a nucleotide value (e.g., A, G, T, or C) for a given nucleotide position being sequenced. Typically, a sequence read (or base call) for a given position will provide more than one value; for example, some reads will indicate T, and some will indicate G. A mutation call is the process of assigning the correct nucleotide value (e.g., one of those values) to a sequence. Although it is called a “mutation” call, it can be applied to assign a nucleotide value to any nucleotide position (e.g., a position corresponding to a transformed nucleic acid sequence) that represents the methylation state compared to an untransformed sequence from the same locus.

[0359] In some cases, the disclosed methods may also include using custom or adapted mutation calling algorithms or their parameters to optimize performance when applied to sequencing data, particularly in methods that rely on massively parallel sequencing (MPS) of numerous different genetic events at a large number of different genomic loci (e.g., CpG loci) in a sample (e.g., a sample from a subject with cancer). Optimization of mutation calling is described in the art, for example, as set forth in International Patent Application Publication No. WO 2012 / 092426.

[0360] Methods for mutation calling may include one or more of the following: independent calling based on information at each position in the reference sequence (e.g., examining sequence reads; examining base calls and quality scores; determining the probability of observed bases and quality scores under a given potential genotype; and assigning genotypes (e.g., using Bayes' rule)); removing false positives (e.g., using depth thresholding to reject SNPs with read depths far below or above the expected depth; local re-alignment to remove false positives due to small insertions or deletions); and performing linkage disequilibrium (LD) / filling-based analysis to refine the calling.

[0361] Equations used to determine the probability of a genotype associated with a specific genotype and location are described, for example, in Li, H. and Durbin, R. Bioinformatics, 2010; 26(5): 589-95. When evaluating samples from this cancer type, prior expectations for specific mutations in a particular cancer type can be used. Such probabilities can be derived from public databases of cancer mutations, such as the Cancer Somatic Mutation Catalogue (COSMIC), HGMD (Human Genome Mutation Database), the SNP Consortium, the Breast Cancer Mutation Database (BIC), and the Breast Cancer Gene Database (BCGD).

[0362] Examples of LD / filled analysis are described, for example, in Browning, BL and Yu, Z. Am. J. Hum. Genet. 2009, 85(6):847-61. Examples of low-coverage SNP invocation methods are described, for example, in Li, Y. et al., Annu. Rev. Genomics Hum. Genet. 2009, 10:387-406.

[0363] Following alignment, substitution detection can be performed using a mutation invocation method (e.g., a Bayesian mutation invocation method). This method applies to each base in each target region, such as the exons of the gene being evaluated or other loci where the presence of a substitutional allele is observed. The method compares the probability of observing a read in the presence of a mutation with the probability of observing a read in the presence of only a base invocation error. If this comparison strongly supports the presence of a mutation, the mutation is identified.

[0364] One advantage of Bayesian mutation detection methods is that the probability of a mutation's presence can be compared to the probability of a base call error alone by weighting it against the prior expectation of a mutation at that site. If some reads of alternative alleles are observed at sites with frequent mutations for a given cancer type, the presence of a mutation can be confidently identified even if the amount of mutation evidence does not reach the usual threshold. This flexibility can then be used to increase the detection sensitivity for even rarer mutations / lower purity samples, or to make the test more robust to reductions in read coverage. The probability of a random base pair in the genome mutating in cancer is approximately 1e-6. In, for example, typical polygenic cancer genomes, the probability of a specific mutation occurring at many sites can be several orders of magnitude higher. These probabilities can be derived from public databases of cancer mutations (e.g., COSMIC).

[0365] Several methods have been developed to address limited deviations from 50% or 100% allele frequencies relative to those used in cancer DNA analysis. (See, for example, SNVMix - Bioinformatics. 2010, March 15; 26(6):730–736.) However, the method disclosed herein allows for the consideration of the possibility of mutated alleles present at frequencies (or allele fractions) ranging from 1% to 100% (i.e., allele fractions ranging from 0.01 to 1.0), and especially at levels below 50%. This method is particularly important for the detection of mutations in low-purity FFPE samples of, for example, native (polyclonal) tumor DNA.

[0366] In some cases, the mutation calling method used to analyze sequence reads is not individually customized or fine-tuned to detect different mutations at different genomic loci. In some cases, different mutation calling methods are used, which are individually customized or fine-tuned for at least one subgroup of different mutations detected at different genomic loci. In some cases, different mutation calling methods are used, which are individually customized or fine-tuned for each different mutant detected at each different genomic locus. Customization or tuning can be based on one or more of the factors described herein, such as the type of cancer in the sample, the gene or locus in which the subject region to be sequenced is located, or the variant to be sequenced. This selection or use of mutation calling methods that are individually customized or fine-tuned for the number of subject regions to be sequenced allows for optimization of the speed, sensitivity, and specificity of mutation calling.

[0367] In some cases, a unique mutation invocation method is used to assign nucleotide values ​​to nucleotide positions in each of X unique subject intervals, and X is at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 200, at least 300, at least 400, at least 500, at least 1000, at least 1500, at least 2000, at least 2500, at least 3000, at least 3500, at least 4000, at least 4500, at least 5000, or more. The invocation method can differ and is therefore unique, for example, by relying on different Bayesian priors.

[0368] In some cases, the assigned nucleotide value is a function of a value that is or represents a prior (e.g., literature) expectation of a read that shows a variant (e.g., a mutation) at the nucleotide position observed in that type of tumor.

[0369] In some cases, the method includes: assigning nucleotide values ​​(e.g., calling mutations) to at least 10, 20, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1,000 nucleotide positions, wherein each assignment is a function of a unique value (relative to the values ​​for other assignments) that is or represents a prior (e.g., literature) expectation of a read showing a variant (e.g., a mutation) observed at the nucleotide position in that type of tumor.

[0370] In some cases, the assigned nucleotide value is a function of a set of values ​​that represent the probability of observing a read of the variant at the nucleotide position if the variant is present in the sample at a specified frequency (e.g., 1%, 5%, 10%, etc.) and / or if the variant is not present (e.g., observed in the read only due to a base call error).

[0371] In some cases, the mutation recall method described herein may include the following: (a) obtaining, for each of the X subject intervals, a nucleotide position: (i) a first value, which is or represents a prior (e.g., literature) expectation of observing a read displaying a variant (e.g., a mutation) at the nucleotide position in a type X tumor; and (ii) a second set of values, which represents the probability of observing a read displaying the variant at the nucleotide position if the variant is present in the sample at a certain frequency (e.g., 1%, 5%, 10%, etc.) and / or if the variant is not present (e.g., observed in the read only due to a base recall error); and (b) in response to the values, assigning a nucleotide value (e.g., recalling a mutation) from the read for each of the nucleotide positions by weighting the comparison between the values ​​in the second set using the first value (e.g., calculating the posterior probability of the presence of the mutation) (e.g., by a Bayesian method described herein).

[0372] Further descriptions of exemplary nucleic acid sequencing methods, mutation recall methods, and genetic variant analysis methods are provided in, for example, U.S. Patent Nos. 9,340,830, 9,792,403, 11,136,619, 11,118,213, and International Patent Application Publication No. WO 2020 / 236941, the entire contents of each of which are incorporated herein by reference.

[0373] B. Methylation state invocation

[0374] In some cases, the methods described herein may include using methylation state recall methods, such as recalling the methylation state of CpG sites based on sequence reads and fragments (complementary pairs of forward and reverse sequence reads) derived from DNA via chemical or enzymatic conversion reactions, for example, converting unmethylated cytosine residues to uracil (interpreted as thymine in sequencing results) and subsequently hybridizing them with decoy nucleic acids designed according to the principles described herein. Examples of such methylation status calling tools include, but are not limited to, Bismark (Krueger et al. (2011), “Bismark: A Flexible Aligner and Methylation Caller for Bisulfite-Seq Applications”, Bioinformatics 27(11):1571-1572), TARGOMICS (Garinet et al. (2017), “Calling Chromosome Alterations, DNA Methylation Statuses, and Mutations in Tumors by Simple Targeted Next-Generation Sequencing - A Solution for Transferring Integrated Pangenomic Studies into Routine Practice?”, J. Molecular Diagnostics 19(5):776-787), Bicycle (Grana et al. (2018), “Bicycle: A Bioinformatics Pipeline to Analyze Bisulfite Sequencing Data”, Bioinformatics 34(8):1414–5), and SMAP (Gao et al. (2015), “SMAP: A Streamlined Methylation Analysis Pipeline for Bisulfite Sequencing", Gigascience 4:29) and MeDUSA (Wilson et al. (2016), "Computational Analysis and Integration of MeDIP-Seq Methylome Data", in: Kulski JK Editor, Next Generation Sequencing: Advances, Applications and Challenges(Rijeka: InTech, pp. 153–69). See also Rauluseviciute et al. (2019), “DNA Methylation Data by Sequencing: Experimental Approaches and Recommendations for Tools and Pipelines for Data Analysis”, ClinicalEpigenetics 11:193.

[0375] XV. Genomic and epigenetic profiles and the diagnosis of subjects as having diseases or conditions.

[0376] In some cases, the values ​​of one or more methylation scores determined using the disclosed methods can be used as prognostic or diagnostic indicators associated with the sample. For example, in some cases, prognostic or diagnostic indicators may include indicators of the presence of a disease (e.g., cancer) in the sample, indicators of the probability of the presence of a disease (e.g., cancer) in the sample, indicators of the probability (i.e., risk factors) that a subject from whom the sample is derived will develop a disease (e.g., cancer), or indicators of the likelihood that a subject from whom the sample is derived will respond to a particular therapy or treatment. Depending on the strength of the methylation score determined for a given sample, the diagnosis may include a binary diagnosis (i.e., indicating the presence or absence of a particular disease or condition) and / or a quantifiable diagnosis (i.e., the degree of progression compared to a control sample).

[0377] In some cases, the disclosed methods for selectively capturing nucleic acid molecules can be implemented as part of a profiling process that includes identifying the presence of epigenetic and potential other multi-omics signatures (e.g., fragmentomics, mutation analysis, proteomics, transcriptomics, etc.). Specifically, in assessing epigenetic signatures, the disclosed methods can evaluate aberrant methylation at one or more loci in a sample derived from a subject as part of detecting, monitoring, predicting risk factors for, or selecting treatments for a specific disease (e.g., cancer). In some cases, selecting a team for genomic and epigenetic profiling to select gene targets and target CpG sites may include detecting aberrant methylation signals at a selected set of loci (e.g., CpG sites). In some cases, selecting a team for profiling may include detecting aberrant methylation signals at multiple loci through comprehensive...

Claims

1. A method for selectively capturing nucleic acid molecules from a sample from a subject, the method comprising: The unmethylated cytosine (C) in one or more of the nucleic acid molecules is converted to uracil (U), or the methylated C in one or more of the nucleic acid molecules is converted to U, to form a transformed nucleic acid molecule; The transformed nucleic acid molecules are amplified into amplicon groups; The single-stranded nucleic acid decoy set is hybridized with the amplicon set to form a plurality of hybrids, wherein at least a portion of the plurality of hybrids comprises decoys from the single-stranded nucleic acid decoy set that are hybridized to each other without mismatch and a nucleic acid molecule containing a target nucleic acid pattern, wherein the target nucleic acid pattern corresponds to a target methylation pattern at a genomic locus in the nucleic acid molecule before transformation; as well as The multiple hybrids were separated from nucleic acid molecules that had not hybridized with the decoy.

2. The method of claim 1, wherein the target methylation pattern corresponds to a hypermethylation signal indicating a disease or condition.

3. The method of claim 1, wherein the target methylation pattern corresponds to a hypomethylation signal indicating a disease or condition.

4. A method for selectively capturing nucleic acid molecules from a sample from a subject, the method comprising: The unmethylated cytosine (C) in one or more of the nucleic acid molecules is converted to uracil (U), or the methylated C in one or more of the nucleic acid molecules is converted to U, to form a transformed nucleic acid molecule; The transformed nucleic acid molecules are amplified into amplicon groups; The nucleic acid decoy set is hybridized with the amplicon set to form multiple hybrids, wherein the nucleic acid decoy set selectively hybridizes with a target nucleic acid pattern, wherein the target nucleic acid pattern corresponds to a target methylation pattern at a genomic locus in the nucleic acid molecule before transformation, wherein the target methylation pattern corresponds to a hypermethylation signal indicating a disease or condition. as well as The multiple hybrids were separated from nucleic acid molecules that had not hybridized with the decoy.

5. A method for selectively capturing nucleic acid molecules from a sample from a subject, the method comprising: The unmethylated cytosine (C) in one or more of the nucleic acid molecules is converted to uracil (U), or the methylated C in one or more of the nucleic acid molecules is converted to U, to form a transformed nucleic acid molecule; The transformed nucleic acid molecules are amplified into amplicon groups; The nucleic acid decoy set is hybridized with the amplicon set to form multiple hybrids, wherein the nucleic acid decoy set selectively hybridizes with a target nucleic acid pattern, wherein the target nucleic acid pattern corresponds to a target methylation pattern at a genomic locus in the nucleic acid molecule before transformation, wherein the target methylation pattern is associated with a hypomethylation signal indicating a disease or condition. as well as The multiple hybrids were separated from nucleic acid molecules that had not hybridized with the decoy.

6. The method of claim 1, further comprising converting multiple target methylation patterns at multiple genomic loci in the nucleic acid molecule of the sample from the subject into multiple target nucleic acid patterns at the multiple genomic loci, and hybridizing multiple nucleic acid decoy sets with the amplicon set, wherein each of the multiple nucleic acid decoy sets selectively hybridizes with a target nucleic acid pattern among the multiple target nucleic acid patterns.

7. The method of claim 6, wherein the plurality of targeted methylation modes comprises a first targeted methylation mode and a second targeted methylation mode, wherein the second targeted methylation mode is associated with a hypermethylation signal indicating a disease or condition.

8. The method of claim 6, wherein the plurality of targeted methylation modes comprises a first targeted methylation mode and a second targeted methylation mode, wherein the second targeted methylation mode is associated with a hypomethylation signal indicating a disease or condition.

9. The method of claim 1, wherein the second hybrid of the plurality of hybrids comprises a single-stranded nucleic acid decoy from the single-stranded nucleic acid decoy group and a nucleic acid molecule that does not contain the target nucleic acid pattern, wherein the hybrid of the second hybrid contains one or more adenine / cytosine (A:C) mismatches.

10. The method of claim 9, further comprising separating the portion of the hybrid from the second portion of the hybrid.

11. The method of claim 4, further comprising converting multiple target methylation patterns at multiple genomic loci in the nucleic acid molecule of the sample from the subject into multiple target nucleic acid patterns at the multiple genomic loci, and hybridizing multiple nucleic acid decoy sets with the amplicon set, wherein each of the multiple nucleic acid decoy sets selectively hybridizes with a target nucleic acid pattern among the multiple target nucleic acid patterns.

12. The method of claim 11, wherein the plurality of targeted methylation modes comprises a first targeted methylation mode and a second targeted methylation mode, wherein the second targeted methylation mode is associated with a hypermethylation signal indicating a disease or condition.

13. The method of claim 12, wherein the plurality of targeted methylation patterns comprises a first targeted methylation pattern and a second targeted methylation pattern, wherein the second targeted methylation pattern is associated with a hypomethylation signal indicating a disease or condition.

14. The method of claim 4, wherein the second hybrid of the plurality of hybrids comprises a single-stranded nucleic acid decoy from the single-stranded nucleic acid decoy group and a nucleic acid molecule not containing the target nucleic acid pattern, wherein the hybrid of the second hybrid contains one or more adenine / cytosine (A:C) mismatches.

15. The method of claim 14, further comprising separating the portion of the hybrid from the second portion of the hybrid.

16. The method of claim 5, further comprising converting multiple target methylation patterns at multiple genomic loci in the nucleic acid molecule of the sample from the subject into multiple target nucleic acid patterns at the multiple genomic loci, and hybridizing multiple nucleic acid decoy sets with the amplicon set, wherein each of the multiple nucleic acid decoy sets selectively hybridizes with a target nucleic acid pattern among the multiple target nucleic acid patterns.

17. The method of claim 16, wherein the plurality of targeted methylation patterns comprises a first targeted methylation pattern and a second targeted methylation pattern, wherein the second targeted methylation pattern is associated with a hypermethylation signal indicating a disease or condition.

18. The method of claim 17, wherein the plurality of targeted methylation modes comprises a first targeted methylation mode and a second targeted methylation mode, wherein the second targeted methylation mode is associated with a hypomethylation signal indicating a disease or condition.

19. The method of claim 5, wherein the second hybrid of the plurality of hybrids comprises a single-stranded nucleic acid decoy from the single-stranded nucleic acid decoy group and a nucleic acid molecule not containing the target nucleic acid pattern, wherein the hybrid of the second hybrid contains one or more adenine / cytosine (A:C) mismatches.

20. The method of claim 19, further comprising separating the portion of the hybrid from the second portion of the hybrid.

21. The method of claim 1, wherein the hybrids in the plurality of hybrids do not contain guanine / thymine (G:T) mismatches.

Citation Information

Patent Citations

  • Preservation of information related to genomic DNA methylation

    US10174372B2

  • Queue based advertisement scheduling and sales

    US10231031B1

  • Optimization of multigene analysis of tumor samples

    US11118213B2

  • Optimization of multigene analysis of tumor samples

    US11136619B2

  • Methods and Compositions for Discrimination Between Cytosine and Modifications Thereof and for Methylome Analysis

    US20130244237A1